

COVER SHEET

1	4	8	0	2	2				
---	---	---	---	---	---	--	--	--	--

S.E.C. Registration Number

E	U	R	O	-	M	E	D		L	A	B	O	R	A	T	O	R	I	E	S		P	H	I	L		I	N	C.
---	---	---	---	---	---	---	---	--	---	---	---	---	---	---	---	---	---	---	---	---	--	---	---	---	---	--	---	---	----

(Company's Full Name)

P	P	L		B	U	I	L	D	I	N	G		U	N	I	T	E	D		N	A	T	I	O	N	S			
---	---	---	--	---	---	---	---	---	---	---	---	--	---	---	---	---	---	---	--	---	---	---	---	---	---	---	--	--	--

A	V	E	N	U	E		C	O	R	.		S	A	N		M	A	R	C	E	L	I	N	O		S	T	.
---	---	---	---	---	---	--	---	---	---	---	--	---	---	---	--	---	---	---	---	---	---	---	---	---	--	---	---	---

M	A	N	I	L	A																								
---	---	---	---	---	---	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

(Business Address: No. Street City/Town/ Province)

Janice R. Ong

Contact Person

8524-0091 to 98

Company Telephone Number

1	2
---	---

Month Day
Fiscal Year

3	1
---	---

Definitive Information Statement

FORM TYPE

June 17, 2026

Month Day
Annual Meeting

--

Secondary License Type, If Applicable

--	--	--

Dept. Requiring this Doc.

--

Amended Articles Number/Section

--

Total No. of Stockholders

Total amount of Borrowings

--

Domestic

--

Foreign

To be accomplished by SEC Personnel concerned

--	--	--	--	--	--	--	--	--	--

File Number

LCU

--	--	--	--	--	--	--	--	--	--

Document I.D.

Cashier

STAMPS

Remarks = pls. use black ink for scanning purposes

NOTICE OF ANNUAL STOCKHOLDERS' MEETING

TO ALL STOCKHOLDERS :

Please be informed that the Annual Shareholders' Meeting of **EURO-MED LABORATORIES PHIL., INC.** will be conducted virtually via <http://meeting.euromedlab.net> on 17 June 2026 at 10:00 o'clock in the morning.

The Agenda for the said meeting shall be as follows:

1. Call to Order;
2. Proof of Notice of Meeting;
3. Certification of Quorum;
4. Reading and Approval of the Minutes of the Previous Meeting;
5. Management Report for the Fiscal Year 2025 and Approval of the Audited Financial Statements as of 31 December 2025;
6. Ratification of all Acts, Proceedings and Resolutions of the Board of Directors and Officers of the Corporation from the date of the last Annual Shareholders' Meeting to the present;
7. Election of Directors for the year 2026-2027;
8. Appointment of External Auditor for the year 2026-2027;
9. Other Matters; and
10. Adjournment.

Stockholders of record at the close of business hours on 18 May 2026 are entitled to receive notice of, and to vote at, the Meeting and at any adjournment thereof.

The conduct of the Annual Stockholders' Meeting shall be via remote communication. Voting shall be done electronically in absentia for a more orderly conduct of the proceedings. Instructions on Online Registration, Online Voting in Absentia and Participation by Remote Communication are set out in Annex "A" of this Notice and will be posted on the Company's website at www.euromedlab.net and at the Company's PSE EDGE profile on or before 25 May 2026.

All shareholders are cordially invited to attend the Meeting. However, if you are unable to do so, you may submit your duly accomplished proxies on or before 10 June 2026 to the Office of the Corporate Secretary at 3rd Floor, PPL Building, United Nations Avenue corner San Marcelino St., Manila or by email to janice.ong@euromedlab.net. For your convenience, proxy forms can be downloaded from the Company website. Proxies shall be validated by the Office of the Corporate Secretary on 11 June 2026.

A copy of the Notice and Agenda of the Annual Stockholders' Meeting together with the Information Statement, Proxy Form, Management Report, Annual Report for the year ended 31 December 2025 and Sustainability Report, and SEC Form 17-Q with Management's Discussion and Analysis for the First Quarter of 2026 will be posted on the Company's website at www.euromedlab.net and at the Company's PSE EDGE profile on or before 25 May 2026. A Stockholder may send his/her questions and/or comments about the items in the Agenda prior to or during the Annual Meeting to corporate@euromedlab.net.

Lastly, there will be a visual and audio recording of the Meeting in compliance with the requirements of the Securities and Exchange Commission.

City of Manila, 21 May 2026.



JANICE R. ONG
Corporate Secretary &
Investment Relations Officer

ANNEX "A"

2026 ANNUAL STOCKHOLDERS' MEETING OF EURO-MED LABORATORIES PHIL., INC.

INSTRUCTIONS AND PROCEDURE FOR ONLINE REGISTRATION, ONLINE VOTING IN ABSENTIA AND PARTICIPATION BY REMOTE COMMUNICATION

ONLINE VOTING IN ABSENTIA

1. Stockholders as of the close of business hours on 18 May 2026 have the option to vote online in absentia on the matters in the Agenda, after complete registration and successful validation.
2. The registration period shall begin on 28 May 2026 and end at the close of business hours on 9 June 2026. Stockholders who have successfully registered during this period are entitled to vote in absentia and to participate in the Annual Meeting by remote communication.
3. A Stockholder who was not able to register by 9 June 2026 can no longer vote via online voting in absentia.
4. Only Stockholders who have registered within the prescribed period, together with the stockholders who voted in absentia or by proxy, will be included in the determination of quorum.

HOW TO REGISTER :

1. Open your preferred web browser such as Google Chrome, Firefox, Safari or the newest version of Internet Explorer, and type <http://euromedlab.net/stockholders2026> in the address bar and press "Enter" key.
2. Click the Register button or Register link to start the registration process.
3. Enter your full first name, last name / company name, email, password, captcha and then agree to the Terms and Conditions by ticking the checkbox before clicking the "Submit" button.
4. Wait for the administrator to activate your account before you can login.
5. Once your account is already activated, you will receive a notification thru your email.
6. After successful login, you can now navigate through the dashboard containing tabs and links where you can update your profile and password, and upload your documentary requirements.
7. The following requirements must be submitted/uploaded :

7.1 For Individual Stockholders

- 7.1.1 A recent photo of the Stockholder, with the face fully visible (in JPG format). The file size should be no larger than 2MB;
- 7.1.2 A scanned copy of the Stockholder's valid government-issued ID* showing photo and personal details, preferably with residential address (in JPG format). The file size should be no larger than 2MB;
- 7.1.3 A valid and active e-mail address; and,
- 7.1.4 A valid and active contact number;

* Acceptable government-issued IDs include: Philippine Identification System ID, Driver's License, Passport, Unified Multi-Purpose ID (UMID), GSIS ID, SSS ID, PRC ID, IBP ID, Comelec Voter's ID, Senior Citizens ID, and Postal ID

7.2 For Stockholders with joint accounts

A scanned copy of an authorization letter signed by all Stockholders named in the joint account, identifying who among them is authorized to cast the vote for the account (in JPG or PDF format). The file size should be no larger than 2MB.

In addition, the authorized Stockholder must submit the requirements listed in No. 7.1 above.

7.3 For Stockholders under Broker accounts

7.3.1 A broker's certification on the Stockholder's number of shareholdings (in JPG or PDF format).

The file size should be no larger than 2MB;

7.3.2 A recent photo of the stockholder, with the face fully visible (in JPG format). The file size should be no larger than 2MB;

7.3.3 A scanned copy of the Stockholder's valid government-issued ID* showing photo and personal details, preferably with residential address (in JPG format). The file size should be no larger than 2MB;

7.3.4 A valid and active e-mail address; and,

7.3.5 A valid and active contact number.

7.4 For corporate Stockholders

7.4.1 A Secretary's Certificate attesting to the authority of the representative to vote for, and on behalf of the Corporation (in JPG or PDF format). The file size should be no larger than 2MB;

7.4.2 A recent photo of the stockholder's representative, with the face fully visible (in JPG format). The file size should be no larger than 2MB;

7.4.3 A scanned copy of the valid government-issued ID* of the stockholder's representative showing photo and personal details, preferably with residential address (in JPG format). The file size should be no larger than 2MB;

7.4.4 A valid and active e-mail address of the Stockholder's representative; and,

7.4.5 A valid and active contact number of the Stockholder's representative.

7.5 For stockholders to be represented by a proxy or authorized person

In addition to the above requirements for the Stockholder, the Proxy or authorized person shall submit the same requirements listed in No. 7.1 together with a scanned copy of the Proxy Form or an authorization letter signed by the Stockholder to cast the vote for the account. This must also be in a digital, JPG format with a file size no larger than 2MB.

8. You will receive an email from Euro-Med informing you that your registration will be subject to validation.
9. A Stockholder who registered on or before 9 June 2026 and whose registration has been validated will receive an email containing his Username and Default Password for use as login credentials to the online voting in absentia, and his Remote Communication Credentials to access the website link of the Annual Meeting, within three (3) business days from date of registration.

Important Note: Incomplete or inconsistent information may result in an unsuccessful registration. Stockholders who are not able to register successfully will not be given access to vote electronically in absentia, but they may still vote by submitting a duly accomplished proxy form, on or before 10 June 2026. Validation of proxies will take place on 11 June 2026.

HOW TO VOTE ONLINE:

1. Open <http://euromedlab.net/stockholders2026> in the address bar and press "Enter" key.
2. Login using your activated account. If your account is not yet activated please contact the Corporate Secretary at janice.ong@euromedlab.net.

3. After successful login, you may now proceed by clicking the voting link or tab. Start by filling in the required fields and select your preferred vote from the choices given.
4. All agenda items indicated in the Notice of the Meeting will be set out in the digital absentee ballot and the registered Stockholder may vote as follows:
 - 4.1 For items other than the Election of Directors, the registered Stockholder has the following options: **For**, **Against**, or **Abstain**. The vote is considered cast for all the registered Stockholder's shares.
 - 4.2 For the Election of Directors, the registered Stockholder may either (a) vote for all nominees, (b) not vote for any of the nominees, or (c) vote for some nominees only, in such number of shares as preferred by the Stockholder, provided that the total number of votes cast shall not exceed the number of shares owned, multiplied by the number of directors to be elected.

Once voting on the agenda items is completed, the registered Stockholder should proceed to submit the accomplished ballot by clicking the 'Submit' button. After the ballot has been submitted, Stockholders may no longer change their votes.

A Stockholder may cast his/her/its vote during the period beginning 28 May 2026 until 10 June 2026.

PARTICIPATION BY REMOTE COMMUNICATION

1. A Stockholder who has successfully registered on or before 9 June 2026 can participate in the Annual Meeting by accessing <http://meeting.euromedlab.net/> using his/her Remote Communication Credentials which will be sent thru the specified email given.
2. Only those Stockholders who have notified the Company of their intention to participate in the Meeting by remote communication, together with the Stockholders who voted in absentia and by proxy, will be included in determining the existence of a quorum.
3. A Stockholder may send his/her questions and/or comments about the items in the Agenda prior to or during the Annual Meeting to corporate@euromedlab.net. The Chairman will endeavor to reply to all the questions received but should, for any reason, a question not addressed, the Office of the Corporate Secretary will reply to the same by email.
4. In compliance with the requirements of the Securities and Exchange Commission, a recording of the proceedings of the Annual Meeting will be secured.

For any clarifications, please contact the Office of the Corporate Secretary through janice.ong@euromedlab.net.

PROXY FORM

THE UNDERSIGNED shareholder of **EURO-MED LABORATORIES PHIL. INC.** hereby appoints:

or in his/her absence, the Chairman of the Meeting, as its true and lawful attorney-in-fact or proxy to represent 100 percent of its voting rights and to vote on its behalf at the annual stockholders' meeting of the Corporation to be held on 17 June 2026, as follows:

	FOR	AGAINST	ABSTAIN
Approval of the Minutes of the Meetings held on 18 June 2025	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Approval of Management Report and the Audited Financial Statements as of 31 December 2025	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Ratification of all Acts and Resolutions of Management and the Board in 2025	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Election of the following as Directors of the Corporation for year 2026 -2027	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Vote shares as follows (Please check one):

- Equally to all ten (10) nominees for directors;
- Abstain for all ten (10) nominees for directors;
- Distribute or cumulate shares to the nominees as follows:

Name of Nominee	Yes*
Medialdea, Atty. Salvador C. (Independent Director)	_____
Lo, M.D., Raymundo W. (Independent Director)	_____
Javier, Dr. Emil Q. (Independent Director)	_____
Evidente, Georgiana S.	_____
Padolina, Dr. William G.	_____
Yap, Basilio C.	_____
Yap, Benjamin C.	_____
Yap Jr., Dr. Enrique Y.	_____
Yap, Dr. Johnny C.	_____
Gaw, Anthony Joseph Y.	_____
TOTAL**	

Appointment of Aquino, Mata, Calica and Associates as the External Auditor for the year 2026-2027	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
---	--------------------------	--------------------------	--------------------------

For any other matter arising during the meeting, the above-named proxy is authorized to vote as he/she may deem fit. This proxy revokes and supersedes any proxy or proxies the undersigned may have previously executed and shall not apply in instances where the undersigned personally attends such stockholders' meeting.

IN WITNESS WHEREOF, the undersigned stockholder has executed this proxy this _____ day of _____ 2026 at _____.

SIGNED IN THE PRESENCE OF:

(name in print below signature)

EURO-MED LABORATORIES PHIL. INC. is not soliciting proxies and a stockholder is NOT required to submit a proxy to **EURO-MED LABORATORIES PHIL. INC.** This Proxy form is being provided only for the convenience, and upon request, of a stockholder.

SECURITIES AND EXCHANGE COMMISSION

SEC FORM 20-IS

INFORMATION STATEMENT PURSUANT TO SECTION 20
OF THE SECURITIES REGULATION CODE

1. Check the appropriate box:

Preliminary Information Statement

Definitive Information Statement

2. Name of Registrant as specified in its charter EURO-MED LABORATORIES PHIL., INC.

3. **Philippines**

Province, country or other jurisdiction of incorporation or organization

4. SEC Identification Number **148022**

5. BIR Tax Identification Code **000-288-655-000**

6. **PPL Building, United Nations Avenue corner San Marcelino Street, Manila 1007**

Address of principal office

Postal Code

7. Registrant's telephone number, including area code **(02) 8524-0091 to 98**

8. **Date - 17 June 2026**

Time - 10:00 A.M.

Online web addresses/URLs

(for participation by remote communication) - <http://meeting.euromedlab.net>

(for voting in absentia) - <http://euromedlab.net/stockholders2026>

Date, time and place of the meeting of security holders

9. Approximate date on which the Information Statement is first to be sent or given to security holders
no later than 25 May 2026

10. Securities registered pursuant to Sections 8 and 12 of the Code or Sections 4 and 8 of the RSA (information on number of shares and amount of debt is applicable only to corporate registrants):

Title of Each Class

Number of Shares of Common Stock
Outstanding or Amount of Debt Outstanding

Common

4,112,140,540

11. Are any or all of registrants securities listed on a Stock Exchange?

Yes No

If yes, disclose the name of such Stock Exchange and the class of securities listed therein :

Philippine Stock Exchange - common

INFORMATION

A. GENERAL INFORMATION

Item 1. **Date, Time & Place of Meeting of Security Holders**

The annual shareholders' meeting of Euro-Med Laboratories Phil., Inc. (hereinafter the "Company" or "Euro-Med") shall be held on:

Date	17 June 2026
Time	10:00 a.m.
Place of Meeting	Remote Communication via Zoom
Mailing Address of the Principal Office of the Company	PPL Building United Nations Ave. cor. San Marcelino St. Manila, Philippines

This Information Statement and a copy of the Company's Management Report are to be sent out to qualified shareholders of record approximately on 25 May 2026.

WE ARE NOT ASKING YOU FOR A PROXY AND YOU ARE REQUESTED NOT TO SEND US A PROXY

Item 2. **Dissenter's Right of Appraisal**

Any dissenting stockholder may exercise his right of appraisal pursuant to Title X, Section 80 of the Revised Corporation Code of the Philippines.

Title X, Section 80 of the Revised Corporation Code of the Philippines allows a stockholder to exercise his right to dissent and demand payment of the fair value of his shares in certain instances, to wit: (1) in case an amendment to the articles of incorporation will change or restrict the rights of such stockholder, or authorize preferences in any respect superior to those of outstanding shares of any class, or extend or shorten the term of the company; (2) in case of the sale, lease, exchange, transfer, mortgage, pledge or other disposition of all or substantially all of the company's properties and assets; or (3) in cases of merger and consolidation; and (4) in case of investment of corporate funds for any purpose other than the primary purpose of the corporation.

Item 3. Interest of Certain Persons in Matters to be Acted Upon

- (a) The interests of incumbent directors and nominees to the Board in the matters to be acted upon in the meeting consist solely of security holdings to the extent described in the item on Security Ownership of Management on page 3.
- (b) The Company has not received any information from any director that he/she intends to oppose any matter to be acted upon in the meeting.

B. CONTROL AND COMPENSATION INFORMATION

Item 4. Voting Securities and Principal Holders Thereof

Shareholders of record at the close of business on 18 May 2026 (the "Record Date") shall be entitled to notice of, and to vote at, the Meeting. As of 30 April 2026, there are a total of Four Billion One Hundred Twelve Million One Hundred Forty Thousand Five Hundred Forty (4,112,140,540) Euro-Med shares that are issued and outstanding, each with a par value of One Peso (₱1.00) per share, held by 538 shareholders.

Each shareholder voting in the election of directors may cumulate such shareholder's votes and give one candidate the number of votes equal to the number of directors to be elected multiplied by the number of votes to which such shareholder's shares are entitled, or said shareholders may distribute such votes on the same principle among as many candidates as the shareholder chooses, provided that votes cannot be cast for more than the total number of directors to be elected at the meeting. However, no shareholder may cumulate votes for any candidate unless the candidate's name has been placed in nomination prior to the voting.

Each share has one vote on all other matters.

Security Ownership of Certain Record Owners

As of 30 April 2026, four (4) shareholders own more than five percent (5%) in the aggregate, of the outstanding stock of the Company, *to wit*:

<u>Title of Class</u>	<u>Name/ Address of Record Owner and Relationship with Issuer</u>	<u>Name of Beneficial Owner and Relationship with Record Owner</u>	<u>Citizen-ship</u>	<u>No. of Shares Held and Nature of Beneficial Ownership</u>	<u>% of Owner-ship</u>
Common	U.S. Automotive Co., Inc. * PPL Building United Nations Avenue, cor. San Marcelino Street, Manila Major stockholder	Yap Family Stockholder/ Director/ Officer	Filipino	2,401,747,112 (R)	58.41%
Common	USAUTOOCO, Inc. * PPL Building United Nations Avenue, cor. San Marcelino Street, Manila Major stockholder	Yap Family Stockholder/ Director/ Officer	Filipino	855,505,147 (R)	20.80%
Common	Philippine Trust Company ** United Nations Ave. cor. San Marcelino Street, Manila	Yap Family Stockholder/ Director/Officer	Filipino	365,111,291 (R)**	8.88%
Common	Evergreen Stock Brokerage & Securities, Inc. * 6/F Tower I Exchange Plaza Ayala Avenue corner Paseo de Roxas, Makati City	various clients	Filipino	298,725,323 (R)	7.26%

**These companies are expected to issue their respective proxies in favor of Mr. Basilio C. Yap, Vice Chairman and Director of the Company.*

***Per previous disclosure of the Top 100 Stockholders as of 31 March 2026, 133,986,446 shares out of the 365,111,291 shares in the name of Philippine Trust Company are held by the Trust Department.*

Security Ownership of Management

The entire capital stock of the Company consists of common shares. The directors merely own qualifying shares while the officers of the Company have no significant shareholdings therein. The following table presents the shareholdings of the incumbent directors and officers of the Company as of 30 April 2026.

<u>Title of Class</u>	<u>Name of Beneficial Owner</u>	<u>Amount and Nature of Beneficial Ownership</u>	<u>Citizenship</u>	<u>% of Ownership</u>
Common	Dr. William G. Padolina	20,564 (D)	Filipino	0.0005%
Common	Edwin D. Feist	11,607 (D)	Australian	0.0003%
Common	Georgiana S. Evidente	1,285,052 (D)	Filipino	0.0313%
Common	Evangeline V. Baviera, M.D.	41,645 (D)	Filipino	0.0010%
Common	Basilio C. Yap	20,564 (D)	Filipino	0.0005%
Common	Dr. Johnny C. Yap	36,980,720 (D)	Filipino	0.8993%
Common	Esperanza I. Cabral, M.D.	1,000 (D)	Filipino	0.00001%
Common	Benjamin C. Yap	1,000 (D)	Filipino	0.00001%
Common	Dr. Enrique Y. Yap, Jr.	41,125 (D)	Filipino	0.0090%
Common	Anthony Joseph Y. Gaw	586,617 (D)	Filipino	0.0142%
Common	Ma. Bernadette M. Doctor	20, 564 (D)	Filipino	0.0005%
Common	Jose A. Emitterio	205,610 (D)	Filipino	0.0050%
Common	Janice R. Ong	51,410 (D)	Filipino	0.0013%
Common	Rosanna Marie S. Suñga	20, 564 (D)	Filipino	0.0005%
Common	Virgilio V. Leyeza, Jr.	41,126 (D)	Filipino	0.0010%
Common	Dinah D. Trivilegio	4,116 (D)	Filipino	0.0001%

Mr. Basilio C. Yap, Mr. Benjamin C. Yap, Dr. Johnny C. Yap and Dr. Enrique Y. Yap, Jr. have indirect interests in the Company thru their ownership of 18.35%, 13.39%, 5.94% and 7.72% respectively in U.S. Automotive Co., Inc., which companies are the controlling stockholders of the Company.

Other than the abovementioned indirect interest of Mr. Basilio C. Yap, Mr. Benjamin C. Yap, Dr. Johnny C. Yap and Dr. Enrique Y. Yap, Jr., the security ownership of Management as above enumerated are all direct.

Voting Trust Agreement

There are no Voting Trust Agreements among holders of 5% or more shares.

Change in Control

There are no arrangements which may result in a change in control of Euro-Med.

Item5. Board of Directors/Executive Officers

In accordance with Section 23 of the Revised Corporation Code of the Philippines, the shareholders, and not the Company itself, nominate and elect the directors of the Company. Hence, the registrant herein, Euro-Med, is not nominating any person to the Board of Directors.

The Corporation maintains a Board of ten (10) Directors.

The following constitute the duly elected and incumbent Board of Directors of the Company:

1. Dr. William G. Padolina*
2. Mr. Edwin D Feist *
3. Esperanza I. Cabral, M.D. *
4. Mr. Basilio C. Yap
5. Dr. Johnny C. Yap
6. Mr. Benjamin C. Yap
7. Mrs. Georgiana S. Evidente
8. Evangeline V. Baviera, M.D.
9. Mr. Anthony Joseph Y. Gaw
10. Dr. Enrique Y. Yap, Jr.

** The Company's independent directors as required by Section 38 of the Securities Regulation Code.*

A brief description of the qualifications of the Directors is contained in Annex "A."

In its meeting on 24 March 2026, the Corporate Governance and Nomination Committee reported to the Board its approval of the nomination of the following as directors for the year 2026-2027:

1. Atty. Salvador C. Medialdea
2. Dr. Emil Q. Javier
3. Dr. Raymundo W. Lo
4. Mr. Basilio C. Yap
5. Mrs. Georgiana S. Evidente
6. Dr. Johnny C. Yap
7. Dr. William G. Padolina
8. Mr. Benjamin C. Yap
9. Mr. Anthony Joseph Y. Gaw
10. Dr. Enrique Y. Yap, Jr.

In the meeting mentioned above, the Chairman of the Corporate Governance and Nomination Committee confirmed that the nominees are qualified and eligible for directorship in the Company.

Atty. Salvador C. Medialdea, Dr. Emil Q. Javier and Dr. Raymundo W. Lo are nominated as independent directors in compliance with the recommendations contained in the SEC Memorandum Circular No. 19, Series of 2016. In its evaluation of nominees, the Corporate Governance and Nomination Committee has determined that they possess all the qualifications and none of the disqualifications of an independent director as set forth under Rule 38 of the Securities Regulation Code and the Company's Revised Manual on Corporate Governance. The nominees for independent directors have been advised of SEC Memorandum Circular No. 5, series of 2017 regarding the requirement to submit a Certificate of Qualification of Independent Director.

The nominees were also informed of SEC Memorandum Circular No. 7, Series of 2026 on the term limits for independent directors.

Dr. William G. Padolina has served the maximum cumulative term of nine (9) years as Independent Director and is now nominated as Non-Independent Director for 2026-2027.

The Corporate Governance and Nomination Committee is composed of:

Chairman - Dr. William G. Padolina (Independent Director)

- Member - Edwin D. Feist (Independent Director)
- Member - Esperanza I. Cabral, M.D. (Independent Director)
- Member - Mrs. Georgiana S. Evidente
- Member - Dr. Johnny C. Yap

In its regular meeting on 24 March 2026, the Board of Directors unanimously approved the list of nominees. The election of said directors will be submitted for approval of the stockholders at the Annual Stockholders' Meeting.

The following are the duly elected and incumbent Executive Officers of the Company: (A brief description of the qualifications of the Executive Officers is contained in Annex "A")

Chairman of the Board	Dr. William G. Padolina
Vice Chairman	Mr. Basilio C. Yap
Vice Chairman	Mr. Edwin D. Feist
President	Mrs. Georgiana S. Evidente
Executive Vice President,	Dr. Johnny C. Yap
Treasurer & Asst. Corp. Sec.	
Executive Vice President	Evangeline V. Baviera, M.D.
Senior Vice President, Chief Risk	Mr. Jose A. Emitterio
Officer & Compliance Officer	
Assistant Treasurer	Mrs. Ma. Bernadette M. Doctor
Corporate Secretary &	Mrs. Janice R. Ong
Investment Relations Officer	
Vice President	Mrs. Rosanna Marie S. Suñga
Vice President	Mrs. Isleen Y. Sy
Vice President	Mr. Virgilio V. Leyeza, Jr.
Vice President	Mrs. Dinah D. Trivilegio
Chief Accountant	Mrs. Sandra N. Pineda
Internal Audit Head	Mrs. Evelyn O. Mangguing
Data Protection Officer &	Atty. David Michael O. Gabriel
Legal Counsel	

Appraisals and Performance Report for the Board of Directors

The Corporate Governance and Nomination Committee of the Corporation oversees the performance evaluation of the Board of Directors in accordance with its Corporate Governance Manual and related SEC issuances. The Company conducts its annual performance evaluation through a Self-Evaluation Questionnaire. The questionnaire has been devised to enable assessment of the effectiveness of the Board and its individual members. The questionnaire is used to rate the extent to which the Board complies with each statement, on a scale of one (1) to five (5).

During the year 2025, the members of the Board indicated their compliance with the following criteria set forth in the Director’s Self-Evaluation Questionnaire.

The statements are as follows :

1. Board members support and debate the company’s strategic vision and values, as to how the Company should be evolving over the next 3 - 5 years.
2. Board members have a clear understanding of the company’s core business, its strategic direction and the financial resources necessary to meet its objectives.
3. Board members make decisions objectively and collaboratively in the best interest of the company and responsible for achieving the organizational goals.
4. Board members recognize the role, which they are expected to play and have the appropriate skills and experience for that role.
5. Board responds positively and constructively to events for effective decisions and implementation and encourage transparency.
6. Board members attend and actively contribute at meetings.
7. The Board has open channels of communication with the executive board and others.
8. The Board uses a well-structured process to manage risk, taking account the company’s activities and functions across the business.
9. Board members attend continuous training/seminar to meet individual development needs.
10. There is an appropriate succession planning for key Board members and Executive Board.
11. The Board sets measures on its performance on an annual basis.

This evaluation system was established by the Company to measure or determine the level of compliance of the Board and top-level management with the Company’s Manual on Corporate Governance.

The Board members likewise assessed the Board as a whole based on their diversity, competencies, background and experience. Board efficiency and importance, as well as Board activities were also given the appropriate ratings.

Results of the 2025 Board assessment showed an overall performance of *Fair* (scale of 3). While the overall performance was *Fair*, some key areas were assessed as needing improvement and additional plans will be developed to improve these key areas.

Based on the results of the assessment, the Corporate Governance and Nomination Committee formulates and implements plans to improve the performance of the Board as well as its individual members.

Training and Continuing Education Attended

On 08 November 2025, members of the Board of Directors and key officers of the Company attended an online course on Advanced Corporate Governance Training conducted by the Institute of Corporate Directors. The Corporate Secretary attended The Next Level in ESG & Sustainability conducted by The Center for Global Practices Foundation, Inc. last 06 November 2025.

Director Attendance Report

In 2025, the Board of Directors held a total of twelve (12) meetings: eleven (11) regular meetings and one (1) organizational meeting. Each Board member complied with the minimum total Board meeting attendance requirement of 50%.

Below is a summary of attendance of each Director to Board, stockholders and committee meetings for the year 2025:

1. Directors' Attendance in Regular and Organizational Board Meetings

Board	Name	No. of Regular & Organizational Board Meetings for year 2025	No. of Meetings Attended	%
Board Chairman/Independent	Dr. William G. Padolina	12	12	100%
Board Vice-Chairman/Independent	Mr. Edwin D. Feist	12	12	100%
Board Vice-Chairman/Member	Mr. Basilio C. Yap	12	12	100%
Board Member/Independent	Esperanza I. Cabral, M.D.	12	12	100%
Board Member	Mr. Johnny C. Yap	12	12	100%
Board Member	Mrs. Georgiana S. Evidente	12	11	92%
Board Member	Evangeline V. Baviera, M.D.	12	11	92%
Board Member	Mr. Benjamin C. Yap	12	12	100%
Board Member	Mr. Anthony Joseph Y. Gaw	12	12	100%
Board Member	Dr. Enrique Y. Yap, Jr.	12	11	92%

Board Meeting Dates	Meeting Type
January 28, 2025	Regular Board Meeting
February 25, 2025	Regular Board Meeting
March 25, 2025	Regular Board Meeting

April 29, 2025	Regular Board Meeting
May 27, 2025	Regular Board Meeting
June 28, 2025	Organizational Meeting
July 29, 2025	Regular Board Meeting
August 26, 2025	Regular Board Meeting
September 30, 2025	Regular Board Meeting
October 28, 2025	Regular Board Meeting
November 25, 2025	Regular Board Meeting
December 16, 2025	Regular Board Meeting

2. Directors who attended the 2025 Annual Stockholders' Meeting

Annual Stockholders Meeting 18 June 2025 Board Attendees	Name
Board Chairman/Independent	Dr. William G. Padolina
Board Vice-Chairman/Independent	Mr. Edwin D. Feist
Board Vice-Chairman/Member	Mr. Basilio C. Yap
Board Member/Independent	Esperanza I. Cabral, M.D.
Board Member	Mr. Johnny C. Yap
Board Member	Mrs. Georgiana S. Evidente
Board Member	Evangeline V. Baviera, M.D.
Board Member	Mr. Benjamin C. Yap
Board Member	Mr. Anthony Joseph Y. Gaw
Board Member	Dr. Enrique Y. Yap, Jr.

3. Attendance in Corporate Governance & Nomination Committee Meeting

Position	Name	No. of Committee Meetings for year 2025	No. of Meetings Attended	%
Committee Chairman	Dr. William G. Padolina	1	1	100%
Committee Member	Mr. Edwin D. Feist	1	1	100%
Committee Member	Esperanza I. Cabral, M.D.	1	1	100%
Committee Member	Mr. Johnny C. Yap	1	1	100%
Committee Member	Mrs. Georgiana S. Evidente	1	1	100%

4. Attendance in Audit & Risk Oversight Committee Meeting

Position	Name	No. of Committee Meetings for year 2025	No. of Meetings Attended	%
Committee Chairman	Mr. Edwin D. Feist	1	1	100%
Committee Member	Dr. William G. Padolina	1	1	100%
Committee Member	Mr. Anthony Joseph Y. Gaw	1	1	100%

Family Relationship

Mr. Basilio C. Yap, the Vice Chairman of the Board is the uncle of Dr. Johnny C. Yap, Executive Vice President, Treasurer and Asst. Corporate Secretary of Euro-Med Laboratories Phil., Inc. Dr. Johnny C. Yap, Dr. Enrique Y. Yap, Jr. and Mr. Anthony Joseph Y. Gaw are cousins and are nephews of the Vice Chairman, Basilio C. Yap.

Mr. Benjamin C. Yap is the older brother of Vice Chairman Basilio C. Yap, uncle of Dr. Johnny C. Yap, Dr. Enrique Y. Yap, Jr. and Mr. Anthony Joseph Y. Gaw.

There are no other family relationships known to the registrant other than the ones disclosed.

Involvement in Legal Proceedings

None of the Directors and Executive Officers of the Company is involved in any of the following in the past five (5) years:

1. A bankruptcy petition by or against any business of which such person was a general partner or Executive Officer either at the time of the bankruptcy or within two (2) years prior to that time;
2. A conviction by final judgment in a criminal proceeding, domestic or foreign, or is being subject to a pending criminal proceeding, domestic or foreign, excluding traffic violations and other minor offenses;
3. An order, judgment, or decree, not subsequently reversed, suspended or vacated, by any court of competent jurisdiction, domestic or foreign, permanently or temporarily enjoining, barring, suspending or otherwise limiting his involvement in any type of business, securities, commodities or banking activities; nor,
4. A conviction by a domestic or foreign court of competent jurisdiction in a civil action, the Commission or comparable foreign body or a domestic or foreign exchange or other organized trading market or self-regulatory organization, to have violated a securities or commodities law or regulation, and the judgment has not been reversed, suspended or vacated.

Significant Employees

The Company acknowledges that each employee contributes to its success. However, it is not dependent on any single employee or group of employees for its operations.

Certain Relationships and Related Transactions

Except for the transactions disclosed in Note 18 of the accompanying Audited Financial Statements of the Company, there are no other transactions or proposed transactions with or involving the Company or any of its subsidiaries during the last two (2) years in which a director, executive officer or stockholder who owns ten percent (10%) or more of the total outstanding shares of the Company and members of their immediate family had or is to have a direct or indirect material interest therein.

The purpose and economic substance of the aforementioned related transactions, as well as their effect on the financial statement and their special risks or contingencies, are as follows:

- a.) The Company is leasing its office at PPL Building, United Nations Avenue corner San Marcelino Street, Manila from US Automotive Co., Inc., a majority stockholder of the Company. The lease is for one (1) year period and is being renewed annually subject to mutual agreement of the parties. The rent charged by management is based on the lease rates charged to the other tenants in the building and in the vicinity. The rent for the period January to December 2025 and 2024 amounted to ₱21.6 million and ₱21.2 million respectively. Dividends paid in cash, amounted to ₱168.1 million for year 2025. No outstanding payable as of December 31, 2025. There are no other ongoing contractual or other commitments as a result of the arrangement.
- b.) The Company has advances to its 100% subsidiary CafeFrance Corp. amounting to ₱998.4 million in 2025 and 2024. Sales to CafeFrance Corp., amounted to ₱1.0 million for the year 2025 and ₱1.2 million for the year 2024, and accounts receivable of ₱10.6 million in 2025 and ₱10.3 million in 2024. Sales to Hemotek Renal Center, Inc. amounted to ₱157.2 million for the year 2025 and ₱143.0 million for the year 2024, and accounts receivable of ₱783.2 million in 2025 and ₱755.8 million in 2024. The sales prices charged to Hemotek and CafeFrance are competitive as those charge to other regular customers. There are no ongoing contractual or other commitments as a result of the arrangement.
- c.) The Company engages in regular bank transactions with Philtrust Bank, an affiliated local commercial bank. Transactions are for deposits and withdrawals requirements of the company. Deposit balances as of December 31, 2025 and 2024 amounted to ₱340.3 million and ₱212.6 million respectively. There are no ongoing contractual or other commitments as a result of the arrangement.
- d.) The Company avails of advertising services of Manila Bulletin Publishing Corp., an affiliate under common control. Advertising rates charged are the same as charged to other regular customers. Total services purchased for

January to December 2025 and 2024 amounted to ₱1.03 million and ₱1.3 million respectively. There are no ongoing contractual or other commitments as a result of the arrangement.

e.) The Company avails of hotel services of Manila Hotel, an affiliate under common control. Hotel charges are the same as charged to other regular customers. Total services purchased for January to December 31, 2025 and 2024 amounted to ₱1.7 million and ₱2.3 million respectively. There are no ongoing contractual or other commitments as a result of the arrangement.

- The Company has no material transactions (that may not be available from others) with other parties falling outside the definition of “related parties”.

Item 6. Compensation of Directors and Top Executive Officers

Summary Compensation Table (in Philippine Peso)

Annual Compensation

	Year	Salary	Bonus	Others*
Georgiana S. Evidente <i>President / CEO</i>	2026 (Estimate)	4,871,790	405,983	685,756
Johnny C. Yap <i>Executive Vice-President / Treasurer</i>				
Evangeline V. Baviera <i>Executive Vice-President</i>	2025	4,782,493	616,695	670,063
Jose A. Emitterio <i>Senior Vice-President</i>	2024	7,357,922	969,045	951,662
Sandra N. Pineda <i>Chief Accountant</i>				

All other Officers and Directors as a group unnamed	2026 (Estimate)	19,917,097	995,656	3,167,496
	2025	19,927,640	1,955,196	2,895,361
	2024	19,379,856	2,250,386	3,139,730

Standard Arrangements. Except for per diems of ₱30,000.00 for the Chairman, ₱20,000.00 for the Vice Chairman and ₱10,000.00 per Director per Board meeting, there are no other standard arrangements pursuant to which directors of the Company are compensated or are expected to be compensated directly or indirectly, for any service provided directly or indirectly to the Company during the Company's last fiscal year and the ensuing year.

Compensation of Directors for the Year 2025

In compliance with Sections 29 and 49 of the Revised Corporation Code on the total compensation of each director, the Directors of the Company actually received the compensation stated below for the year 2025:

Name of Director	Total Compensation Received in 2025
Dr. William G. Padolina	₱ 360,000
Mr. Edwin D. Feist	₱ 240,000
Esperanza I. Cabral, M.D.	₱ 120,000
Dr. Basilio C. Yap	₱ 120,000
Mrs. Georgiana S. Evidente*	₱3,796,012
Dr. Johnny C. Yap*	₱3,188,294
Evangeline V. Baviera, M.D.*	₱3,081,404
Mr. Benjamin C. Yap	₱ 120,000
Mr. Anthony Joseph Y. Gaw	₱ 120,000
Dr. Enrique Y. Yap, Jr.	₱ 120,000

*Inclusive of salary as Executive Director

Warrants and Options Outstanding. No warrants or options on the Company's shares of stock have been issued or given to the Directors or Executive Officers as a form of compensation for services rendered.

Item 7. Independent Public Accountants

Mendoza, Querido & Co., CPA's was appointed External Auditor for the years 2018 to 2021. As the Audit & Risk Oversight Committee Charter prescribes the rotation of the External Auditor after every three to five years pursuant to SEC Rule 68, the

Committee recommended the engagement of Aquino, Mata, Calica and Associates as External Auditor for the period 2022-2023, which was approved and ratified by the stockholders during the annual stockholders' meeting on 15 June 2022.

For the fiscal years 2023-2024, 2024-2025 and 2025-2026, the Audit & Risk Oversight Committee also recommended the engagement of Aquino, Mata, Calica and Associates as External Auditor. The appointment was ratified and approved by the stockholders during the annual stockholders' meetings held on 21 June 2023, 19 June 2024 and 18 June 2025. Aquino, Mata, Calica and Associates' accreditation was renewed by the Securities and Exchange Commission last July 25, 2023 and it was classified under Group A. The accreditation is valid for a period of five years.

In its meeting held on 24 March 2026, the Audit & Risk Oversight Committee recommended the appointment of Aquino, Mata, Calica and Associates as External Auditor of the Company for the fiscal year 2026-2027. Representatives of the said auditing firm are expected to be present during the annual stockholders' meeting on 17 June 2026 and they will have the opportunity to make a statement if they desire to do so and to respond to appropriate questions.

There were no disagreements with the Company's accountants on any accounting and financial disclosure during the recent fiscal year or any subsequent interim period.

The Audit and Risk Oversight Committee is composed of:

- Chairman - Mr. Edwin D. Feist (Independent Director)
- Member - Dr. William G. Padolina (Independent Director)
- Member - Mr. Anthony Joseph Y. Gaw (Non-Executive Director)

The Financial Statements of the Corporation duly approved by the Audit Committee are submitted to the Board of Directors for final approval prior to their release.

C. ISSUANCE AND EXCHANGE OF SECURITIES

Item 8. Authorization or issuance of Securities Other than for Exchange

No action will be presented for stockholders' approval at this year's Annual Stockholders' Meeting that involves the authorization or issuance of any securities.

Item 9. Modification or Exchange of Securities

No action will be presented for stockholders' approval at this year's Annual Stockholders' Meeting which involves the modification of any class of the Corporation's securities or the issuance of one class of the Corporation's securities in exchange for outstanding securities of another class.

Item 10. Financial and Other Information

Please refer to the accompanying Management Report and Audited Financial Statements of the Company. The Company has incorporated by reference the Audited Financial Statements, Management's Discussion and Analysis, and other data related to the Company's financial information for the period ending 31 December 2025 and 31 March 2026 in its Management Report prepared in accordance with Rule 68 of the Securities Regulation Code.

Item 11. Mergers, Consolidations, Acquisitions, and Similar Matters

No action will be presented for stockholders' approval at this year's Annual Stockholders' Meeting with respect to (i) merger or consolidation of the Company with any other person, (ii) acquisition by the Corporation or any of its stockholders of securities of another person, (iii) acquisition by the Company of any other going business or of the assets thereof, (iv) the sale or transfer of all or any substantial part of the assets of the Company, nor (v) liquidation or dissolution of the Company.

Item 12. Acquisition or Disposition of Property

No action will be presented for stockholders' approval at this year's Annual Stockholders' Meeting with respect to acquisition or disposition of property of the Corporation.

Item 13. Restatement of Account

No action will be presented for stockholders' approval at this year's Annual Stockholders' Meeting, which involves the restatement of any of the Corporations' assets, capital, or surplus account.

D. OTHER MATTERS

Item 14. Action with Respect to Reports

The minutes of the previous Annual Stockholders' Meeting held on 18 June 2025 was prepared by the Corporate Secretary, Janice R. Ong, and will be submitted to the shareholders for approval. A copy of the minutes of the previous stockholders' meeting was made available in the Company's website at <https://euromedlab.net>.

SUMMARY OF MINUTES OF THE 2025 ANNUAL MEETING

At the Annual Meeting of Shareholders of Euro-Med Laboratories Phil., Inc. held on 18 June 2025 in which a quorum was present and acting throughout, the following matters were approved:

1. The minutes of the previous stockholders' meeting was approved.
2. The Management Report for fiscal year 2024 and Audited Financial Statements as of 31 December 2024 were approved.
3. The acts of the Board of Directors and the Management for the previous year were ratified by the shareholders.
4. The re-nomination of Dr. William G. Padolina and Mr. Edwin D. Feist as Independent Directors.
5. The following were elected to the Board of Directors for the year 2025-2026:
 - Dr. William G. Padolina (Independent Director)
 - Mr. Edwin D. Feist (Independent Director)
 - Esperanza I. Cabral, M.D. (Independent Director)
 - Mr. Basilio C. Yap
 - Dr. Johnny C. Yap
 - Mr. Benjamin C. Yap
 - Mrs. Georgiana S. Evidente
 - Evangeline V. Baviera, M.D.
 - Mr. Anthony Joseph Y. Gaw
 - Dr. Enrique Y. Yap, Jr.
6. The appointment of the auditing firm Aquino, Mata, Calica and Associates as External Auditor for the year 2025 was approved and ratified.

For the last year's stockholders' meeting, the stockholders who successfully completed the registration and validation process cast their votes by logging in at <http://euromedlab.net/stockholders2025> and accomplishing the virtual ballot posted therein. The stockholders had until 11 June 2025 to vote. Proxies were also sent to the Corporate Secretary on or before 12 June 2025.

Stockholders had an opportunity to ask questions regarding the items in the agenda for the 2025 Annual Stockholders' Meeting. They were given until 12 June 2025 to send queries, clarifications and comments. However, the Company did not receive any questions during the period allotted, hence, no disclosure on the questions asked and responses given can be included in this report.

During the meeting, the Chairman of the Board opened the floor to questions/comments however, none was received.

In compliance with Section 49 of the Revised Corporation Code, a record of the resolutions reached, voting results for each agenda item and the list of directors, officers and stockholders who attended the Annual Stockholders' Meeting held on 18 June 2025 is attached to this report as Annex "B".

The votes cast *in absentia* and via proxies were validated and counted under the supervision of the Office of the Corporate Secretary and the Company's stock transfer agent. The same method of voting and counting will be implemented this year.

Item 15. Matters Not Required To Be Submitted

Ratification of Legal Acts, Proceedings and Resolutions for 2025

Also submitted for approval of the stockholders are the acts, proceedings and resolutions approved by the Board of Directors and Officers of the Company for the fiscal year ending 31 December 2025. A copy of the Management Report (Annual Report) and the Audited Financial Statements of the Company for the period ended 31 December 2025 will be posted on the website of the Company.

Please refer to Annex "C" for the summary of the acts, proceedings and resolutions of the Board of Directors and Officers for ratification. A stockholder may also wish to verify with the Exchange the disclosures made by the Company during the year.

Item 16. Other Proposed Actions

1. Election of Directors

Ten (10) Directors will be elected for the year 2026 – 2027.

2. Appointment of External Auditor

The current External Auditor will be appointed for the year 2026 – 2027.

Other than the matters indicated in the Notice and the Agenda included in this Information Statement, there are no other actions proposed to be taken at this year's Annual Stockholders' Meeting.

Item 17. Voting Procedures

- (a) Every stockholder of record as of the close of business hours on 18 May 2026 shall have the right to vote, either *in absentia* or by proxy, the number of shares registered in his name. Stockholders who have successfully registered online will receive a link to an online voting platform for purposes of voting *in absentia*.
- (b) Stockholders may also vote via proxy. A sample proxy will be posted on the website of the Corporation. Proxies, signed by the stockholders and duly submitted to the Corporate Secretary through electronic mail at janice.ong@euromedlab.net on or before 10 June 2026 for inspection and recording, shall be honoured for purposes of voting. Validation of proxies shall be held on 11 June 2026.
- (c) The affirmative vote of at least a majority of the stockholders who voted *in absentia* or by proxy shall be sufficient to carry the vote for any of the matters submitted to a vote at the Annual Stockholders' Meeting, except for the election of Directors.
- (d) For the election of directors, the system of cumulative voting shall be followed. Each stockholder has a number of votes equal to the number of shares he owns multiplied by ten (10), the number of Directors to be elected. The stockholder has the option to (i) cast all votes in favor of one (1) nominee, or (ii) cast votes for as many Directors to be elected, or (iii) distribute the votes among as many nominees he shall see fit. The total number of votes cast by the stockholder shall not exceed the number of shares owned by him multiplied by the number of Directors to be elected. The nominees with the ten highest votes shall be elected Directors of the Company.

UNDERTAKING

THE COMPANY HEREBY UNDERTAKES TO PROVIDE SEC FORM 17-A TO ANY SHAREHOLDER REQUESTING FOR THE SAME, FREE OF CHARGE, UPON RECEIPT OF A WRITTEN REQUEST FROM ANY SUCH INTERESTED SHAREHOLDER. ANY SUCH WRITTEN REQUEST MAY BE SENT TO THE MAILING ADDRESS AT PPL BUILDING, UNITED NATIONS AVENUE CORNER SAN MARCELINO STREET, MANILA, PHILIPPINES.

SIGNATURE

After a reasonable inquiry and to the best of my knowledge and belief, I hereby certify that the information set forth in this report is true, complete and correct.

This report is signed on 21 May 2026 in Manila.

EURO-MED LABORATORIES PHIL., INC.

By:

A handwritten signature in black ink, appearing to read 'JANICE R. ONG', is written over a vertical line that serves as a signature line.

JANICE R. ONG

Corporate Secretary & Investment Relations Officer

ANNEX "A"

Below is a brief description of the qualification/s of the nominees to the Board for 2026-27 as well as that of executive officers.

DR. WILLIAM G. PADOLINA

Chairman of the Board

Director since 1999

79 years of age

Dr. William G. Padolina, married, Filipino, graduated magna cum laude from the University of the Philippines, Los Baños with the degree of Bachelor of Science in Agricultural Chemistry in 1968. Subsequently as a Fulbright-Hays Scholar, he obtained his Ph.D in Botany/Phytochemistry in 1973 from the University of Texas at Austin. Upon his return from studies abroad, he continued teaching at the Institute of Chemistry, University of the Philippines Los Baños where he became a full Professor of Chemistry in 1987. He was a Consultant for Euro-Med Laboratories Phil., Inc. from 1990 to 1992. Dr. Padolina was appointed as an Undersecretary, Acting Secretary and Secretary of Department of Science and Technology from September 1992 to January 1999. He served as Deputy Director General of the International Rice Research Institute in Los Banos, Laguna from February 1999 to November 2011 and also served as Senior Advisor in 2012. He was first appointed Chairman of the Board of Euro-Med Laboratories Phil., Inc. on 17 May 2010 and is still the incumbent Chairman of the Board of the Company, He is currently a Senior Fellow at the Southeast Asian Center for Graduate Study and Research in Agriculture. He was elected President of the National Academy of Science and Technology, Philippines in October 2012 for a term of three years. Dr. Padolina has attended various trainings on Corporate Governance, the most recent of which is the Advanced Corporate Governance Training conducted by the Institute of Corporate Directors (ICD) held last November 8, 2025.

MR. BASILIO.C YAP*

Vice Chairman/Director

Director since 2014

76 years of age

Mr. Basilio C. Yap, Filipino, graduated from De La Salle University with the degree of Bachelor of Science in Commerce major in Accounting, graduated Cum Laude in 1972, a Certified Public Accountant and Asian Institute of Management with the degree of Masters in Business Management in 1977. He has held the position of Assistant Vice President in Bank of America up to 1985. He is currently the Chairman, President and a Director of U.S. Automotive Co. Inc., Usautoco Inc., Philtrust Realty Corporation, Manila Prince Hotel, Cocusphil Development Corporation, U.N. Properties

Development Corporation and Seebreeze Enterprises, Inc.; the Vice Chairman and Director of Philtrust Bank; and Director of Manila Hotel Corporation. Mr. Yap was elected Director of Euro-Med on 18 June 2014. He has attended various trainings on Corporate Governance, the most recent of which is the Advanced Corporate Governance Training conducted by the Institute of Corporate Directors (ICD) held last November 8, 2025.

RAYMUNDO W. LO, MD, FPSP, FCAP, FASCP

Nominee for Independent Director

74 years of age

Dr. Lo is an American-trained and board-certified anatomic and clinical pathologist, with a subspecialty in immunopathology. He is a pioneer in laboratory testing, specifically in immunologic testing including transplantation testing and paternity testing.

He is recognized by his pathologist-peers and holds the distinction of being awarded Pathologist of the Year (2x), Liborio Gomez Memorial Lecturer, and Distinguished Service Awardee by the Philippine Society of Pathologists Inc. In addition, he was also named Most Distinguished Alumnus 2025 by the University of the Philippines Medical Alumni Association and is a nominee for Outstanding Alumnus by the UP Alumni Association.

His career spans several decades in public and private hospitals. At the Philippine Children's Medical Center, he was the chief of Pathology, Allied Medical Department Manager and Deputy Executive Director for Professional Services, retiring in 2016. Dr. Lo's private practice in St. Luke's Medical Center is where he pioneered many laboratory techniques. He established and head the Cellular Immunology and Immunogenetics section and is the director of the St. Luke's Medical Center Relationship Testing Laboratory, which is the only one accredited in the Philippines and the first outside the Western Hemisphere by the Association for the Advancement of Blood and Biotherapies (AABB). His laboratory caters to most embassies (including the American embassy) for their immigration cases.

Dr. Lo recognized as the authority on relationship testing, is often called on to testify in court on paternity cases. He is in demand as well as a speaker in medical conventions and has authored many research articles, including those on COVID-19 RT-PCR testing. He also writes a weekly column in the Manila Bulletin under the byline, Under the Microscope, for which he was awarded the Best Newspaper Columnist 2023 by the People's Management Association of the Philippines (PMAP).

His spare time is devoted to purebred dogs, and his Pekingese are known around the world with the American Kennel Club bestowing the Breeder of Merit Gold Level on

his achieving over 50 of his Pekingese becoming American champions. He is an all-breed dog judge and has officiated at dog shows around the world.

Another of Dr. Lo's passions is orchid breeding, where he has produced many hybrids registered with the Royal Horticultural Society in London.

Dr. Lo believes that whatever one does, he must do with passion and integrity. That philosophy has served him well.

DR. EMIL Q. JAVIER
Nominee for Independent Director
85 years of age

Dr. Emil Q. Javier is a Filipino plant geneticist and agronomist best known for having served as the 17th President of the University of the Philippines between 1993 and 1999. He was conferred the rank of National Scientist of the Philippines for contributions in Agriculture in August 2019.

He holds a degree of M.S. Agronomy from the University of Illinois and earned his Ph.D. in Plant Breeding and Genetics from Cornell University, his master's degree from the University of Illinois at Urbana-Champaign and bachelor's degree from the University of the Philippines College of Agriculture (now the University of the Philippines Los Baños) graduated Cum Laude.

Dr. Javier served as President of the University of the Philippines System from 1993 to 1999. His administration oversaw the creation of the UP Open University and UP Mindanao, as well as the formal institutionalization of the Ugnayan ng Pahinungod volunteer service program. He likewise advanced the university's biotechnology efforts by consolidating them into the National Institutes of Molecular Biology and Biotechnology (NIMBB), a multi-campus network spanning major UP constituent universities.

He is currently the Chairman of the University's Audit Committee and a member of the Nomination Committee. He is a Trustee of the Asia Rice Foundation, Head Advisor of the Biotech Coalition of the Philippines and Academician of the National Academy of Science and Technology (Phil.) He is likewise a Board Member of the International Service for the Acquisition of Agri-Biotech Applications (South East Asia Center), and Nutrition Center of the Philippines. He is also an Independent Director of Centro Escolar University Hospital, Inc. and an Independent Director of Del Monte Pacific Ltd. and Member, Advisory Committee of Japan International Cooperation Agency (JICA) Philippines.

ATTY. SALVADOR C. MEDIALDEA

Nominee for Independent Director

74 years of age

Atty. Salvador Campo Medialdea is a Filipino lawyer and former government official. He served as the Executive Secretary from 2016 to 2022 in the administration of President Rodrigo Duterte. He previously served as Presidential Assistant for Political Affairs and president of the National Livelihood Development Corporation under President Joseph Estrada.

He received his BS Commerce Major in Management from Colegio de San Juan de Letran in 1972 and his law degree from San Beda College of Law in 1976. He passed the bar exams the following year.

Medialdea began his legal career as a senior associate at ACCRA Law Offices. He then worked as a partner at Pecabar Law Offices before becoming a managing partner at Medialdea Ata Bello Guevarra Suarez Law Firm (MABGS).

From 1998 to 2000, he served as chairman of the Northern Foods Corporation based in Sarrat, Ilocos Norte. He began work in government in 1998 at the Livelihood Corporation (now National Livelihood Development Corporation). He became a member of the board of trustees and administrator of the government-owned corporation while also serving as chairman of the Guarantee Fund for Small and Medium Enterprises. In 2000, he was appointed by Estrada as presidential assistant for political affairs.

Medialdea still serves as partner at the MABGS law firm. He is also director for Manchester International Holdings and Accette Insurance. He also served briefly as bar examiner for the Supreme Court in 2006.

MRS. GEORGIANA S. EVIDENTE

Director and President

Director since 1993

66 years of age

Mrs. Georgiana S. Evidente, married, Filipino, holds a degree of Bachelor of Arts in Communication Arts from Maryknoll College in Quezon City. She joined the Company in 1990 and assisted in the completion of the Cavite plant. In 1991, she was promoted to Vice President and was responsible for setting up the nationwide marketing and distribution network of the Company. Through her management and marketing efforts, Euro-Med's domestic sales grew to what it is today and export sales were developed. She is the President and Chief Executive Officer of the Company with over 20 years of marketing and management experience. Mrs. Evidente was elected Director of Euro-Med in 1993 to present. She has attended various trainings on Corporate Governance in,

the most recent of which is the Advanced Corporate Governance Training conducted by the Institute of Corporate Directors (ICD) held last November 8, 2025.

DR. JOHNNY C. YAP*

Director, Executive Vice President, Treasurer and Asst. Corp. Secretary

Director since 1994

53 years of age

Johnny C. Yap, Filipino, graduated from De La Salle University in 1993 with the degree of Bachelor of Science in Management of Financial Institutions. He was consistently in the Dean's List and was awarded "Best in Thesis" for his work, "Derivation of the Security of the Market Line". He joined the Company in 1993 and subsequently became a Director, Assistant Treasurer and Assistant Corporate Secretary. He became a Director of the Company in 1994. At present, he is a Director and the Treasurer of the Company. He is also the Director and Chief Financial Officer of Centro Escolar University (CEU). In January 01, 2009, he was promoted to Executive Vice President of Euro-Med Laboratories Phil., Inc. On March 21, 2010, Foundation University, Dumaguete conferred upon him the degree of Doctor of Humanities. He served as Director of Philtrust Bank from April 25, 2012 until April 26, 2016. He is currently the Chairman of the Board of CafeFrance Corp., a wholly owned subsidiary of Euro-Med Laboratories Phil., Inc. Dr. Yap has attended various trainings on Corporate Governance, the most recent of which is the Advanced Corporate Governance Training conducted by the Institute of Corporate Directors (ICD) held last November 8, 2025.

MR. BENJAMIN C. YAP*

Director

Director since 2016

80 years of age

Mr. Benjamin C. Yap, Filipino, graduated from the University of the East with a Bachelor's Degree in Business Administration. Currently, Mr. Yap is the Chairman of the Board of Benjamin Favored Son, Inc. and House of Refuge Foundation. He is a Director of USAUTOOCO Inc., Manila Hotel Corporation and Centro Escolar University. Mr. Yap was elected Director of Euro-Med on 15 June 2016. He has attended various trainings on Corporate Governance, the most recent of which is the Advanced Corporate Governance Training conducted by the Institute of Corporate Directors (ICD) held last November 8, 2025.

DR. ENRIQUE Y. YAP, JR.*

Director

Director since 2020

51 years of age

Dr. Enrique Y. Yap, Jr., is a Director and Vice President of Business Development at Manila Bulletin Publishing Corp. He is also the Executive Vice President and Director of Manila Hotel Corporation and the CEO, President and member of the Board of Directors of Tim Hortons Philippines, Inc. He is one of the recipients of the Ten Outstanding Manilan Awardee 2012 conferred by the Hon. Alfredo S. Lim (Former Mayor of the City of Manila). He holds a Doctorate degree in Business Administration (Honoris Causa) from the Polytechnic University of the Philippines. He is additionally a Director of U.S. Automotive Co., Inc., USAUTOCO. Inc., U.N. Properties Development Corporation, Manila Prince Hotel Corporation, Philtrust Bank, Philtrust Realty Corporation, and Centro Escolar Las Piñas, Inc. He was elected Director of Euro-Med last 14 August 2020. Dr. Yap has completed the General Management Program at Harvard Business School. Obtained his Master of Business Administration from New York University Stern School of Business, London School of Economics and Political Science and HEC Paris School of Management. Dr. Yap has attended trainings on Corporate Governance, the most recent of which is the Advanced Corporate Governance Training conducted by the Institute of Corporate Directors (ICD) held last November 8, 2025.

MR. ANTHONY JOSEPH Y. GAW

Director

Director since 2021

37 years of age

Anthony Joseph Y. Gaw, Filipino, graduated with a Bachelor's Degree in Business Administration from the International Academy of Management and Economics in 2008. He also obtained his Master's degree in Business Management from the same institution in 2012. He is currently the President of Goldclass Inc. At present he is serving as a private PA rifleman at the Service Company Headquarters, 402nd IBFTR CDC at Camp Riego de Dios, Cavite. He was elected Director of Euro-Med last 16 June 2021. Dr. Yap has attended trainings on Corporate Governance, the most recent of which is the Advanced Corporate Governance Training conducted by the Institute of Corporate Directors (ICD) held last November 8, 2025.

MRS. JANICE R. ONG
Corporate Secretary & Investment Relations Officer
55 years of age

Mrs. Janice R. Ong, married, Filipino, graduated from St. Scholastica's College with a degree of Bachelor of Arts in Mass Communication. After graduation, she joined Banco de Oro. In January 1992, she joined Euro-Med as Secretary to the Executive Vice President. She was promoted to Manager in 1999 and was elected by the Board of Directors as Corporate Secretary on September 01, 2007. She was appointed as Investment Relations Officer last 2013. Currently, Mrs. Ong was appointed as Asst. Treasurer and Corporate Secretary of Hemotek Renal Center, Inc. and Corporate Secretary of CafeFrance Corp., a subsidiaries of the Corporation.

EVANGELINE V. BAVIERA, M.D.
Executive Vice President
71 years of age

Dr. Evangeline V. Baviera, married, Filipino, graduated in 1976 from the University of the Philippines with the degree of Bachelor of Science in Pre-Medicine. She completed her course in Medicine at the University of the East Ramon Magsaysay Memorial Medical Center in 1980. After graduation, she took her specialization in Pediatrics in the hospital of the same university. In 1986, she became a faculty member of the Department of Pharmacology. She served as a consultant to the Bureau of Food and Drugs from 1988 to 1990. She was the Chairman of the Department of Pharmacology, De La Salle University Health Science Campus in Dasmariñas, Cavite from 1990 to 1992. In 1990, she joined Euro-Med as a medical consultant and subsequently became the Medical Director. She was promoted to Vice President in 1992 and Senior Vice President in 1997. She became a Director of the Company in 1996. Dr. Baviera is the head of all plant operations. She was promoted to Executive Vice President of the Company in 2004.

MR. JOSE A. EMITERIO
Senior Vice President, Chief Risk Officer & Compliance Officer
75 years of age

Mr. Jose A. Emitterio, married, Filipino, graduated from the University of the East with a degree of Bachelor of Science in Commerce, major in Accounting in 1972. Subsequently, he passed the board examination for Certified Public Accountant (CPA) in 1973. He worked with a bank for nine (9) years in various positions, the latest of which was as a branch manager until his resignation in 1983. In 1984, he became a faculty member of the Department of Accountancy in National College of Business and Arts (NCBA) and engaged in public accountancy. He joined the Company in 1992 as its Chief Accountant. He was promoted to Vice President in 1998 and to Senior Vice President in 1999, the

position he occupied until his resignation in January 2004. He rejoined the Company in January 2007 as Senior Vice President. On March 28, 2017, the Board approved his appointment as Chief Risk Officer and Compliance Officer of the Company.

MRS. ROSANNA MARIE S. SUÑGA

Vice President

59 years of age

Mrs. Rosanna Marie S. Suñga, married, Filipino, graduated from University of the Philippines, Diliman with the degree of Bachelor of Arts in Mass Communication. After graduation, she joined an airline industry for eight years in the field of customer service and airline operations. In 1997, she joined Euro-Med as Executive Assistant and subsequently became Personnel Manager in 1999. She was promoted to Vice President on July 01, 2004.

MRS. ISLEEN Y. SY

Vice President

50 years of age

Mrs. Isleen Yu-Sy, married, Filipino, graduated from the University of the Philippines in 1997 with the degree of Bachelor of Science in Pharmacy. In June 1999, she joined Euro-Med as a purchasing assistant and was promoted to materials manager in January 2001. She earned her Master's Degree in Business Administration in 2004 from the University of the Philippines. In January 01, 2009, she was promoted to Vice President.

MRS. DINAH D. TRIVILEGIO

Vice President

49 years of age

Mrs. Dinah D. Trivilegio, married, Filipino, graduated as a gold medalist from Centro Escolar University in 1993 with the degree of Bachelor of Science in Pharmacy. She joined Euro-Med in 1997 as a production pharmacist. In January 2000, she was promoted to Assistant Production Manager, Cavite Plant and to Research & Development Manager in November 2000. In February 2007, she was appointed as Quality Assurance Manager & Research Development Manager for the Mandaluyong Plant of the Company. In October 2007, she was promoted to Quality Assurance Manager, Cavite Plant and to Vice President of the Company in January 01, 2009.

MR. VIRGILIO V. LEYEZA, JR.

Vice President

58 years of age

Mr. Virgilio Villanueva Leyeza, Jr., Filipino, graduated from the Adamson University in 1989 with a degree of Bachelor of Science in Computer Engineering. After graduation, he started working in Microcircuits Corporation as a technician. He joined Euro-Med in 1990 as a computer engineer. In June 2007, he was promoted to chief engineer, Cavite Plant and promoted to Vice President on 01 November 2009.

MRS. MA. BERNADETTE M. DOCTOR

Assistant Treasurer

60 years of age

Mrs. Ma. Bernadette M. Doctor, married, Filipino, graduated from De La Salle University Manila in 1987 with a degree of Bachelor of Science in Commerce major in Accounting. She passed the CPA Board examination in 1988. She joined Security Diners International Corp. in the same year. In 1990, she transferred to Republic-Asahi Glass Corporation. She then joined Euro-Med in 1993 as an Executive Assistant. She was promoted to Credit & Collection Manager in 1994 and subsequently became Assistant Treasurer in 2004.

MRS. SANDRA N. PINEDA

Chief Accountant

59 years of age

Mrs. Sandra N. Pineda, married, Filipino, graduated from National College of Business and Arts with a degree of Bachelor of Science in Business Administration - Major in Accounting in 1987. She passed the board examination for Certified Public Accountant (CPA) in 1989. She worked in an Auditing Firm for four (4) years as Junior Auditor. She joined the Company in 1992 as Disbursement Accountant, promoted as Assistant Chief Accountant in 1998 and Chief Accountant since 2004.

MRS. EVELYN O. MANGGUING

Internal Audit Head

59 years of age

Evelyn O. Mangguing, married, Filipino, graduated from University of the East, with a degree of Bachelor of Science in Business Administration - Major in Accounting in 1984. She passed the board examination for Certified Public Accountant (CPA) in 1986. She joined the company in 1989 as General Accountant and appointed as Acting Head -

Euro-Med Group Internal Audit Services last 01 January 2020 and subsequently promoted as Internal Audit Head last 01 March 2022.

ATTY. DAVID MICHAEL O. GABRIEL
Data Protection Officer and Legal Counsel
54 years of age

Atty. David M. O. Gabriel is a degree holder in Bachelor of Arts in Behavioral Science from the University of the Philippines, before proceeding to obtain his degree as Juris Doctor from the Ateneo de Manila University College of Law in 1998. He became part of the Ad-Hoc Independent and Investigative Committee, chaired by former Sen. Rene A. V. Saguisag, wherein he conducted investigations on various public works projects undertaken by all national and local government units all over the country. His investigative work then allowed him to coordinate and work closely with various government agencies. He worked as Special Project Counsel for Petron Corporation. As such, he was made to handle all the legal requirements for the negotiations and the eventual purchase of water wells and real estate properties for Petron. He likewise formulated tax avoidance courses of action aside from handling the civil and criminal litigation requirements of the company.

Atty. Gabriel also worked as Bank Attorney of the Office of Special Investigation (OSI) under the Bangko Sentral ng Pilipinas. In this office, he was primarily involved in investigating and prosecuting bank anomalies, irregularities and other forms of financial fraud in the banking system. He also acted as Chairman of BSP Committee that looked into spurious checks and suspicious banking transactions (precursor of the AMLA). He was also named as the BSP representative to the National Law Enforcement and Coordinating Committee and the Sub-Committees on Interpol and Intelligence. His last exposure in government was being the Corporate Legal Counsel of the Philippine Health Insurance Corporation (PHILHEALTH) from 2009 to 2011 where he handled legal concerns of the PHILHEALTH in support of the directives of its goals and objectives.

He has been a partner of the Gabriel and Mendoza law firm for the past twelve (12) years and previously as a partner in the Del Rosario Mendoza Tiamson Gabriel & Pulido Law Firm since 2001.

ANNEX "B"

MINUTES OF THE ANNUAL SHAREHOLDERS' MEETING

EURO-MED LABORATORIES PHIL., INC.

virtually via <http://meeting.euromedlab.net>

18 June 2025

(FOR APPROVAL AT THE 2026 ANNUAL MEETING OF STOCKHOLDERS)

TOTAL OUTSTANDING SHARES	SHAREHOLDERS' PRESENT	ABSTENTIONS
4,112,140,540	3,697,404,213	0

DIRECTORS PRESENT :

Dr. William G. Padolina (<i>Independent Director</i>)	Chairman of the Board Chairman, Nomination Committee Member, Audit Committee
Mr. Edwin D. Feist (<i>Independent Director</i>)	Vice Chairman of the Board Chairman, Audit Committee Member, Nomination Committee
Mr. Basilio C. Yap	Vice Chairman of the Board
Esperanza I. Cabral, M.D. (<i>Independent Director</i>)	Member, Nomination Committee
Mrs. Georgiana S. Evidente	President Member, Nomination Committee
Evangeline V. Baviera, M.D.	Executive Vice President
Dr. Johnny C. Yap	Exec. Vice President, Treasurer & Asst. Corporate Secretary Member, Nomination Committee
Mr. Benjamin C. Yap	
Dr. Enrique Y. Yap, Jr.	

Esperanza I. Cabral, M.D. (*Independent Director*) Member, Nomination Committee

Mr. Anthony Joseph Y. Gaw Member, Audit Committee

DIRECTORS/OFFICERS PRESENT THRU ZOOM :

Mr. Jose A. Emitterio
Mrs. Ma. Bernadette M. Doctor
Mrs. Rosanna Marie S. Sunga
Mrs. Sandra N. Pineda

STOCKHOLDERS/BROKERS PRESENT THRU ZOOM :

Dr. Emilio C. Yap, III
Mr. Franklin R. Evidente
Mr. Magno Emitterio
Mrs. Teresita Emitterio
Mrs. Lolita Jalalon-Gaylo
Mrs. Nancy R. Lampano
Mrs. Maria Gina F. Bacungan
Mr. Julius S. Sanvictores
Ms. Joanna Marie Aviles
Mr. Walter Briones

CORPORATE STOCKHOLDERS THRU PROXY - REPRESENTED BY MR. BASILIO C. YAP

U.S. Automotive Co., Inc. (with 58.41% shares ownership)
USAUTO CO, Inc. (with 20.80% shares ownership)
Philippine Trust Company (with 8.8% shares ownership)

EXTERNAL AUDITOR :

Mr. Ariel D. Gonzales (Partner)
Ms. Antoinette Mariano-Cruz

CALL TO ORDER :

After the Opening Prayer, Dr. William G. Padolina, Chairman of the Board, called the meeting to order at 10:00 a.m. and presided over the same. He welcomed the stockholders, members of the Board, the President and other Officers of the Corporation who joined the meeting virtually.

The Secretary, Ms. Janice R. Ong, recorded the minutes of the proceedings.

PROOF OF NOTICE OF MEETING :

The conduct of the Annual Stockholders' Meeting shall be via remote communication. Voting shall be done electronically in absentia for a more orderly conduct of the proceedings. Instructions on Online Registration, Online Voting in Absentia and Participation by Remote Communication are set out in Annex "A" in the Notice of Annual Stockholders' Meeting and posted on the Company's website at www.euromedlab.net under the tab "Company Disclosures" on or before May 28, 2025 and at the Company's PSE EDGE profile.

The notice for today's stockholders' meeting was published in the business section of two newspapers of general circulation – The Manila Bulletin, and The Manila Times – in print and online format, for two consecutive days. The last day of publication, May 28, 2025, is at least twenty-one (21) days prior to the date of this meeting.

CERTIFICATION OF QUORUM :

The Secretary certified that there being present at the meeting, in person or by proxy, stockholders owning **3,697,404,213** shares out of 4,112,140,540 shares issued and outstanding or 90% of the total issued and outstanding shares, a quorum was present for the transaction of any business at hand.

READING AND APPROVAL OF THE MINUTES OF THE PREVIOUS MEETING :

The Chairman then proceeded with the approval of the minutes of the annual stockholders' meeting held on June 19, 2024. He stated that a copy of the minutes could be accessed on the website of the Corporation.

There were a total **3,697,404,213** or 90% voting shares represented at the meeting, voting in favor of the approval of the previous stockholders meeting minutes dated June 19, 2024, there being neither dissenting nor abstaining votes; and no proxy voting received by the Corporate Secretary against this item; the stockholders approved the minutes of the

stockholders' meeting held on June 19, 2024, and passed and adopted the following resolution.

TOTAL OUTSTANDING SHARES PRESENT	VOTES IN FAVOR	VOTES AGAINST	ABSTENTIONS
4,112,140,540	3,697,404,213	0	0

Resolution No. S-25-06-001

“RESOLVED, to approve the minutes of the Annual Stockholders' Meeting held on 19 June 2024.”

MANAGEMENT REPORT FOR THE FISCAL YEAR 2024 :

Director and President, Mrs. Georgiana S. Evidente delivered her report to the stockholders on the highlights of the previous year and results of operations

The Company's net sales increased by 10.1% from ₱5.2 billion in 2023 to ₱5.7 billion in 2024. The domestic sales increased by 9.4% from ₱4.9 billion in 2023 to ₱5.4 billion in 2024 while Export sales increased by 23.9% from ₱266.9 million in 2023 to ₱334.4 million in 2024. The increase/decrease in sales indicator was chosen by management as it disclosed the level of performance the Company has attained against the targeted growth. The percentage change is computed by dividing the peso increase (decrease) in sales by the peso sales during the comparable period of previous year.

The gross profit on sales increased by 6.1% from ₱1.9 billion for the year 2023 to ₱2.0 billion for the year 2024. Cost of sales and service increased by 12.4% from ₱3.3 billion in 2023 to ₱3.7 billion in 2024. However, as a percentage of net sales, cost of sales and service increased from 63.5% in 2023 to 64.9% in 2024. The gross profit indicator provides information about product selling prices relative to production costs. The percentage change in gross profit is computed by dividing the peso increase (decrease) in gross profit by the peso gross profit during the comparable period of previous year.

Operating expenses (administrative, selling, distribution and other expenses) increased by 7.8% from ₱1.2 billion in 2023 to ₱ 1.3 billion in 2024. The increase was due to the increase in operating expenses i.e. gasoline, repairs, electricity and other expenses. As a percentage of net sales, operating expenses decreased from 24% in 2023 to 23.5% in 2024. Changes in operating expenses are management's indicators for the degree of control over the Company's spending on administrative, selling, distribution and other expenses. The percentage change in

operating expenses is calculated by dividing the peso increase (decrease) in operating expenses by the peso operating expenses during the comparable period of previous year.

Net finance and miscellaneous income/cost decreased by 8.5% from ₱253.1 million in 2023 to ₱231.6 million for 2024. Changes in net finance and miscellaneous income/cost indicator provides information on significant elements of income and other expenditures that did not arise from the Company's continuing operations. The percentage change is calculated by dividing the peso increase (decrease) in net finance and miscellaneous income/cost by the net finance and miscellaneous income/cost during the comparable period of previous year.

Provision for income tax decreased by 8% from ₱108.4 million in 2023 to ₱98.8 million in 2024. The total net income increased by 16.5% from ₱289.9 million for the year 2023 to ₱337.7 million for the year 2024. Changes in total net income are indicators of the adequacy of amount to satisfy stockholders' dividend and rate-of-return expectations. The percentage change in total net income is calculated by dividing the peso increase (decrease) in total net income by the peso total net income during the comparable period of previous year.

The Company's total assets increased by 1.7% from ₱10.7 billion in 2023 to ₱10.9 billion in 2024. Current ratio decreased from 1.31:1 in 2023 to 1.36:1 in 2024. Debt ratio increased by 1.3% from 0.457:1 in 2023 to 0.46:1 in 2024, while the equity ratio decreased by 1.1% from 0.54:1 in 2023 to 0.53:1 in 2024.

Euro-Med, the parent company had a total of 1,188 employees as of December 31, 2024.

The consolidated sales forecast for 2025 would be an increase in sales of about 10% totaling to about ₱6.4 billion. The expected net income for 2025 is about ₱378 million which is about 6% of sales.

The Corporate Secretary informed that there any no inquiries received online regarding the performance of the Corporation for the period as reflected in the Annual Report made available to the stockholders.

The Chairman of the Board has opened the floor to questions/comments however, none was received.

There were a total of **3,697,404,213** or 90% voting shares represented at the meeting, voting in favor of the approval of the management report for the fiscal year 2024, there being neither dissenting nor abstaining votes; and no proxy voting received by the Corporate Secretary against this item; the stockholders approved the management report for the fiscal 2024, and passed and adopted the following resolution.

Resolution No. S-25-06-002

“RESOLVED, that the Management Report as reflected in the Annual Report, together with the financial statements for the period ending 31 December 2024, be noted and approved.”

RATIFICATION OF ALL ACTS, PROCEEDINGS AND RESOLUTIONS OF THE BOARD OF DIRECTORS AND OFFICERS OF THE CORPORATION FROM THE DATE OF THE LAST ANNUAL SHAREHOLDERS’ MEETING TO THE PRESENT :

There were a total of **3,697,404,213** or 90% voting shares represented at the meeting, voting in favor of the approval of the ratification of all acts, proceedings and resolutions of the Board of Directors and Officer of the Corporation for the date of the last Annual Shareholders’ Meeting to the present, there being neither dissenting nor abstaining votes; and no proxy voting received by the Corporate Secretary against this item; the stockholders approved and ratified all acts of the Board and the Management for the date of the last Annual Shareholders’ Meeting to the present, and passed and adopted the following resolution.

TOTAL OUTSTANDING SHARES PRESENT	VOTES IN FAVOR	VOTES AGAINST	ABSTENTIONS
4,112,140,540	3,697,404,213	0	0

Resolution No. S-25-06-003

“RESOLVED, that all resolutions approved by the Board of Directors and Acts of Management for the year 2024 up to the present be, as they are hereby, approved, confirmed and ratified as if each of the resolutions had been adopted with specific and special authorization by the stockholders in a meeting duly convened and held.”

RE-NOMINATION OF DR. WILLIAM G. PADOLINA AND MR. EDWIN D. FEIST AS INDEPENDENT DIRECTORS :

There were a total of **3,697,404,213** or 90% voting shares represented at the meeting, voting in favor of the re-nomination of Dr. William G. Padolina and Mr. Edwin D. Feist as Independent Directors, there being neither dissenting nor abstaining votes, the stockholders approved and ratified the engagement and passed and adopted the following resolution.

TOTAL OUTSTANDING SHARES PRESENT	VOTES IN FAVOR	VOTES AGAINST	ABSTENTIONS
4,112,140,540	3,697,404,213	0	0

Resolution No. S-25-06-004

“RESOLVED, that the following be re-nominated as Independent Directors for the year 2025-2026.”

Dr. William G. Padolina
Mr. Edwin D. Feist

ELECTION OF DIRECTORS FOR YEAR 2025-2026 :

The meeting proceeded to the election of directors for the ensuing year 2025-2026. The Chairman informed the body that the By-Laws provide for ten seats including two independent directors.

The Member of the Corporate Governance and Nominations Committee read out the names of the nominees approved by the Nominations Committee for the ten seats in the Board. Dr. William G. Padolina, Mr. Edwin D. Feist and Dr. Esperanza I. Cabral were duly nominated as independent directors in accordance with the rules of the Securities and Exchange Commission.

1. Dr. William G. Padolina *
2. Mr. Edwin D. Feist *
3. Dr. Esperanza I. Cabral *
4. Mr. Basilio C. Yap
5. Dr. Johnny C. Yap
6. Mr. Benjamin C. Yap
7. Mrs. Georgiana S. Evidente
8. Dr. Evangeline V. Baviera
9. Dr. Enrique Y. Yap, Jr.
10. Mr. Anthony Joseph Y. Gaw

Mr. Edwin D. Feist, Dr. William G. Padolina and Dr. Esperanza I. Cabral are nominated as independent directors in compliance with the recommendations contained in the SEC Memorandum Circular No. 19, Series of 2016. In its evaluation of nominees, the Corporate Governance and Nomination Committee has determined that they possess all the qualifications and none of the disqualifications of an independent director as set forth under Rule 38 of the Securities Regulation Code and the Company’s Revised Manual on Corporate Governance. The nominees for independent directors

have been advised of SEC Memorandum Circular No. 5, series of 2017 regarding the requirement of Certificate of Qualification of Independent Directors.

The nominees were also informed of SEC Memorandum Circular No. 15, Series of 2017 on the term limits for independent directors. Of the three nominees for independent directors, Dr. William G. Padolina and Mr. Edwin D. Feist have served the maximum cumulative term of nine (9) years. The Committee resolved to approve the re-nomination of Dr. Padolina and Mr. Feist for the position of independent director for the term 2025-2026.

In the meeting held on 25 March 2025, the Corporate Governance and Nomination Committee endorsed the re-nomination of Dr. Padolina and Mr. Feist as independent directors for another year.

Dr. Padolina's academic and research background enabled him to give valuable advice to the Board of Directors and greatly helped the decision-making process of the Board in matters related to science and technology. Further, having served in the government, Dr. Padolina is knowledgeable about regulatory requirements which the Company would need to comply with.

Mr. Feist has established a distinguished and extensive global career in both the pharmaceutical and nutrition industry in Asia and Latin America. As such, Mr. Feist has in depth knowledge about the business of Euro-Med as a pharmaceutical company and the industry in which it belongs.

There being no other nominations, it was duly moved and seconded that the ten nominees be proclaimed as elected directors for the ensuing year for the ten board seats of the Corporation.

There being no objection, the Chairman directed the Corporate Secretary to cast all votes equally among the nominees and declared them as duly elected members of the Board of Directors of the Corporation to act as such until their successors shall have been duly elected and shall have qualified.

The following were elected as directors for the ensuing year 2025 to 2026 with the number of votes equally obtained by each.

Director	Votes For	Votes Against	Abstain
Dr. William G. Padolina	3,697,404,213	0	0
Mr. Edwin D. Feist	3,697,404,213	0	0
Esperanza I. Cabral, M.D.	3,697,404,213	0	0
Basilio C. Yap	3,697,404,213	0	0
Georgiana S. Evidente	3,697,404,213	0	0

Dr. Johnny C. Yap	3,697,404,213	0	0
Evangeline V. Baviera, M.D.	3,697,404,213	0	0
Benjamin C. Yap	3,697,404,213	0	0
Dr. Enrique Y. Yap, Jr.	3,697,404,213	0	0
Anthony Joseph Y. Gaw	3,697,404,213	0	0

Resolution No. S-25-06-005

“RESOLVED, that the following be elected as directors of the Company to serve as such for the period 2025-2026 and until the election and qualification of their successors.”

Dr. William G. Padolina
 Mr. Edwin D. Feist
 Esperanza I. Cabral, M.D.
 Mr. Basilio C. Yap
 Mrs. Georgiana S. Evidente
 Dr. Johnny C. Yap
 Evangeline V. Baviera, M.D.
 Mr. Benjamin C. Yap
 Dr. Enrique Y. Yap, Jr.
 Mr. Anthony Joseph Y. Gaw

APPOINTMENT OF EXTERNAL AUDITOR :

There were a total of **3,697,404,213** or 90% voting shares represented at the meeting, voting in favor of the approval of the appointment of Aquino, Mata, Calica and Associates as External Auditor for the year 2025. Aquino, Mata, Calica and Associates accreditation has been renewed by the Securities and Exchange Commission last July 25, 2023 and classified under Group A and is valid for a period of five years to engage in the audit of 2023 to 2027 financial statements.

There being neither dissenting nor abstaining votes; and no proxy voting received by the Corporate Secretary against this item; the stockholders approved and ratified the appointment of external auditor for the year 2025 and passed and adopted the following resolution.

TOTAL OUTSTANDING SHARES PRESENT	VOTES IN FAVOR	VOTES AGAINST	ABSTENTIONS
4,112,140,540	3,697,404,213	0	0

Resolution No. S-25-06-006

“RESOLVED, that Aquino, Mata, Calica and Associates be, as it is hereby, appointed as the External Auditor of the Company for the year 2025-2026, subject to said Auditor securing the required accreditation from the Securities and Exchange Commission.”

OTHER MATTERS :

The Chairman informed the Stockholders pertaining to the Corporation acting as surety to secure the payment of the credit facilities of its subsidiary, CafeFrance Corp. doing business under the name and style of Flavours of China, Tempura Japanese Grill, Holy Cow! Steak Ranch and American Grill, Karate Kid, Kidomanga, Congo Grille with China Banking Corporation, including any renewals, extensions and/or roll-over thereof, as well as those which may thereafter be granted to said subsidiary.

The Corporate Secretary informed that there were no further questions submitted online.

The Chairman of the Board has opened the floor to questions/comments however, none was received.

ADJOURNMENT :

There being no further business to discuss, upon motion duly made and seconded, the Stockholders' Meeting was adjourned at 10:45 A.M.

ANNEX "C"

SUMMARY OF THE ACTS, PROCEEDINGS AND RESOLUTIONS OF THE BOARD OF DIRECTORS AND OFFICERS FOR RATIFICATION

DATE	MEETING	RESOLUTION NO.	RESOLUTION
28 January 2025	Regular BOD meeting	25-01-001	Bidding for Procurement of Enteral Products under PB 14-2025 by the Bicol Regional Hospital and Medical Center
		25-01-002	Bidding for Supply and Delivery of Various Hemodialysis Supplies - Batch 1 to Eversley Childs Sanitarium and General Hospital (Framework Agreement) by the Eversley Childs Sanitarium and General Hospital
		25-01-003	Bidding for the HO-CMB25-006 Supply and Delivery of Various Medicines for NPC Head Office Clinic (CY2025) by the National Power Corporation
		25-01-004	Bidding for Supply and Delivery of Various Drugs and Medicines - Lot 2 under ITB No. G-2025-043-Lot 2 by the Provincial Government of Bukidnon
		25-01-005	Bidding for Supply and Delivery of Various Drugs and Medicines and Other Related Products for FY 2025 Use (02-2025DM-BACB-ITB) by the Mariano Marcos Memorial Hospital and Medical Center
		25-01-006	Bidding for IB No. DM 2025-01B Supply and Delivery of Various Pharmaceuticals by the Western Visayas Medical Center
		25-01-007	Bidding for Supply and Delivery of Drugs and Medicines - Fluids for One (1) Year (Single Year Framework Agreement) under Project Reference No. : BAC-2024-12-1132 by the UPM - Philippine General Hospital
		25-01-008	Bidding for Supply and Delivery of Drugs and Medicines - Emergency Drug Ampules and Vials for One (1) Year (Single Year Framework Agreement) under Project Reference No. : BAC-2024-10-0910 by the UPM - Philippine General Hospital
		25-01-009	Bidding for the Various Drugs and Medicines (Anthelmintics, Anticholinergic, etc.) with P.R. #2025-01-0040 by the Corazon Locsin Montelibano Memorial Regional Hospital
			Bidding for the Various Drugs and Medicines

		25-01-010	(Framework Agreement : Diagnostic Agents, Drug Affecting the Blood, etc.) with P.R. #2025-01-0033 by the Corazon Locsin Montelibano Memorial Regional Hospital
		25-01-011	Bidding for the Purchase of Medical Supplies B-2025-004/P.R. 250183 (2025-01-011) by the Benguet General Hospital
		25-01-012	Bidding for the Consignment of Various Drugs and Medicines with Consignment Request No. 2025-01-001 of Benguet General Hospital (BeGH) CY 2025-2026 by the Benguet General Hospital
		25-01-013	Bidding for the Consignment of Various Medical Supplies with Consignment Request No. 2025-01-002 of Benguet General Hospital (BeGH) CY 2025-2026 by the Benguet General Hospital
		25-01-014	Bidding for the 2025 59 th Public Bidding Procurement of Drugs and Medicines under Framework Agreement under ITB No. BGHMCPB-2025-59 by the Bataan General Hospital and Medical Center
		25-01-015	Bidding for the ITB No. 2025-008 Procurement of IV Fluids by the Cotabato Sanitarium and General Hospital
		25-01-016	Bidding for the ITB No. 2025-001 Procurement of Antiseptics (Rebid) by the Cotabato Sanitarium and General Hospital
		25-01-017	Bidding for Supply and Delivery of Drugs and Medicines (BRGHGMC-GS-2025-02) by the Bicol Region General Hospital and Geriatric Medical Center
		25-01-018	Bidding for Procurement of Drugs and Medicines (Dextrose + Lactated Ringer's 5% & etc.) under PR#200-25-02-003(Q) by the Provincial Government of Zamboanga Del Norte (PGSO-Dipolog)
		25-01-019	Bidding under Supply and Delivery of Various Pharmaceutical Drugs and Medicines with IB No. 2025-02-026-G by the Far North Luzon General Hospital and Training Center
		25-01-020	Bidding for the Procurement, Supply and Delivery of Drugs and Medicines via Ordering Agreement with Contract ID No. 25-02-005 by the Labuan General Hospital
		25-01-021	Bidding under Procurement of Various Intravenous Fluids for Six (6) Provincial Hospital for 1 st SEM 2025 with ID No. 101-25-01-0134 by the Provincial Government of Lanao

			Del Norte
		25-01-022	Bidding for the Procurement of Drugs and Medicines (Chemotherapeutic) with Identification No. R2TMC-BAC1-2025-14 by the Region II Trauma and Medical Center
		25-01-023	Bidding for the Procurement of Drugs and Medicines (Analgesic, Anaesthetic and Muscle Relaxant) with Identification No. R2TMC-BAC1-2025-07 by the Region II Trauma and Medical Center
		25-01-024	Bidding for the Procurement of Drugs and Medicines (Antimicrobial) with Identification No. R2TMC-BAC1-2025-15 by the Region II Trauma and Medical Center
		25-01-025	Re-bidding for Supply and Delivery of Eighty-Three Thousand Two Hundred Fifty (83,250) Vials of 0.9% Sodium Chloride 50mL (Framework Agreement for One (1) Year) by the National Kidney and Transplant Institute
		25-01-026	Bidding for the Procurement of Drugs and Medicines CY 2025 (Re-Bid) with IB 2025-01-0002R by the Quirino Memorial Medical Center
		25-01-027	Bidding for Procurement of Drugs and Medicines (IV Fluids - Dextrose) for the use of Godofredo P. Ramos Hospital, Province of Aklan (ITB No. 2025-218) by the Provincial Government of Aklan/Godofredo P. Ramos Hospital
		25-01-028	Requirements of Jose B. Lingad Memorial General Hospital, for the Purchase Order No. 25-01-0005 Negotiated Procurement - Small Value Procurement
		25-01-029	Requirements of Governor Celestino Gallares Memorial Medical Center, for the Requirements of Accreditation
		25-01-030	Requirements of Bataan General Hospital and Medical Center, for the Request for Quotation (Negotiated Procurement - Small Value Procurement) under P.R. No. 25 - 01 - 042
		25-01-031	Requirements of Bataan General Hospital and Medical Center, for the Request for Quotation (Negotiated Procurement - Small Value Procurement) under P.R. No. 25 - 02 - 064
		25-01-032	Requirements of National Kidney and Transplant Institute, for the Request of Requirements under IB No. 25-016 (Nutritional's)
		25-01-033	Requirements of National Kidney and Transplant Institute, for the RFQ No. 25-053:

			Supply and Delivery of Various Drugs (259 Line Items)
		25-01-034	Requirements of Province of Misamis Occidental, for the Negotiated Procurement - Small Value Procurement under P.R. #2025-01-0150
		25-01-035	Quotation of City Government of Pasig (Pasig City General Hospital), for the Supply and Delivery of Various Medical Equipment - PCGH under RFQ No. 100-24-06-839
		25-01-036	Authorization for AGQ Freight Logistics Inc. as its authorized representatives, to deliver, process, sign, execute and to transact business with the Bureau of Internal Revenue ("BIR"), for the issuance of the Company's Authority to Release Imported Goods (ATRIG), surety bond and securing TEC
		25-01-037	Appointment of Chief Accountant as the authorized representative before the Bureau of Internal Revenue, to sign the application and/or documentary requirements for the renewal of the Corporation's Tax Clearance Certificate
25 February 2025	Regular BOD meeting	25-02-001	Bidding of the Supply and Delivery of Various Drugs, Medicines and IV Fluids for CY 2025 (Batch 5) with Reference No. BAC-IB No. 2025-B-23 by the Research Institute of Tropical Medicine (RITM)
		25-02-002	Re-bidding for Supply and Delivery of Various Drugs and Medicines under IB No. A3-2025-1 by the East Avenue Medical Center
		25-02-003	Bidding for the Re-bidding of Various Drugs and Medicines under IB No. 2025-03-10 (15) by the Jose B. Lingad Memorial General Hospital
		25-02-004	Bidding for Procurement Supply and Delivery of Medical Supplies for Hemodialysis under Reference No. LCP IB No. 25-06 by the Lung Center of the Philippines
		25-02-005	Bidding for the Supply and Delivery of Various Pharmaceutical Supplies for CY 2025 under IB-2025-070 by the Philippine Children's Medical Center
		25-02-006	Bidding under Procurement of Medical Supplies for the use of Davao Oriental Provincial Medical Center (DOPMC) Pharmacy (Admitted Patients) under P.R. No. 2025-02-0041 DOPMC by the Provincial Government of Davao Oriental (Province of Davao Oriental)
			Bidding for Purchase of Drugs and Medicines B-

		25-02-007	2025-008 / PR No. 250487 by the Benguet Provincial Government
		25-02-008	Bidding for Purchase of Medical Supplies B-2025-013 / PR No. 250463 by the Benguet Provincial Government
		25-02-009	Bidding for Purchase of Medical Supplies B-2025-015 / PR No. 250484 by the Benguet Provincial Government
		25-02-010	Bidding for Purchase of Drugs and Medicines B-2025-011 / PR No. 250489 by the Benguet Provincial Government
		25-02-011	Bidding for the Supply and Delivery of Medical Supplies for Ophthalmology and Anesthesiology and Pain Medicine Department under Framework Agreement with ITB No. 2025-02-003 by the Southern Isabela Medical Center (SIMC)
		25-02-012	Bidding for Procurement of Drugs and Medicines under PB 17-2025 by the Bicol Regional Hospital and Medical Center
		25-02-013	Bidding for Supply and Delivery of Drugs and Medicines (IV Fluids) IB No. PB-2025-02-11 under PR No. 2025-02-030 by the Dr. Jose Rizal Memorial Hospital
		25-02-014	Bidding for Supply and Delivery of "Drugs and Medicines" P.R. No. 2025-03-053 "Small Value Procurement" 2025-03-004 by the Dr. Jose Rizal Memorial Hospital
		25-02-015	Bidding for Procurement of Various Intravenous Fluids (SLRGH IB 2025-015) by the San Lorenzo Ruiz General Hospital (SLRGH)
		25-02-016	Bidding for Procurement of IV Fluids for Misamis Occidental Provincial Hospital under PB-G-2025-02-0291 by the Province of Misamis Occidental
		25-02-017	Bidding for Procurement of IV Fluids for the Various PGMO Hospitals PB-G-2025-03-0502 by the Province of Misamis Occidental
		25-02-018	Bidding under Consignment offer of Drugs and Medicines 2025 by the Vicente Sotto Memorial Medical Center
		25-02-019	Bidding for the Supply and Delivery of Various Enteral Nutrition Formulas - PCGH under ITB No. BAC-25-0221A by the City Government of Pasig (Pasig City General Hospital)
		25-02-020	Bidding under Procurement of IV Fluids for QIP, Cabarroguis, Quirino under ITB No. PB-GS-2025-008 by the Provincial Government of Quirino Through Quirino Integrated Pharmacy

		25-02-021	Bidding for 2025 6 th Public Negotiated Procurement: Two-Failed Biddings - Supply and Delivery of Drugs and Medicines under ITB No. P.R. No. 25-02-090 by the Bataan General Hospital and Medical Center
		25-02-022	Bidding for Purchase of First Quarterly Dialysis Supplies for the Dasmacares Dialysis Center in the City of Dasmariñas under ITB No. GEPS 043-2025 by the City Government of Dasmariñas
		25-02-023	Bidding for Purchase & Delivery of Fluids for the different hospitals of the Province under ITB No. PGIS-075-2025 by the Provincial Government of Ilocos Sur
		25-02-024	Bidding for Procurement of Various Drugs and Medicines under IB No. 2025-02-004-G by the Western Visayas Sanitarium and General Hospital
		25-02-025	Bidding for Supply and Delivery of Medical Supplies for NCGH Hemodialysis Unit (4 Lots) with Project/Contract Reference Number : 2025-017 by the City Government of Naga/Naga City Hospital
		25-02-026	Bidding for Supply and Delivery of Medicines and Medical Supplies (Multiple Lots) with Project/Contract Reference Number : 2025-019 by the City Government of Naga/Naga City Hospital
		25-02-027	Bidding for Procurement of Drugs and Medicines Bid No. HMO-25-201-B by the Iloilo Provincial Capitol - PGSO
		25-02-028	Bidding for Procurement of IV Fluids Bid No. HMO-25-202-B by the Iloilo Provincial Capitol - PGSO
		25-02-029	Requirements of Lung Center of the Philippines, for Haemodialysis for Quotation 25-106 Negotiated Procurement - Small Value Procurement
		25-02-030	Requirements of Don Emilio Del Valle Memorial Hospital, for Purchase Order Number 2025-03-0130
		25-02-031	Requirements of University of the Philippines Manila/Philippine General Hospital, for Request for Quotation (Negotiated Procurement - Emergency Cases) under Proj Reference No. BAC-2025-03-0169
		25-02-032	Requirements of University of the Philippines Manila/Philippine General Hospital, for Request for Quotation (Negotiated Procurement - Emergency Cases) under Project Reference

			No. BAC-2025-02-0133 (Re-process)
		25-02-033	Authorization for TN & C Enterprises Co. to execute, process receipts for business with Bureau of Internal Revenue (BIR) RDO 116
		25-02-034	Update of accounts of the Corporation with Landbank of the Philippines, Taft Avenue Branch; authorization to sign, withdraw, encash, transfer funds, enter into contract, agreement, to direct investments including renewals, roll-overs and extensions, or such other powers deemed necessary
		25-02-035	Authorization to act as continuing surety for all obligations arising from or in connection with all credit accommodations extended and may be extended in the future to Hemotek Renal Center, Inc. by BDO Unibank, Inc.
25 March 2025	Regular BOD meeting	25-03-001	Fixing date for year 2025 Annual Stockholders' Meeting and Record Date
		25-03-002	Approval and authorization on the issuance of the Corporation's Audited Financial Statements as of and for the year ended 31 December 2024 as audited by the Corporation's External Auditor Aquino, Mata, Calica and Associates
		25-03-003	Approval on the Corporate Governance and Nomination Committee's selection of nominees of directors for the year 2025-2026
		25-03-004	Bidding for Request for Quotation Procurement of Drugs and Medicine with Reference Number: 25-03-40 by the Bicol Region General Hospital and Geriatric Medical Center
		25-03-005	Request for a quotation requirement of Davao Regional Medical Center, for Procurement of Drugs and Medicines with RFQ No. 2025-03-0100 (R-0131) Negotiated - Emergency Case
		25-03-006	Bidding for Request for Supply and Delivery of Drugs and Medicines, IV Fluids, Solution for Injection and Parenteral Solution P.R. No. 2025-03-104 Lot 2 by the Provincial Government of Guimaras
		25-03-007	Bidding for Request for the Supply and Delivery of Foods Supplies (EPA CY: 2025) PIN 2024-11-037A by the Dr. Jose N. Rodriguez Memorial Hospital and Sanitarium
		25-03-008	Bidding for Request for the Adult Nutritional Formula (Vanilla Flavor) (P.R. No. 2025-02-0246) by the Corazon Locsin Montelibano Memorial Regional Hospital
			Bidding for the Supply and Delivery of Various

		25-03-009	Drugs and Medicines - PCGH/PCCH with ITB No. BAC-25-0321B by the City Government of Pasig (Pasig City General Hospital/Pasig City Children's Hospital)
		25-03-010	Bidding for the Supply and Delivery of Various Drugs and Medicines, and Medical Supplies for Pasig City Hemodialysis Center and Manggahan Super Health Dialysis Center - CHD with ITB No. BAC-25-0328D by the City Government of Pasig (Pasig City Health Department)
		25-03-011	Bidding for Supply and Delivery of IV Solutions Through Framework Agreement F-IB No. 2025-10 by the Bicol Medical Center
		25-03-012	Bidding for Supply and Delivery of Various Pharmaceuticals Through Framework Agreement F-IB No. 2025-11 by the Bicol Medical Center
		25-03-013	Bidding for Supply and Delivery of Various Enteral Formulas under IB 2025-014 by the Batangas Medical Center
		25-03-014	Bidding under Procurement of Drugs and Medicines - Hemodialysis RFQ No. 2025-04-0130 (R-0160) Negotiated - Emergency Case by the Davao Regional Medical Center
		25-03-015	Bidding under Supply and Delivery of Drugs and Medicines (Early Procurement Activity) EPA-2025-11 by the Vicente Sotto Memorial Medical Center
		25-03-016	Bidding under Procurement of Drugs and Medicines for the Consumption of the Three (3) Davao Del Norte Hospitals with BID No. B20251280 by the Provincial Government of Davao Del Norte
		25-03-017	Bidding for the Negotiated Procurement for Small Value Procurement under (2025-SVP-153) for Supply and Delivery of CG4 + Cartridge by the East Avenue Medical Center
		25-03-018	Bidding for Purchase of IV Fluids and Medical Supplies for the Pharmacy Department of the Pagamutan ng Dasmariñas under Reference No. 11945182 by the City Government of Dasmariñas
		25-03-019	Bidding for Purchase for Procurement of Sterile Water for Injection for Respiratory Services (SRS) under Reference No. LCP IB No. 25-11 by the Lung Center of the Philippines
		25-03-020	Bidding for Procurement of Various Drugs and Medicines under IB No. 2025-05-06 (26) by the

			Jose B. Lingad Memorial General Hospital
		25-03-021	Bidding for Procurement of Drugs and Medicines 2025-02 (Framework Agreement) under Project Reference No. 11928298 with IB 2025-05-002 by the Don Jose S. Monfort Medical Center
		25-03-022	Bidding for Procurement of Drugs and Medicines 2025-05-001 by the Don Jose S. Monfort Medical Center
		25-03-023	Requirement of University of the Philippines Manila/Philippine General Hospital, for Request for Quotation (Negotiated Procurement - Emergency Cases) under Proj. Ref. No. BAC-2025-03-0232
		25-03-024	Requirement of University of the Philippines Manila/Philippine General Hospital, for Request for Quotation (Negotiated Procurement - Emergency Cases) under Project Reference No. BAC-2025-03-0169 (2 nd Re-Process)
		25-03-025	Requirement of University of the Philippines Manila/Philippine General Hospital, for Request for Quotation (Negotiated Procurement - Emergency Cases) under Project Reference No. BAC-2025-03-0232 (Re-Process)
		25-03-026	Request for a quotation requirement of Provincial Government of Quirino Through Quirino Integrated Pharmacy, for Supply and Delivery of IV Fluids under ITB No. GS-GF-2025-0271
		25-03-027	Requirement of Bicol Medical Center, for Collection Purposes
		25-03-028	Requirements of Governor Benjamin T. Romualdez General Hospital and Schistosomiasis Center, under Supply and Delivery of Milk Supplements for Nutrition and Dietetics Department under IB No. 2025-07 BAC A
		25-03-029	Requirements of Brigada Pharmacy, for Suppliers Accreditation
		25-03-030	Requirements of Rizal Medical Center, for the Supply and Delivery of Sodium Chloride 0.9% 1L Solution under ITB No. 2025-244
		25-03-031	Authorization to process and obtain the Bureau of Internal Revenue (BIR) Tax Clearance Certificate for final Settlement of Government Contracts; to sign any document, submit and obtain any and all relevant documents pursuant to the authority granted
			Authorization to apply for and obtain from

29 April 2025	Regular BOD meeting	25-04-001	East West Banking Corporation (“EWBC”) credit accommodations/facilities in the aggregate principal amount not exceeding PESOS: FOUR HUNDRED SIXTY MILLION (Php460,000,000.00), Philippine Currency
		25-04-002	Authorization to enter into the following transactions (Deposit & Cash Management, Loans & Other Credit Accommodation, Treasury Transactions) with PHILIPPINE NATIONAL BANK (hereinafter called the “Bank” or “PNB”)
		25-04-003	Re-Bid of Various Drugs and Medicines from June 1, 2025 to December 31, 2025 under IB No. 2025-20 by the Dr. Paulino J. Garcia Memorial Research and Medical Center
		25-04-004	Re-Bid of Various Drugs and Medicines from June 1, 2025 to December 31, 2025 under IB No. 2025-20 by the Dr. Paulino J. Garcia Memorial Research and Medical Center
		25-04-005	Bidding for Procurement of Drugs and Medicines (Dextrose) for the use of Don Leovigildo N. Diapo Sr Municipal Hospital, Province of Aklan (ITB No. 2025-424) by the Provincial Government of Aklan (Don Leovigildo N. Diapo Sr. Municipal Hospital)
		25-04-006	Bidding for the Supply and Delivery of Various Drugs and Medicines - Parenteral Preparations (IM, IV, IV Infusion) Dr. Jose Rizal Memorial Hospital, Dapitan City under IB No. PB-2025-04-19 by the Dr. Jose Rizal Memorial Hospital
		25-04-007	Bidding for Purchase of IV Fluids Bid No. FRT-25-287-B by the Iloilo Provincial Government/Federico Roman Tirador Sr. Memorial District Hospital
		25-04-008	Bidding for the Supply and Delivery of Various IV Fluids for CY 2025 (Re-Bid) under ITB No. 2025-258 by the Rizal Medical Center
		25-04-009	Bidding for Purchase of I.V. Fluids Bid No. HMO-25-571-B by the Iloilo Provincial Capitol - PGSO
		25-04-010	Bidding for the Procurement of Goods: Supply and Delivery of Various Drugs and Medicines through Framework Agreement under IB No. 2025-05-013 by the Governor Celestino Gallares Memorial Medical Center
		25-04-011	Bidding for the Procurement of Drugs and Medicines 3 rd Q - 2025 under ITB No. 2025-00-09 by the Mayor Hilarion A. Ramiro Sr. Medical Center (MHARSMC)

		25-04-012	Bidding for Supply and Delivery of Various Drugs and Medicines (Lot No. 3, Lot No. 6 and Lot No. 8); PR No. 25-0110 dated February 6, 2025; SN 35a-2025 by the City Government of Cagayan De Oro
		25-04-013	Requirements of Bataan General Hospital and Medical Center, for the Request for Quotation (Negotiated Procurement - Small Value Procurement) under P.R. No. 25 - 04 - 246
		25-04-014	Requirements of Research Institute for Tropical Medicine (RITM), under the category Request for Quotation Mode of Procurement: Small Value Procurement PR No. 25-04-0567 RFQ No. 12814
		25-04-015	Requirements of Dr. Jose Rizal Memorial Hospital, for the Supply and Delivery of "Hemodialysis Supplies (Compatible with Fresenius 4008S Next-Gen Dialysis Machine) - Rebid" under P.R. No. 2025-03-084 Negotiated "Small Value Procurement" Request for Quotation No. 2025-04-029
		25-04-016	Requirements of Provincial Government of Antique/Angel Salazar Memorial General Hospital, for Negotiated Procurement (Small Value Procurement) under SVP No. DD-2025-011(m)
		25-04-017	Requirements of Lung Center of the Philippines, for Small Volume Procurement of Arterial Cannula for Operating Room Use
		25-04-018	Authorization to execute and sign a Philippine Government Electronic Procurement System (PhilGEPS) Sworn Statement, upload and maintain in the PhilGEPS system the required documents as stated in the Sworn Statement
27 May 2025	Regular BOD meeting	25-05-001	Approval on list of five nominees of Hemotek Board of Directors 2025-2026 and appointment of Euro-Med's authorized representative/proxy
		25-05-002	Requirements of Bataan General Hospital and Medical Center, for the Request for Quotation Negotiated Procurement - Small Value Procurement under PR No. 25-05-329
		25-05-003	Bidding for Procurement of Medical Supplies under PB 23-2025 by the Bicol Regional Hospital and Medical Center
		25-05-004	Bidding for Procurement of Drugs and Medicines under PB 22-2025 (FA) by the Bicol Regional Hospital and Medical Center
		25-05-005	Bidding for Purchase of IV Fluids Bid No. NTH-25-550-B by the Iloilo Provincial

			Government/Gov. Niel Tupas Sr. District Hospital
		25-05-006	Bidding for the Supply and Delivery of Various Drugs and Medicines (Re-bid) for Fiscal Year 2025 Through Framework Agreement under Hospital Income with ITB No. 2025-05-018 by the Southern Isabela Medical Center (SIMC)
		25-05-007	Bidding under Procurement of Antipyretic Drugs, Respiratory Drugs, Cardiovascular Drugs and IV Fluids/Electrolytes for the Consumption of Three (3) Davao Del Norte Hospitals with BID No. B20252107 by the Provincial Government of Davao Del Norte
		25-05-008	Bidding for Supply and Delivery of Medical Fluids with BID No. 2025-05-09-072 (ABC No.: 2025-037) by the Southern Philippines Medical Center
		25-05-009	Bidding for Supply and Delivery of Medical Fluids with BID No. 2025-05-09-072 (ABC No.: 2025-037) by the Southern Philippines Medical Center
		25-05-010	Bidding for EDM-002-2025 Consignment of Essential Drugs and Medicines by the Cebu South Medical Center
		25-05-011	Bidding for Purchase of I.V. Fluids Bid No. HMO-25-202-B (Rebid) by the Iloilo Provincial Capitol - PGSO
		25-05-012	Bidding under Supply and Delivery of Drugs and Medicines under ITB No. 2025-05-0168 by the Davao Regional Medical Center
		25-05-013	Bidding under Supply and Delivery of Fluids under ITB No. 2025-05-0169 by the Davao Regional Medical Center
		25-05-014	Bidding for the Consignment Request No.: 25-04-001 For Use of the San Carlos City Hospitals, this City by the San Carlos City Hospital
		25-05-015	Bidding for Supply and Delivery of Various Operating Room Supplies with IB No. UMC 25-20 by the West Visayas State University Medical Center
		25-05-016	Rebidding of Drugs and Medicines Charged to Trust Fund 2025 / 2025-18 by the Mariveles Mental Wellness and General Hospital
		25-05-017	Bidding for the Supply and Delivery of Various Drugs and Medicines for CY 2025 (SPPMP) under ITB No. 2025-307 by the Rizal Medical Center
		25-05-018	Bidding for the Procurement of I.V. Fluids for CY 2025 (SPPMP) under ITB No. 2025-303 by

			the Rizal Medical Center
		25-05-019	Bidding under Supply and Delivery of Drugs and Medicines for the use of DdOPH-Montevista-PEEMO under ITB No. 25-041 and with Bid No. B-25-0136 / 25-3563 by the Provincial Government of Davao De Oro (Provincial Government of Compostela Valley)
		25-05-020	Bidding under Supply and Delivery of Drugs and Medicines for the use of DdOPH-Pantukan-PEEMO under ITB No. 25-041 and with Bid No. B-25-0137 / 25-3493 by the Provincial Government of Davao De Oro (Provincial Government of Compostela Valley)
		25-05-021	Bidding under Supply and Delivery of Drugs and Medicines for the use of DdOPH-Maragusan-PEEMO under ITB No. 25-041 and with Bid No. B-25-0138 / 25-3562 by the Provincial Government of Davao De Oro (Provincial Government of Compostela Valley)
		25-05-022	Bidding under Supply and Delivery of Drugs and Medicines for the use of DdOPH-Laak-PEEMO under ITB No. 25-041 and with Bid No. B-25-0139 / 25-3492 by the Provincial Government of Davao De Oro (Provincial Government of Compostela Valley)
		25-05-023	Bidding for Procurement of Drugs and Medicines with ITB No. MRH-038-2025 by the Margosatubig Regional Hospital
		25-05-024	Bidding for Procurement of Various Medical Supplies for the Use of Central Supply and Sterilization Unit with IB No. 2025-027 by the Western Visayas Medical Center
		25-05-025	Bidding under Supply and Delivery of Drugs and Medicines (Line Item Bidding) under Framework Agreement under IB No. 2025-FA-34 by the Eastern Visayas Medical Center
		25-05-026	Procurement of Various Medical Supplies of CSR for July to December (Re-Bid) under IB No. 2025-012 BAC I by the Baguio General Hospital and Medical Center
		25-05-027	Bidding for Supply and Delivery of Drugs and Medicines (Lot No. 1 to 13); PR No. 25-1625 dated April 10, 2025; SN 66-2025 by the City Government of Cagayan De Oro
		25-05-028	Bidding under Supply and Delivery of Drugs and Medicines - Framework Agreement (Single Year) with ITB No. SAMCH-2025-PB (FA)-10 by the St. Anthony Mother and Child Hospital
			Bidding for Procurement of Medical Supplies

		25-05-029	under PB 26-2025 by the Bicol Regional Hospital and Medical Center
		25-05-030	Bidding for Purchase of IV Fluids Bid No. RPT-25-293-B(REBID) by the Iloilo Provincial Government/Rep. Pedro Trono Memorial District Hospital
		25-05-031	Supplier's requirements of Tri-City Medical Center, for signing of Contract Agreement
		25-05-032	Requirements of Bicol Regional Hospital and Medical Center, for Canvass N-25-03-049
		25-05-033	Requirements of Apayao Central Pharmacy, for the Request for Quotation with PR No. 015-05-2025
		25-05-034	Requirements of UPM - Philippine General Hospital, for Request for Quotation (Negotiated Procurement - Emergency Cases) under Project Reference No. BAC-2025-05-0407
		25-05-035	Requirements of Benguet Provincial Government, for Purchase of Drugs and Medicines with Bid No. 2025-0119 / PR No. 250858
		25-05-036	Requirements of St. Anthony Mother and Child Hospital, under Request for Quotation (Small Value Procurement) with RFQ No. 2025-092 under PR No. 2504018 / 103
		25-05-037	Requirements of National Kidney and Transplant Institute, for Request for Quotation under Procurement Opportunity (Small Value Procurement) with RFQ No. 25-275
		25-05-038	Requirements of Bicol Region General Hospital and Geriatric Medical Center, for Supply and Delivery of Drugs and Medicines (Bicol Skin Clinic) under BRGHGMC-GS-2025-10
		25-05-039	Authorization to hold all the proxies of the Corporation in Euro-Med Laboratories Phil., Inc. (hereafter "Euro-Med") and to attend any of the stockholders/organizational meetings of Hemotek Renal Center, Inc.
		25-05-040	Authorization to transact business with, sign for, submit, secure documents and payments and credits, for and in behalf of the company, with the Bureau of Internal Revenue, (BIR)
18 June 2025	Organizational Meeting	25-06-001	Appointment of Company Officers for the year 2025-2026
		25-06-002	Appointment of Audit and Risk Oversight Committee members for year 2025-2026
		25-06-003	Appointment of Corporate Governance and Nomination Committee for year 2025-2026

		25-06-004	Approval of the list of seven (7) nominees of CafeFrance Corp. Board of Directors for year 2025-2025 and Euro-Med's authorized representative
		25-06-005	Bidding for the Various Drugs and Medicines (Electrolyte Binders, Parenteral Nutrition & Solution Correcting Electrolysis, Acid-Base and Caloric Disturbances) (Framework Agreement) (P.R.# 2025-04-0580) by the Corazon Locsin Montelibano Memorial Regional Hospital
		25-06-006	Bidding for Supply and Delivery of Drugs and Medicines - Respiratory System for One (1) Year (Single Framework Agreement) under Project Reference No. BAC-2025-05-0339 by the UP - Philippine General Hospital
		25-06-007	Bidding for Procurement of Various Drugs and Medicines (Re-Bidding) under IB No. UMC 25-21 by the West Visayas State University Medical Center
		25-06-008	Bidding for Procurement of Drugs and Medicines under Bid No. IPH-25-759-B by the Iloilo Provincial Government
		25-06-009	Bidding for Procurement of Drugs and Medicines with Bid No. JCH-25-860-B by the Iloilo Provincial Government/Jesus Colmenares District Hospital
		25-06-010	Bidding for Consignment of Drugs and Medicines with Consignment Offer No. 2025-2 by the Bicol Medical Center
		25-06-011	Bidding for the Drugs and Medicines under ITB No. 2025-029 by the Cotabato Sanitarium and General Hospital
		25-06-012	Bidding for the Supply and Delivery of Drugs and Medicines for Diabetes Mellitus Program and Cardiovascular Disease Program for 3 rd and 4 th Quarter by the Municipality of Limay, Bataan
		25-06-013	Bidding for Purchase of I.V. Fluids with Bid No. HMO-25-700-B by the Iloilo Provincial Capitol - PGSO
		25-06-014	Bidding for Purchase and Delivery of Fluids for the different Hospitals of the Province under ITB No. PGIS-133-2025 by the Provincial Government of Ilocos Sur
		25-06-015	Bidding for Supply and Delivery of Drugs and Medicines under BRGHGMC-GS-2025-11 by the Bicol Region General Hospital and Geriatric Medical Center
			Bidding for the Procurement of Various Drugs

		25-06-016	and Medicines with Project Identification No. R2TMC-BAC1-2025-72 by the Region II Trauma and Medical Center
		25-06-017	Bidding under Supply and Delivery of Drugs and Medicines with IB No. 2025-06-044-G by the Far North Luzon General Hospital and Training Center
		25-06-018	Bidding for Medical Supplies under ITB No. 2025-12-065 by the Cotabato Regional and Medical Center
		25-06-019	Bidding for Drugs and Medicines (RF) Category 1 under ITB No. 2025-12-069 by the Cotabato Regional and Medical Center
		25-06-020	Bidding for Drugs and Medicines (RF) Category 2 under ITB No. 2025-12-070 by the Cotabato Regional and Medical Center
		25-06-021	Bidding for Drugs and Medicines (RF) Category 3 under ITB No. 2025-12-071 by the Cotabato Regional and Medical Center
		25-06-022	Bidding for Procurement of Drugs and Medicines under PB 27-2025 by the Bicol Regional Hospital and Medical Center
		25-06-023	Bidding for Supply and Delivery of Various Hemodialysis Supplies under IB 2025-031B by the Batangas Medical Center
		25-06-024	Bidding for the Procurement of Drugs and Medicines Supplies for Public Bidding, AFPMC for CY 2025 (Per Line Item Bidding) (Single Year Framework Agreement) (1 st Rebidding) under Identification No. GHQBAC1-PB-008-GHQ-25 by the AFP Medical Center
		25-06-025	Bidding for Supply and Delivery of Various Drugs and Medicines (Framework Agreement) with Reference No. 12182942 by the Eversley Childs Sanitarium and General Hospital
		25-06-026	Bidding for the Procurement of Various Drugs and Medicines under IB No. 2025-096 by the Tondo Medical Center
		25-06-027	Bidding for the Procurement of Drugs and Medicines with IB PB GOODS No. 2025-015 by the Amang Rodriguez Memorial Medical Center
		25-06-028	Bidding for Supply and Delivery of Various Drugs and Medicines under ITB No. G-2025-150 by the Provincial Government of Bukidnon
		25-06-029	Bidding for Supply and Delivery of Various Drugs and Medicines for July to December 2025 under IBTGH 2025 - 17 by the Talavera General Hospital
			Bidding for Supply and Delivery of Cardiac

		25-06-030	Catheterization Laboratory and Cardiac OR Supplies Through Framework Agreement under F-IB No. 2025-16 by the Bicol Medical Center
		25-06-031	Bidding for Procurement of Drugs and Medicines under Bid No. IPH-25-759-B by the Iloilo Provincial Government/Iloilo Provincial Hospital
		25-06-032	Requirements of National Kidney and Transplant Institute, for the Supply and Delivery of Eleven Thousand Six Hundred Fifty Three (11,653) Bottles of Sterile Water for Injection 1L Twist Cap (for Irrigation Plastic) with RFQ No. 25-293
		25-06-033	Requirements of New Era General Hospital, for the Supplier's Accreditation
		25-06-034	Requirements of Jose B. Lingad Memorial General Hospital, for the Procurement of Various Drugs and Medicines under IB No. 2025-05-06 (26)
		25-06-035	Request for quotation requirements of Jose B. Lingad Memorial General Hospital, for the Procurement of Balanced Salt Solution 500mL Bottle and other Drugs and Medicines through RFQ No. 2025-5-062BAC under P.O. No. 25-06-0552
		25-06-036	Requirements of Far North Luzon General Hospital and Training Center, for the Request for Quotation: Bicarbonate Powder for Hemodialysis under PR#2025-06-628
		25-06-037	Requirements of Amang Rodriguez Memorial Medical Center, for the Supplier's Registration
		25-06-038	Request for quotation requirements of Don Jose S. Monfort Medical Center, for RFQ 25-05-364 under Procurement of Various Drugs and Medicines
		25-06-039	Request for quotation requirements of Don Jose S. Monfort Medical Center, for RFQ 25-06-420 under Procurement of Nutritional Supplement
		25-06-040	Request for quotation requirements of Don Jose S. Monfort Medical Center, for RFQ 25-06-420 under Procurement of Nutritional Supplement
		25-06-041	Request for quotation requirements of Las Piñas General Hospital and Satellite Trauma Center, for the Request for Quotation - Bupivacaine Hydrochloride 5mg/mL (0.5%) Solution for Spinal Injection with 8% Dextrose, 4mL under Ref. No. 12186535
			Request for quotation requirements of Cagayan

		25-06-042	Valley Medical Center, under Dialyzer (High Flux) with Quotation No. CN-2025-07-28 / PR No. CN-2025-06-96
		25-06-043	Request for quotation requirements of Pag-IBIG Fund Corporate Headquarters - Makati, under Pag-IBIG Fund CHQ (Supply and Delivery of Various Medicines with PR No. 25-07-0233
		25-06-044	Request for quotation requirements of Governor Celestino Gallares Memorial Medical Center, for the 0.9% Sodium Chloride, 50mL Bottle, Injection with Reference No. 12220063
		25-06-045	Collection requirements of Mayor Hilarion A. Ramiro Sr. Medical Center (MHARSMC), for the Purchase Order Nos. 24-0639 and 24-0635
		25-06-046	Request for post-qua requirements of AFP Medical Center, for the Procurement of Drugs and Medicines Supplies for Public Bidding, AFPMC for CY 2025 (Per Line Item Bidding) (Single Year Framework Agreement) (1 st Rebidding) under Identification No. GHQBAC1-PB-008-GHQ-25
		25-06-047	Authorized to open and maintain deposit accounts and/or trust accounts (the "Deposit Account/s") with Philippine Veterans Bank; (hereinafter referred to as the "Bank") MOSD Branch
		25-06-048	Approval to guarantee the obligations of its subsidiary, Hemotek Renal Center, Inc. in favor of Yulon Finance Philippines Corporation with principal office at the 17/F The Curve Building, 3 rd Ave. cor. 32 nd St., Bonifacio Global City, Taguig pursuant to the Continuing Surety Agreement between the Corporation and Hemotek Renal Center, Inc
		25-06-049	Approval to procure the necessary insurance from a reputable insurance and bonding company for purposes of entering into government bidding
		25-06-050	Authorization to represent Euro-Med and authorized to sign with respect to the processing and obtaining the Certificate of Registration (BIR Form 2303)
		25-06-051	Appointment as responsible officer in the facilitation of the licenses and permits of dangerous drugs and/or CPECs of the Corporation
		25-06-052	Bank resolution to apply for and obtain credit accommodations/facilities from East West Banking Corporation

29 July 2025	Regular BOD meeting	25-07-001	Bidding for the Various Drugs and Medicines (Parenteral Nutrition and Solution, Correcting Electrolysis, Acid-Base and Caloric Disturbances) (Framework Agreement) under (P.R. # 2025-07-1050) by the Corazon Locsin Montelibano Memorial Regional Hospital
		25-07-002	Bidding for the Various Drugs and Medicines (Anesthetics and Drugs Acting on the Musculo-Skeletal System) under (P.R. # 2025-07-1060) by the Corazon Locsin Montelibano Memorial Regional Hospital
		25-07-003	Bidding for Supply and Delivery of Various Hemodialysis Consumables with IB No. UMC 25-26 by the West Visayas State University Medical Center
		25-07-004	Bidding for Supply and Delivery of Food Supplies with Identification No. PIN 2025-07-014 by the Dr. Jose N. Rodriguez Memorial Hospital and Sanitarium
		25-07-005	Bidding for Procurement of Drugs and Medicines 2025-03 (Part 3) under Project Reference No. 11202831 with IB 2025-08-003 (PDAM 03) by the Don Jose S. Monfort Medical Center
		25-07-006	Bidding for Supply and Delivery of Various Drugs and Medicines under IB No. A6-2025-1 by the East Avenue Medical Center
		25-07-007	Bidding for Procurement of Drugs and Medicines with IB No. JCH-25-860-B (Rebid) by the Iloilo Provincial Government/Jesus Colmenares District Hospital
		25-07-008	Bidding for Supply and Delivery of Various Pharmaceuticals with IB No. DM 2025-02B by the Western Visayas Medical Center
		25-07-009	Bidding for Procurement of Various Drugs and Medicines under (IB 2025-PB-017) by the Southern Tagalog Regional Hospital
		25-07-010	Bidding for the Supply and Delivery of Various Medicines for NPC Head Office Clinic (CY 2025) under P.R. No. HO-CBM25-006 / PB250205-NA00011 (PB2) by the National Power Corporation
		25-07-011	Bidding for the Medical Supplies and Laboratory Instrument under Purchase Request No. 9-25-07-1264 for use of San Carlos City Hospital by the San Carlos City Hospital
		25-07-012	Bidding for Procurement of Various Drugs and Medicines under IB No. 2025-08-022-G by the Western Visayas Sanitarium and General

			Hospital
		25-07-013	Bidding under Supply and Delivery of Drugs and Medicines - Lot Bid under ITB No. DEVMH-2025-029 by the Don Emilio Del Valle Memorial Hospital
		25-07-014	Bidding for the Supply and Delivery of Various IV Fluids (13 Line Items - Framework Agreement for One (1) Year) (Early Procurement Activity for CY 2026) under Reference No. IB No. 26-002 by the National Kidney and Transplant Institute
		25-07-015	Requirements of Bataan General Hospital and Medical Center for the Request for Quotation (Negotiated Procurement - Small Value Procurement) under P.R. No. 25-07-474
		25-07-016	Requirements of East Avenue Medical Center for the Notice for Negotiated Procurement (2025-SVP-417) Negotiated Procurement - Small Value Procurement - Supply and Delivery of Various Drugs and Medicines
		25-07-017	Requirements of National Kidney and Transplant Institute, for the Notice of Procurement Opportunity (Emergency Procurement) under P.R. No. 65556C
		25-07-018	Requirements of Bataan General Hospital and Medical Center, for the Request for Quotation (Negotiated Procurement - Small Value Procurement) under P.R. No. 25-07-485
		25-07-019	Requirements of Las Piñas General Hospital and Satellite Trauma Center, for the Sodium Chloride 2.5mEq/mL, 20mL vial under Reference No. 12265966
		25-07-020	Requirements of Las Piñas General Hospital and Satellite Trauma Center, for the Bicarbonate for Hemodialysis under Reference No. 12264421
		25-07-021	Requirements of Lung Center of the Philippines, for the Lidocaine Polyamp, 5mL (44U) with Reference No. 12146736
		25-07-022	Requirements of University of the Philippines Manila/Philippine General Hospital, for the Supply and Delivery of Drugs and Medicines: Glucose (dextrose) 50%, 50mL vial (IV) under Project Reference No. BAC-2025-03-0188 (2 nd Re-Process)
		25-07-023	Requirements of Far North Luzon General Hospital and Training Center, for the Request for Quotation: Drugs and Medicines under PR# 2025-07-731
			Request for Quotation requirements of Don Jose

		25-07-024	S. Monfort Medical Center, for RFQ 25-07-470 Procurement of Various Drugs and Medicines
		25-07-025	Request for Quotation requirements of Governor Celestino Gallares Memorial Medical Center, for the 0.9% Sodium Chloride, 500mL (Glass) (bottle) with Reference No. 07-1003-2025
		25-07-026	Request for Quotation requirements of Governor Celestino Gallares Memorial Medical Center, for the Metformin HCL, 500mg with Reference No. 07-0995-2025
		25-07-027	Request for Quotation requirements of Governor Celestino Gallares Memorial Medical Center, for the Furosamide, 10mg/ml 2ml or 20mg/2ml and Ipratropium Bromide + Salbutamol, 500mcg + 2.5mg x 2.5ml with Reference No. 07-0985-2025
		25-07-028	Request for Quotation requirements of Governor Celestino Gallares Memorial Medical Center, for the Lactated Ringer's Solution, 1 Liter with Reference No. 07-1082-2025
		25-07-029	Request for Quotation requirements of Governor Celestino Gallares Memorial Medical Center, for the 0.9% Sodium Chloride, 1 Liter with Reference No. 07-1081-2025
		25-07-030	Requirements of Province of Apayao, for the Request for Quotation under PR No. 027-07- 2025
		25-07-031	Request for Quotation requirements of Department of the Interior and Local Government, under Procurement of Medicines under RFQ No. 2025-08-127
		25-07-032	Requirements of Province of Misamis Occidental, for the Negotiated Procurement - Small Value Procurement under P.R. No. 2025- 08-1509
		25-07-033	Requirements of Research Institute for Tropical Medicine (RITM), under the category Request for Quotation Mode of Procurement: Small Value Procurement under PR No. 25-08-1258 with RFQ No. 13536
		25-07-034	Authorization to file a Declaration of Actual Use renewal of the trademark, Hivent EM, with Document No. HIVENT EM 4/2019/00009258 with the Intellectual Property Office
		25-07-035	Supplier's renewal of accreditation requirements of The Medical City
		25-07-036	Authorization to file, represent and sign, submit requirements for the company's renewal/amendment application for License to

			Purchase Controlled Chemicals with the Philippine National Police, Crame
		25-07-037	Notification to PrimeWater Infrastructure Corp. for termination of any further use of PrimeWater Infrastructure Corp. facilities in Euro-Med La Union Warehouse/Depot
		25-07-038	Authorization to execute, process receipts for business with Bureau of Internal Revenue (BIR) RDO 116, for Euro-Med Laboratories Phil., Inc., Head Office
26 August 2025	Regular BOD meeting	25-08-001	Bidding for the Procurement of Drugs and Medicines 4 th Quarter - 2025 under ITB No. 2025-00-16 by the Mayor Hilarion A. Ramiro Sr. Medical Center (MHARSMC)
		25-08-002	Bidding for the Supply and Delivery of Various Drugs and Medicines (SPPMP) under ITB No. 2025-495 by the Rizal Medical Center
		25-08-003	Request for quotation Supply and Delivery of Various Medicines (10 lots), as per BSP Terms of Reference: 1) Lot 1 - 5,000 pcs. Ascorbic Acid 500mg Tablet, 2) Lot 2 - 700 pcs. Ciprofloxacin 500mg Tablet, 5) Lot 5 - 5,000 pcs. Paracetamol 500mg Tablet, 8) Lot 8 - 100 pcs. Fluocinonide 0.05% cream 5g, 9) Lot 9 - 3,000 pcs. Cetirizine 10mg Tablet, and 10) Lot 10 - 500 pcs. Levofloxacin 500mg Tablet by the Bangko Sentral ng Pilipinas (BSP)
		25-08-004	Bidding for Procurement of Drugs and Medicines with IB No. 2025-09-09(34) by the Adela Serra Ty Memorial Medical Center
		25-08-005	Bidding under Supply and Delivery of Fluids-Rebid under ITB No. 2025-08-0323 by the Davao Regional Medical Center
		25-08-006	Bidding for the Supply and Delivery of Various Drugs and Medicines for Poison Control Unit for FY 2025 with IB No. BAC II 2025-012 by the Baguio General Hospital and Medical Center
		25-08-007	Bidding for the Supply and Delivery of Various Drugs and Medicines for FY 2025 with IB No. BAC II 2025-013 by the Baguio General Hospital and Medical Center
		25-08-008	Bidding for the Supply and Delivery of Various Pharmaceutical Supplies (9 Items - Line Bidding) Early Procurement Activity (EPA) for CY 2026 under Reference No. IB No. 26-003 by the National Kidney and Transplant Institute
		25-08-009	Bidding for the Supply and Delivery of Various Medicines (142 Line Items - Framework Agreement for One (1) Year) Early Procurement

			Activity (EPA) for CY 2026 under Reference No. IB No. 26-021 by the National Kidney and Transplant Institute
		25-08-010	Bidding for Supply and Delivery of Drugs and Medicines (Lot No. 1 to Lot No. 14); PR No. 25-3094 dated 25 July 2025; SN 111-2025 by the City Government of Cagayan de Oro
		25-08-011	Bidding for the Consignment Request No. 25-08-002 for use of the San Carlos City Hospital by the San Carlos City Hospital
		25-08-012	Bidding for the Line Procurement of Drugs and Medicines with (IB No. 2025-019) by the Joni Villanueva General Hospital
		25-08-013	Bidding for the Supply and Delivery of Various Drugs and Medicines for 4 th Quarter 2025 Use (05-2025DM-BACB-ITB) by the Mariano Marcos Memorial Hospital and Medical Center
		25-08-014	Bidding for the Supply and Delivery for Various Medicine by the Minglanilla District Hospital
		25-08-015	Bidding for the Supply and Delivery of Various Drugs and Medicines - IM, IV, IV Preparations for Dr. Jose Rizal Memorial Hospital, Dapitan City under IB No. PB-2025-09-40 by the Dr. Jose Rizal Memorial Hospital
		25-08-016	Bidding for the Supply and Delivery of Drugs and Medicines with PIN 2025-09-020 by the Dr. Jose N. Rodriguez Memorial Hospital and Sanitarium
		25-08-017	Bidding for the Drugs and Medicines Under Purchase Request No. 9-25-08-1507 for use of San Carlos City Hospital, This City by the San Carlos City Hospital
		25-08-018	Bidding for Small Value Procurement under PR No. 25-09-1399 by the Research Institute for Tropical Medicine (RITM)
		25-08-019	Bidding for Supply and Delivery of Medicines for NCGH operations with Project/Contract Reference Number: 2025-032 by the City Government of Naga/Naga City General Hospital
		25-08-020	Bidding for the CSSU Supplies - Acid Concentrate, Bloodlines, Bloodlines with Blood Transfusion Port, Catheter Set, Citric Acid Anhydrous, Dialyzer, Sodium Carbonate under (PR No. 2025-08-1482) by the Corazon Locsin Montelibano Memorial Regional Hospital
		25-08-021	Bidding for the Various Drugs and Medicines: Cardiovascular Drugs and Respiratory Drugs (Framework Agreement) under (PR No. 2025-

			08-1469) by the Corazon Locsin Montelibano Memorial Regional Hospital
		25-08-022	Bidding for the Various Drugs and Medicines: Anesthetics, Drugs Affecting the Blood and Drugs to Reduce Cerebral Edema (Framework Agreement) under (PR No. 2025-08-1471) by the Corazon Locsin Montelibano Memorial Regional Hospital
		25-08-023	Bidding for the Supply and Delivery of Drugs and Medicines - Framework Agreement (Single Year) under ITB No. SAMCH-2025-PB(FA)-19 by the St. Anthony Mother and Child Hospital
		25-08-024	Bidding under Procurement of Various Intravenous Fluids for Six (6) Provincial Hospitals CY 2025, (2 nd SEM) with ID No. PGLDN 101-25-08-2185 by the Provincial Government of Lanao Del Norte
		25-08-025	Bidding under Supply and Delivery of Various Drugs and Medicines Public Bidding 2025 (Lot 1-Fluids) under Philgeps IB Ref. No. 12388194 by the Cagayan Valley Medical Center
		25-08-026	Bidding for the Supply and Delivery of Various Pharmaceutical Supplies for CY 2025 under IB-2025-120 by the Philippine Children's Medical Center
		25-08-027	Bidding for the Early Procurement Activity (EPA) of Various Drugs and Medicines IV Fluids Drugs & Electrolytes CY 2026 under ITB No. 2026-DM-29/PIN No. 2026-DM-29 by the Jose R. Reyes Memorial Medical Center
		25-08-028	Request for quotation requirements of Metro Pacific Health Solutions, under Metro Pacific Health - Industrial RFQ for Medicines
		25-08-029	Request for quotation requirements of St. Anthony Mother and Child Hospital, under Request for Quotation (Small Value Procurement) with RFQ No. 2025-144 under PR No. 2508008 / 178
		25-08-030	Request for quotation requirements of Don Jose S. Monfort Medical Center, for Procurement of Drugs and Medicines under PR No. 25-09-638
		25-08-031	Requirements of Province of Misamis Occidental, for the Negotiated Procurement - Small Value Procurement under P.R. No. 2025-07-1493
		25-08-032	Requirements of Province of Misamis Occidental, for the Negotiated Procurement - Small Value Procurement under P.R. No. 2025-08-1581

		25-08-033	Requirements of Province of Misamis Occidental, for the Negotiated Procurement - Small Value Procurement under P.R. No. 2025-09-1704
		25-08-034	Requirements of Veterans Memorial Medical Center, for the Request for Quotation (RFQ) of PH - 0.9% Sodium Chloride 1L Bottle for Irrigation (2 nd Posting)
		25-08-035	Requirements of Veterans Memorial Medical Center, for the Request for Quotation (Negotiated Procurement - Small Value Procurement) under P.R. No. 25-09-543
		25-08-036	Requirements of Research Institute for Tropical Medicine (RITM), under the category Request for Quotation Mode of Procurement: Small Value Procurement under PR No. 25-07-1169 with RFQ No. 13573
		25-08-037	Requirements of Research Institute for Tropical Medicine (RITM), under the category Request for Quotation Mode of Procurement: Small Value Procurement under PR No. 25-09-1387 with RFQ No. 13816
		25-08-038	Requirements of Research Institute for Tropical Medicine (RITM), under the category Request for Quotation Mode of Procurement: Small Value Procurement under PR No. 25-09-1409 with RFQ No. 13826
		25-08-039	Requirements of Bataan General Hospital and Medical Center, for the Request for Quotation (Negotiated Procurement - Small Value Procurement) under P.R. No. 25-09-543
		25-08-040	Requirements of Bataan General Hospital and Medical Center, for the Request for Quotation (Negotiated Procurement - Small Value Procurement) under P.R. No. 25-09-546
		25-08-041	Requirements of Danao District Hospital, for the Purchase Order No. 25-000352
		25-08-042	Requirements of Province of Apayao, for the Request for Quotation under P.R. No. 032-09-2025
		25-08-043	Requirements of East Avenue Medical Center, for the Notice for Small Value Procurement 2025-NGPA-SVP-013
		25-08-044	Requirements of Don Emilio Del Valle Memorial Hospital, under Procurement of Drugs and Medicines under P.O. No. 2025-07-0409
		25-08-045	Requirements of Eversley Childs Sanitarium and General Hospital, for Medical Devices and

			Reagent
		25-08-046	Requirements of University of the Philippines Manila/Philippine General Hospital, for Negotiated Procurement - Emergency Cases (Sec.35.2 d) under Project Reference No. BAC-2025-09-0779
		25-08-047	Requirements of Philippine Red Cross, for processing and issuance of Purchase Order under Supply and Delivery of Hemodialysis Treatment Supplies for Philippine Red Cross Dialysis Center
		25-08-048	Request for quotation requirements of Lung Center of the Philippines, for Procurement of Drugs and Medicine for OR Use - Levobupivacaine 0.5% AMP
		25-08-049	Request for quotation requirements of Lung Center of the Philippines, for NSS 100mL Vial for Quotation with Reference No. 12383593
		25-08-050	Request for quotation requirements of Governor Celestino Gallares Memorial Medical Center, for the Dextrose 5% in Lactated Ringer's Solution, 500mL and Dextrose 5% Water, 500mL under Canvass Form No. 09-1346-2025
		25-08-051	Request for quotation requirements of Dr. Jose Rizal Memorial Hospital, for the Request for Quotation No. 2025-09-113 Negotiated (Small Value Procurement) under Project Reference No. 2025-09-337
		25-08-052	Authorization to sign contract or do any other act it enters with Avega Managed Care Inc.
		25-08-053	Authorization to sign, execute and deliver contracts, documents, agreements and other writings of whatever nature, kind and description, with G-Xchange, Inc. relative to the Corporation's application for GCash services
		25-08-054	Authorization to open and maintain deposit accounts and/or trust accounts (the "Deposit Account/s") with Philippine Veterans Bank, MOSD Branch
		25-08-055	Authorization to act as surety for the purpose of securing the obligations incurred or which hereafter may be incurred by the Corporation subsidiary, Hemotek Renal Center, Inc., doing business under the name and style of Hemotek Dialysis Center and Hemotek Renal Solutions, in whose financial success the Corporation has financial interest with China Banking Corporation

30 September 2025	Regular BOD meeting	25-09-001	Approval on the appointment Mr. Edward Trono Hizon, as Vice President for Sales of the Corporation effective 01 October 2025
		25-09-002	Authorization and approval to transact with the Land Bank of the Philippines, its branches, subsidiaries and affiliates for the availment of banking products and services and subscribe to WeAccess facility
		25-09-003	Bidding for Supply and Delivery of Medical, Dental and Laboratory Supplies for NCGH operations with Project/Contract Reference Number: 2025-033 by the City Government of Naga/Naga City General Hospital
		25-09-004	2025 133 rd Public Bidding - Supply and Delivery of Pedia Products and Supplies for Nutrition and Dietetics Department Use under ITB No. BGHMCPB-2025-09-133 by the Bataan General Hospital and Medical Center
		25-09-005	Bidding for the Procurement of Goods: Supply and Delivery of Drugs and Medicines for F.Y. 2026 under IB 2025-30 by the National Children's Hospital
		25-09-006	Bidding for Procurement of Drugs and Medicines 2025-05 (Part 5) with IB 2025-10-005 (PDAM 05) under Project Reference No. 12381162 by the Don Jose S. Monfort Medical Center
		25-09-007	Bidding for Supply and Delivery of Various Vaccines, Immunologicals, Vitamins, Minerals and IV Fluids and Various Drugs and Medicines - Framework Agreement under IB2025-052C by the Batangas Medical Center
		25-09-008	Bidding for Purchase of I.V. Fluids with Bid No. HMO-25-1192-B by the Iloilo Provincial Capitol - PGSO
		25-09-009	Bidding for the Early Procurement Activity (EPA) of Various Grocery Products CY 2026 under ITB No. 2026-FS-38/PIN No. 2026-FS-38 by the Jose R. Reyes Memorial Medical Center
		25-09-010	Bidding for Supply and Delivery of Drugs, Medicines, Anaesthetic, Radiographic Contrast Medium, Parenteral Nutrition, Controlled Substances, Oxytocic Drugs, IV Fluids and Solutions for Injection under P.R. No. 2025-09-401 Lot Bid Lot 5 Delivery of IV Fluids and Solutions for Injection by the Provincial Government of Guimaras
			Bidding for Procurement of Drugs and

		25-09-011	Medicines with Project Reference No. MRH-064-2025 by the Margosatubig Regional Hospital
		25-09-012	Bidding for Purchase of Fourth Quarter Dialysis Supplies for the Dialysis Center in the City of Dasmariñas under Reference No. 12443298 by the City Government of Dasmariñas
		25-09-013	Bidding for Supply and Delivery of Various Drugs and Medicines - Batch 1 (Early Procurement Activity) (Framework Agreement) with Project Reference No.: 25-10-000029AM-EPA by the Eversley Childs Sanitarium and General Hospital
		25-09-014	Bidding for Supply and Delivery of Various Common Medical Supplies - Batch 3 (EPA) (Framework Agreement) with Project Reference No.: 25-10-000078N-EPA by the Eversley Childs Sanitarium and General Hospital
		25-09-015	Bidding for Supply and Delivery of Various Drugs and Medicines - Batch 4 (Early Procurement Activity) (Framework Agreement) with Project Reference No.: 25-10-000032AM-EPA by the Eversley Childs Sanitarium and General Hospital
		25-09-016	Bidding for Supply and Delivery of Various Drugs and Medicines - Batch 3 (Early Procurement Activity) (Framework Agreement) under Project Reference No.: 25-10-000031AM-EPA by the Eversley Childs Sanitarium and General Hospital
		25-09-017	Bidding for Supply and Delivery of Various Oral Nutritional Supplements to Eversley Childs Sanitarium and General Hospital (Framework Agreement) with Project Reference No.: 25-10-000026AM-EPA by the Eversley Childs Sanitarium and General Hospital
		25-09-018	Bidding for the Line Procurement of Drugs and Medicines with (IB No. 2025-023) by the Joni Villanueva General Hospital
		25-09-019	Bidding for the Pharmaceutical Supplies under ITB No.: 095.25 by the Philippine Heart Center
		25-09-020	Bidding for the Procurement of Drugs and Medicines (Subject to Framework Agreement) with IB No. PB-GOODS 2026-002 by the Amang Rodriguez Memorial Medical Center
		25-09-021	Bidding for Procurement of Drugs and Medicines under PB 33-2025 by the Bicol Regional Hospital and Medical Center
		25-09-022	Bidding for the Procurement of Drugs and Medicines for Anesthesia, Neurology and Pain

			Management (Early Procurement Activity for 2026) with Project Identification No. R2TMC-BAC1-2025-100 by the Region II Trauma and Medical Center
		25-09-023	Bidding for the Procurement of Drugs and Medicines for Cardiovascular, Renal and Endocrine (Early Procurement Activity for 2026) with Project Identification No. R2TMC-BAC1-2025-102 by the Region II Trauma and Medical Center
		25-09-024	Bidding for the Procurement of Drugs and Medicines for Gastrointestinal and Nutritional Agents (Early Procurement Activity for 2026) with Project Identification No. R2TMC-BAC1-2025-103 by the Region II Trauma and Medical Center
		25-09-025	Bidding for the Procurement of Various Drugs and Medicines (Early Procurement Activity for 2026) with Project Identification No. R2TMC-BAC1-2025-105 by the Region II Trauma and Medical Center
		25-09-026	Bidding for the 2026 6 th Public Bidding: Supply and Delivery of Drugs and Medicines and Medical Gas for 2026 Consumption (Early Procurement Activity) under ITB No. BGHMCPB-2026-06 by the Bataan General Hospital and Medical Center
		25-09-027	Bidding for the Supply and Delivery of Various Drugs and Medicines - PCGH with ITB No. BAC-25-1015D by the City Government of Pasig/Pasig City General Hospital (PCGH)
		25-09-028	Request for quotation requirements of Development Bank of the Philippines, under Request for Quotation (RFQ) Supply and Delivery of Medical Supplies and Equipment under Solicitation No. P-ERD-25-00482
		25-09-029	Request for quotation requirements of Governor Celestino Gallares Memorial Medical Center, for the Lactated Ringer's Solution, 1 Liter under Canvass Form No. 09-1416-2025
		25-09-030	Request for quotation requirements of Governor Celestino Gallares Memorial Medical Center, for the Dextrose 5% in Lactated Ringer's Solution, 1L and Mannitol 20%, 500mL, Intravenous under Canvass Form No. 10-1603-2025
		25-09-031	Request for quotation requirements of Governor Celestino Gallares Memorial Medical Center, for the 0.9% Sodium Chloride, 1L under Canvass Form No. 10-1577-2025

		25-09-032	Request for quotation requirements of Las Piñas General Hospital and Satellite Trauma Center, for the Request for Quotation - Normal Saline (0.9% Sodium Chloride) 1000mL under Ref. No. 12450166
		25-09-033	Requirements of Argao District Hospital, for the Drugs and Medicines as Emergency Purchase
		25-09-034	Requirements of Valenzuela Medical Center, under RFQ - Supply and Delivery of Various Drugs and Medicines and IV Fluids for 4 th Quarter of CY 2025
		25-09-035	Requirements of Jose B. Lingad Memorial General Hospital, for the Purchase Order No. 25-10-1047 Small Value Procurement
		25-09-036	Requirements of Badian District Hospital, for the Procurement of Various Drugs and Medicine
		25-09-037	Requirements of Badian District Hospital, for the Drugs and Medicines as Emergency Purchase
		25-09-038	Requirements of Balamban District Hospital, for the Drugs and Medicines as Emergency Purchase
		25-09-039	Requirements of Bantayan District Hospital, for the Drugs and Medicines as Emergency Purchase
		25-09-040	Requirements of Bogo District Hospital, for the Drugs and Medicines as Emergency Purchase
		25-09-041	Requirements of Camotes District Hospital, for the Drugs and Medicines as Emergency Purchase
		25-09-042	Requirements of Carcar District Hospital, for the Drugs and Medicines as Emergency Purchase
		25-09-043	Requirements of Daanbantayan District Hospital, for the Drugs and Medicines as Emergency Purchase
		25-09-044	Requirements of Danao District Hospital, for the Drugs and Medicines as Emergency Purchase
		25-09-045	Requirements of Malabuyoc District Hospital, for the Drugs and Medicines as Emergency Purchase
		25-09-046	Requirements of Minglanilla District Hospital, for the Drugs and Medicines as Emergency Purchase
		25-09-047	Requirements of Oslob District Hospital, for the Drugs and Medicines as Emergency Purchase
		25-09-048	Requirements of Pinamungajan District Hospital, for the Drugs and Medicines as Emergency Purchase

		25-09-049	Requirements of Sogod District Hospital, for the Drugs and Medicines as Emergency Purchase
		25-09-050	Requirements of Tuburan District Hospital, for the Drugs and Medicines as Emergency Purchase
		25-09-051	Requirements of Veterans Memorial Medical Center, for the PH - 0.9% Sodium Chloride 1L Bottle for Irrigation (4 th Posting)
		25-09-052	Requirements of National Kidney and Transplant Institute, for the Disease Specific Powder Formula for Diabetic Patients, Oral/Tube Feeding (Repeat Order)
		25-09-053	Requirements of Corazon Locsin Montelibano Memorial Regional Hospital, for the Request for Quotation under Purchase Request No. 2025-09-1776
		25-09-054	Requirements of Office of the Ombudsman, under Request for Quotation - QN 2025-044-OCT (GAO) : Medical Clinic Medicines for CY 2025
		25-09-055	Requirements of University of the Philippines Manila/Philippine General Hospital for Negotiated Procurement under Project Reference No. BAC-2025-10-0889
		25-09-056	Requirements of West Visayas State University Medical Center, for Consignment under Drugs and Medicines
		25-09-057	Requirements of Provincial Government of Davao Oriental (Province of Davao Oriental), for the Procurement of Drugs and Medicines - Fluids (D5 0.9 NSS 1L, etc)
		25-09-058	Requirements for payment requirements of Bangko Sentral ng Pilipinas
28 October 2025	Regular BOD meeting	25-10-001	Declaration of cash dividend of ₱0.07 per share to be taken from the unrestricted retained earnings of the Corporation as of 31 December 2024, to all stockholders of record as of 14 November 2025 and payable on 01 December 2025
		25-10-002	Bidding for Supply and Delivery of Various Pharmaceuticals under IB No. 2025-39 by the Bicol Medical Center
		25-10-003	Requirements of Amang Rodriguez Memorial Medical Center, for the Procurement of Various Drugs and Medicines
		25-10-004	Requirements of Corazon Locsin Montelibano Memorial Regional Hospital, for the Request for Quotation (PR# 2025-10-1897)
			Requirements of San Lorenzo Ruiz General

		25-10-005	Hospital, for Procurement of Various Drugs & Medicines and Intravenous Fluids under OMP 2025-10-114
		25-10-006	Bidding for Purchase of Fourth Quarter IV Fluids and Medical Supplies for the Pharmacy Department of the Pagamutan ng Dasmariñas under Reference No. 12478642 by the City Government of Dasmariñas
		25-10-007	Bidding for the Line Procurement of Drugs and Medicines under (IB No. 2026-005) by the Joni Villanueva General Hospital
		25-10-008	Bidding for Supply and Delivery of Medical Supplies CY 2026 (Three Hundred Nine (309) Line Items (Early Procurement Activity) under IB No. G-09-2026-PB by the National Center for Mental Health
		25-10-009	Bidding for the Purchase & Delivery of Fluids for the Different Hospitals of the Province-PGIS-201-2025 by the Provincial Government of Ilocos Sur
		25-10-010	Bidding for the Supply and Delivery of Various Drugs and Medicines (Early Procurement Activity) under IB No. 2025-11-11 (47) by the Jose B. Lingad Memorial General Hospital
		25-10-011	Bidding under Supply and Delivery of Special Medical Supplies (Early Procurement Activity) under EPA-2026-07 by the Vicente Sotto Memorial Medical Center
		25-10-012	Bidding for Medicines under IB No. DD-2025-217(m) by the Provincial Government of Antique/Angel Salazar Memorial General Hospital
		25-10-013	Bidding for Supply and Delivery of Various Medical Supplies for Patient Use for Section of Respiratory Services (SRS) under Single - Year Framework Agreement under Reference No. LCP (EPA) IB No. 25-93 by the Lung Center of the Philippines
		25-10-014	Bidding for Supply and Delivery of Various IV Fluids in Glass and Plastic Bag/Bottle Packages and Small Volume IV in Bag/Plastic/Glass Subject to Single Year Framework Agreement under Reference No. LCP (EPA) IB No. 25-108 by the Lung Center of the Philippines
		25-10-015	Bidding for Procurement of IV Fluids under Bid No. IPH-25-1396-B(Rebid) by the Iloilo Provincial Government/Iloilo Provincial Hospital
			Bidding for the Supply and Delivery of Drugs

		25-10-016	and Medicines for CY 2026 (Early Procurement Activity) under IB No. 2026-02 by the Dr. Jose Fabella Memorial Hospital
		25-10-017	Bidding for the Supply and Delivery of Various Pharmaceutical Supplies for CY 2026 under Early Procurement Activity with IB-2026-001 by the Philippine Children's Medical Center
		25-10-018	Bidding for Supply and Delivery of Various Intravenous Fluids under BAC No. FA 2026-002 by the Cebu South Medical Center
		25-10-019	Bidding under Supply & Delivery of Drugs and Medicines under IB No. 2025-10-0403 by the Davao Regional Medical Center
		25-10-020	Bidding under Supply & Delivery of Fluids under IB No. 2025-10-0404 by the Davao Regional Medical Center
		25-10-021	Bidding for Procurement of Drugs and Medicines Package 1-A: Fast Moving - Early Procurement Activity (EPA) with IB No. 2025-11-18(47) by the Adela Serra Ty Memorial Medical Center
		25-10-022	Bidding for Procurement of Drugs and Medicines: I.V. Fluids - Early Procurement Activity (EPA) with IB No. 2025-11-18(49) by the Adela Serra Ty Memorial Medical Center
		25-10-023	Bidding under Supply & Delivery of Fluids under IB No. 2025-11-0444 by the Davao Regional Medical Center
		25-10-024	Bidding for Supply and Delivery of IV Fluids, Solution for Injection and Parenteral Solution under P.R. No. 2025-10-485re-bid by the Provincial Government of Guimaras/Buenavista Emergency Hospital
		25-10-025	Bidding for Supply and Delivery of Various Drugs and Medicines under Framework Agreement with ITB No. 2025-10-052 by the Southern Isabela Medical Center
		25-10-026	Bidding for Supply and Delivery of Drugs and Medicines with Bid No. 2025-10-15-147 (ABC 2025-055) by the Southern Philippines Medical Center
		25-10-027	Bidding for Supply and Delivery of Various Drugs and Medicines for Pharmacy and Various Drugs and Medicines for Palliative Care with IB No. 2026-02 by the West Visayas State University Medical Center
		25-10-028	Bidding for the CSSU Various Medical Supplies - Adhesive Plaster, Airway Guedel, Alcohol, Alcohol Swab, Catheter Umbilical, Diaper,

			Enteral Feeding Container, Lubricating Jelly, Oxygen Humidifier and Skin Marker Fine Tip with Ruler under (P.R. No. 2025-10-1961) by the Corazon Locsin Montelibano Memorial Regional Hospital
		25-10-029	Bidding for the Adult Nutritional Formula under (P.R. No. 2025-10-1943) by the Corazon Locsin Montelibano Memorial Regional Hospital
		25-10-030	Bidding for the Drugs and Medicines - Anti-Infectives, Parenteral Nutrition & Solution Correcting Electrolysis, Acid-Base and Caloric Disturbances (Framework Agreement) under (P.R. No. 2025-10-1918) by the Corazon Locsin Montelibano Memorial Regional Hospital
		25-10-031	Bidding for the CSSU Supplies - Acid Concentrate, AV Fistula Needle, Bloodlines, Catheter Set, Citric Acid Anhydrous, Dialyzer and Sodium Bicarbonate under (P.R. No. 2025-10-1807) by the Corazon Locsin Montelibano Memorial Regional Hospital
		25-10-032	Bidding for Supply and Delivery of IV Fluids for CY 2026 with Public Bidding No. VMC-2026-004 by the Valenzuela Medical Center
		25-10-033	Bidding for Supply and Delivery of Various Medical Supplies for Hemodialysis Unit (Framework Agreement) (Early Procurement Activity) with Project Reference No. 25-10-000073M-EPA by the Eversley Childs Sanitarium and General Hospital
		25-10-034	Bidding for the Ancillary Supplies (Early Procurement Activity) under PB-AS-2026-002 by the Las Piñas General Hospital and Satellite Trauma Center
		25-10-035	Bidding for the Supply and Delivery of Various Drugs and Medicines and Other Related Products for FY 2026 Use under (01-2026DM-BACB-ITB) by the Mariano Marcos Memorial Hospital and Medical Center
		25-10-036	Bidding for Supply & Delivery of Local Anesthetics under IB No. A1-2026-16 by the East Avenue Medical Center
		25-10-037	Bidding for Supply & Delivery of Ophthalmological Medicines under IB No. A1-2026-17 by the East Avenue Medical Center
		25-10-038	Bidding for Supply & Delivery of ORS & Electrolytes under IB No. A1-2026-19 by the East Avenue Medical Center
			Bidding for Supply & Delivery of Respiratory

		25-10-039	Medicines under IB No. A1-2026-23 by the East Avenue Medical Center
		25-10-040	Bidding for Supply & Delivery of Cardiovascular Medicines under IB No. A1-2026-11 by the East Avenue Medical Center
		25-10-041	Bidding for Supply & Delivery of Parenteral Solutions (Single-Year Framework Agreement) under IB No. A1-2026-21 by the East Avenue Medical Center
		25-10-042	Bidding for Supply & Delivery of Drugs and Medicines for Department of Anesthesiology Use under IB No. A1-2026-1 by the East Avenue Medical Center
		25-10-043	Bidding for Supply & Delivery of Drugs and Medicines for Department of Anesthesiology Use - VAT Exempt under IB No. A1-2026-2 by the East Avenue Medical Center
		25-10-044	Bidding for Supply & Delivery of Analgesics & Antipyretics under IB No. A1-2026-5 by the East Avenue Medical Center
		25-10-045	Bidding for Supply & Delivery of Cardiovascular Medicines - VAT Exempt under IB No. A1-2026-12 by the East Avenue Medical Center
		25-10-046	Bidding for Supply & Delivery of Gastrointestinal Medicines under IB No. A1-2026-14 by the East Avenue Medical Center
		25-10-047	Bidding under Supply and Delivery of Various Drugs and Medicines (IV Fluids/Parenterals) with IB No. 2025-10-058-G-EPA by the Far North Luzon General Hospital and Training Center
		25-10-048	Bidding for Supply and Delivery of Various Pharmaceutical Drugs, Medicines and Contrast Media (EPA) with IB No. 2026-GOODS-007-02-1103 by the Ilocos Training and Regional Medical Center (ITRMC)
		25-10-049	Bidding for Procurement of IV Fluids for the use of Libacao Municipal Infirmary and Godofredo P. Ramos Hospital, Province of Aklan (Re-Bidding) under (ITB No. 2025-1000) by the Provincial Government of Aklan (Libacao Municipal Infirmary and Godofredo P. Ramos Hospital)
		25-10-050	Bidding under Supply and Delivery of Drugs and Medicines (Early Procurement Activity) Lot Bid under EPA-2026-22 by the Vicente Sotto Memorial Medical Center
			Bidding for Request for Quotation - Lactated

		25-10-051	Ringer's Solution, 1000mL and 0.9 Sodium Chloride for Irrigation, 1000mL by the Lung Center of the Philippines
		25-10-052	Bidding for the Various Direct Medical Supplies CY 2026 - Nephrology Hemodialysis Supplies / Peritoneal Dialysis Supplies with IB-2026-008 C by the Philippine Children's Medical Center
		25-10-053	Bidding for Procurement of Various Drugs and Medicines (EPA 2026) under (IB 2026-PB-002) by the Southern Tagalog Regional Hospital
		25-10-054	Requirements of Province of Misamis Occidental, for the Small Value Procurement under P.R. No. 2025-11-2065
		25-10-055	Requirements of Province of Apayao, for the Request for Quotation under PR No. 2025-10-118
		25-10-056	Requirements of City Government of Pasig, for the Supply and Delivery of Various Drugs and Medicines - PCGH & PCCH under RFQ No. 100-25-08-971
		25-10-057	Request for quotation requirements of Dr. Jose Fabella Memorial Hospital, for the Request for Quotation
		25-10-058	Request for quotation requirements of Dr. Jose Rizal Memorial Hospital, for the Negotiated (Small Value Procurement) under Quotation No. 2025-11-153
		25-10-059	Authorized to represent Euro-Med and authorized to sign with respect to the processing and obtaining the Certificate of Registration (BIR Form 2303) with the Bureau of Internal Revenue (BIR)
		25-10-060	Authorization to open bank account (s) with the Development Bank of the Philippines (DBP); to effect fund transfers and/or enroll the corporate bank account(s) in Fund Transfer Facilities (Debit One-Credit All or DOCA); enter into Agreements and sign any and all documents necessary for availing from DBP, in the name of the corporation, its Electronic Banking (e-Banking) services and all its related modules/function, to include but not limited to cashless collections via Point-of-Sale (POS) terminals
25 November 2025	Regular BOD meeting	25-11-001	Bidding for Supply and Delivery of Drugs and Medicines (Retail Pharmacy) under ITB No. 2026-01-02-LUMC by the La Union Medical Center
			Bidding for Supply and Delivery of Drugs and

		25-11-002	Medicines (Regular Pharmacy) under ITB No. 2026-01-01-LUMC by the La Union Medical Center
		25-11-003	Bidding for the Procurement of IV Fluids and Small Volume Parenterals EPA 2026 under IB No. 2026-015 by the Tondo Medical Center
		25-11-004	Bidding under Supply and Delivery of Food and Food Products Early Procurement Activity under (EPA-2026-12) by the Vicente Sotto Memorial Medical Center
		25-11-005	Bidding for Supply and Delivery of Various Drugs and Medicines C.Y 2026 under Public Bidding No. 2025-018 by the Amai Pakpak Medical Center
		25-11-006	Bidding under Supply and Delivery of Various Drugs and Medicines under Single-Year Framework Agreement (Early Procurement Activity) with IB No. 2025-12-01 (56) by the Caraga Regional Hospital
		25-11-007	Bidding for the Medical Supplies by the Philippine Heart Center
		25-11-008	Bidding for the Pharmaceutical Supplies by the Philippine Heart Center
		25-11-009	Bidding under Procurement of Various Pharmaceuticals under IB No. 2025-14-014 by the Northern Mindanao Medical Center
		25-11-010	Bidding for the Procurement of Various I.V. Fluids for CY 2026 with ITB No. 2025 - 669 by the Rizal Medical Center
		25-11-011	Bidding for the Supply and Delivery of Various Drugs and Medicines for CY 2026 under ITB No. 2025-614 by the Rizal Medical Center
		25-11-012	Bidding for the Procurement of Emergency Drugs and Medicine for CY 2026 under ITB No. 2025 - 666 by the Rizal Medical Center
		25-11-013	Bidding for the Procurement of Anesthesia Drugs and Medicine for CY 2026 under ITB No. 2025 - 668 by the Rizal Medical Center
		25-11-014	Bidding for the Supply and Delivery of Various Oral Nutritional Supplements for CY 2026 under ITB No. 2025-714 by the Rizal Medical Center
		25-11-015	Bidding for Supply and Delivery of OR Medical Supplies under (BRGHGMC-GS-2025-16) by the Bicol Region General Hospital and Geriatric Medical Center
		25-11-016	Bidding for Supply and Delivery of Drugs and Medicines (Early Procurement Activity) under (BRGHGMC-GS-2025-20) by the Bicol Region

			General Hospital and Geriatric Medical Center
		25-11-017	Bidding for Supply and Delivery of Various Drugs & Medicines - Lot 2 under ITB No. G-2026-001-LOT 2 by the Provincial Government of Bukidnon
		25-11-018	Bidding for Supply and Delivery of Various Hemodialysis Supplies - Framework Agreement 2026 under IB2025-066C by the Batangas Medical Center
		25-11-019	Bidding for Supply and Delivery of Various Drugs and Medicines - Framework Agreement 2026 under IB2025-066A by the Batangas Medical Center
		25-11-020	Bidding for the Early Procurement Activities (EPA) for the Procurement of Drugs and Medicines CY 2026 under IB 2025-11-0049 by the Quirino Memorial Medical Center
		25-11-021	Bidding under Supply and Delivery of Various Meal Replacement for Nutrition and Dietetics Department (Early Procurement Activity) under IB No. 2025-27 BAC A by the Governor Benjamin T. Romualdez General Hospital and Schistosomiasis Center
		25-11-022	Bidding for the Procurement of Adult Milk Supplement Enteral Nutrition Formula 2026 under 2025-37 by the Mariveles Mental Wellness and General Hospital
		25-11-023	Bidding for the Procurement of Supplemental General Medicines under 2025-29 by the Mariveles Mental Wellness and General Hospital
		25-11-024	Bidding for the Procurement of General Medicines 2026 under 2025-30 by the Mariveles Mental Wellness and General Hospital
		25-11-025	Bidding for the Supply and Delivery of Food Supplies CY: 2026 under PIN 2025-11-027 by the Dr. Jose N. Rodriguez Memorial Hospital and Sanitarium
		25-11-026	Bidding for the Early Procurement Activity (FY 2026) for the Procurement of Goods: Supply and Delivery of Various Drugs and Medicines through Framework Agreement under IB No. 2025-11-032 by the Governor Celestino Gallares Memorial Medical Center
		25-11-027	Bidding for Procurement of Drugs and Medicines (Early Procurement Activity) under MRH-B-004-2026 by the Margosatubig Regional Hospital
			Bidding for Procurement of Oral Nutrition

		25-11-028	Supplement (ONS) (Early Procurement Activity) under MRH-A-005-2026 by the Margosatubig Regional Hospital
		25-11-029	Bidding for Supply and Delivery of Various Pharmaceuticals under Early Procurement Activities (EPA) with (IB No. DM 2026-01B) by the Western Visayas Medical Center
		25-11-030	Bidding for Supply and Delivery of Drugs and Medicines under Bid No. 2025-10-17-172 (ABC 2025-079) by the Southern Philippines Medical Center
		25-11-031	Bidding under Procurement of I.V. Fluids, Medical Supplies, Drugs, Medicines, Laboratory Reagents, Laboratory Supplies and Sutures (Early Procurement Activity) under ITB No. 26-04 (P.R. No. 25-2313) Lot 1 I.V. Fluids by the Province of Biliran/Provincial Government of Biliran
		25-11-032	Bidding for Procurement of Four Thousand (4,000) Pieces NSS 500mL Glass for Pharmacy Use by the Lung Center of the Philippines
		25-11-033	Bidding for the Supply and Delivery of Various Intravenous (IV) Fluids for FY 2026 (Per Line Item Bidding) Single Year Framework Agreement under LOT 04-NEP-2026 (EPA) by the Veterans Memorial Medical Center
		25-11-034	Bidding for the Essential Drugs (Early Procurement Activity) under PB-ED-2026-015 by the Las Piñas General Hospital and Satellite Trauma Center
		25-11-035	Bidding for the Anesthetics Drugs (Early Procurement Activity) under ITB No. PB-AD-2026-013 by the Las Piñas General Hospital and Satellite Trauma Center
		25-11-036	Bidding for the IV Fluids Drugs (Early Procurement Activity) under ITB No. PB-IVF-2026-017 by the Las Piñas General Hospital and Satellite Trauma Center
		25-11-037	Bidding for the Supply and Delivery of Drugs and Medicines EPA CY: 2026 under PIN 2025-11-035 by the Dr. Jose N. Rodriguez Memorial Hospital and Sanitarium
		25-11-038	Bidding for Supply and Delivery of Various Drugs and Medicine for January to December 2026 (Early Procurement Activity) under IB No. 2026-15 by the Dr. Paulino J. Garcia Memorial Research and Medical Center
		25-11-039	Public bidding for the Supply and Delivery of Oral Nutritional Supplements CY 2026 (Seven

			(7) Line Items) (Early Procurement Activity) under IB No. G-012-2026-PB by the National Center for Mental Health
		25-11-040	Public bidding for the Supply and Delivery of Drugs and Medicines (Service Patients) CY 2026 (Two Hundred Twenty-Two (222) Line Items) (Early Procurement Activity) under IB No. G-013-2026-PB by the National Center for Mental Health
		25-11-041	Bidding for Procurement of One Thousand Five Hundred Sixty (1,560) Pieces NSS 500mL (Plastic) Bot for Pharmacy Use by the Lung Center of the Philippines
		25-11-042	Requirements of Province of Misamis Occidental, for the Small Value Procurement under P.R. No. 2025-10-2039
		25-11-043	Requirements of Province of Apayao, for the Request for Quotation under PR No. 2025-10-117
		25-11-044	Requirements of Province of Apayao, for the Request for Quotation under PR No. 039-11-2025
		25-11-045	Requirements of Southern Philippines Medical Center, for the Repeat Order for Purchase Order No. 2025-09-1397
		25-11-046	Request for quotation requirements of Las Piñas General Hospital and Satellite Trauma Center, for the Request for Quotation (RFQ) - Medical Supplies and Laboratory Instruments
		25-11-047	Request for quotation requirements of Governor Celestino Gallares Memorial Medical Center, for the Mefenamic Acid, 500mg under Canvass Form No. 11-1743-2025
		25-11-048	Request for quotation requirements of Governor Celestino Gallares Memorial Medical Center, for the Dobutamine, 50mg/mL, Intravenous and Tramadol, 50mg/mL 2mL or 100mg/2mL, injection
		25-11-049	Authorized to apply, borrow, avail and renew its loans/credit accommodations with Bank of Commerce (" <i>BankCom</i> ") under Omnibus Credit Line available via Promissory Note Loan Facility, Trade Finance Facility with Trust Receipt Facility, and Standby Letter of Credit Facility
16 December 2025	Regular BOD meeting	25-12-001	Bidding under Supply and Delivery of Various Drugs and Medicines under Framework Agreement (Early Procurement Activity) under IB No. 25-FA-90 by the Eastern Visayas Medical

			Center
		25-12-002	Bidding under Supply and Delivery of Various Nutritional, Fluid, Electrolyte Replacement Solutions and Plasma Expanders under Framework Agreement (Early Procurement Activity) under IB No. 2025-FA-96 by the Eastern Visayas Medical Center
		25-12-003	Bidding for Supply and Delivery of Various Medical Supplies and Other Supplies for Hemodialysis under Single - Year Framework Agreement with Reference No. LCP (EPA) IB No. 25-103 by the Lung Center of the Philippines
		25-12-004	Bidding under Supply and Delivery of Drugs and Medicines for FY 2026 - Framework Agreement (Single Year) (Early Procurement Activity) under ITB No. SAMCH-2026-PB(FA)-EPA-04 by the St. Anthony Mother and Child Hospital
		25-12-005	Bidding for the Early Procurement Activities (EPA) for the Supply and Delivery of Various Drugs and Medicines for FY 2026 under IB No. BAC II 2025-019 by the Baguio General Hospital and Medical Center
		25-12-006	Bidding for the Early Procurement Activities (EPA) for the Supply and Delivery of Various Enteral Nutrition Formulas for FY 2026 under IB No. BAC II 2025-017 by the Baguio General Hospital and Medical Center
		25-12-007	Bidding for Procurement of Various Drugs and Medicines under PB 04-2026 (EPA) by the Bicol Regional Hospital and Medical Center
		25-12-008	Bidding for Supply and Delivery of Various Pharmaceuticals for FY 2026 through Framework Agreement under F-IB No. 2025-23 by the Bicol Medical Center
		25-12-009	Bidding for Supply and Delivery of IV Solutions and Parenteral Nutrients for FY 2026 through Framework Agreement under F-IB No. 2025-22 by the Bicol Medical Center
		25-12-010	Bidding for Supply and Delivery of Anesthesia Medicines for FY 2026 through Framework Agreement under F-IB No. 2025-24 by the Bicol Medical Center
		25-12-011	Bidding under Supply and Delivery of Electrolytes (Lot 13) under Philgeps IB No. 12616203 by the Cagayan Valley Medical Center
		25-12-012	Bidding under Early Procurement for Supply and Delivery of Fluids (Lot 4) under Philgeps IB

			No. 12646348 by the Cagayan Valley Medical Center
		25-12-013	Bidding under Supply and Delivery of Anti-Infectives (Lot 1) under Philgeps IB No. 12599504 by the Cagayan Valley Medical Center
		25-12-014	Bidding under Supply and Delivery of Cardiometabolic Medicines (Lot 3) under Philgeps IB No. 12655659 by the Cagayan Valley Medical Center
		25-12-015	Bidding under Supply and Delivery of Medicines Acting on Nervous System (Lot 2) under Philgeps IB No. 12653926 by the Cagayan Valley Medical Center
		25-12-016	Bidding for Supply and Delivery of Elderly Care Milk Supplements for Senior Citizen's of the City of Sto. Tomas, Batangas with Reference No. 12643141 by the City Government of Sto. Tomas, Batangas
		25-12-017	Bidding for the Procurement of Goods: Drugs and Medicine Early Procurement Activity under ITB-BAC2-2026-005 by the San Lazaro Hospital
		25-12-018	Bidding for the Procurement of Goods: Drugs and Medicine Early Procurement Activity under ITB-BAC2-2026-006 by the San Lazaro Hospital
		25-12-019	Bidding for the Early Procurement Activity: Supply and Delivery of Various Drugs and Medicines under ITB No. 2025-00-35 by the Mayor Hilarion A. Ramiro Sr. Medical Center (MHARSMC)
		25-12-020	Bidding under Procurement of Various Intravenous Fluids for Six (6) Provincial Hospitals for 1 st sem 2026 with Project No. 101-25-12 2811 by the Provincial Government of Lanao Del Norte
		25-12-021	Bidding for the Supply and Delivery of Medical Supplies for Dialysis under Framework Agreement under Early Procurement Activity with ITB No. 2025-12-075 by the Southern Isabela Medical Center
		25-12-022	Bidding for the Supply and Delivery of Drugs and Medicine under Framework Agreement under Hospital Income under Early Procurement Activity for FY 2026 with ITB No. 2025-12-073 by the Southern Isabela Medical Center
		25-12-023	Bidding for the Procurement of Supply and Delivery of Various Drugs and Medicines under Framework Agreement under Early Procurement Activity for FY 2026 with ITB No.

			2025-12-072 by the Southern Isabela Medical Center
		25-12-024	Bidding for Supply and Delivery of Medical Fluids under Bid No. 2025-10-15-163 (ABC 2025-071) by the Southern Philippines Medical Center
		25-12-025	Bidding for Supply and Delivery of Nutrition Formulas under Bid No. 2025-10-15-156 (ABC 2025-064) by the Southern Philippines Medical Center
		25-12-026	Bidding for Supply and Delivery of Antiseptics under Bid No. 2025-10-15-160 (ABC 2025-068) by the Southern Philippines Medical Center
		25-12-027	Bidding for IV Fluids under Negotiated Procurement No. GG-2025-251(m) by the Provincial Government of Antique (President Diosdado Macapagal District Hospital)
		25-12-028	Bidding for IV Fluids under Negotiated Procurement No. JJ-2025-237(m) by the Provincial Government of Antique (Ramon Maza Sr. Memorial District Hospital)
		25-12-029	Bidding for the Drugs and Medicines under Purchase Request No. 9-25-11-2113 for Use of San Carlos City Hospital, This City by the San Carlos City Hospital
		25-12-030	Requirements of Southern Philippines Medical Center, for the Repeat Order for Purchase Order No. 2025-10-1693
		25-12-031	Requirements of Province of Apayao, for the Request for Quotation under PR No. 2025-12-126
		25-12-032	Requirements of Las Pinas General Hospital and Satellite Trauma Center, for the Mannitol 20% 500mL, Plastic Bottle with Reference No. 12715101
		25-12-033	Requirements of Province of Misamis Occidental, for the Small Value Procurement under P.R. No. 2025-12-2417
		25-12-034	Request for quotation requirements of Governor Celestino Gallares Memorial Medical Center, for the 0.9% Sodium Chloride for Irrigation 1 L under Canvass Form No. (11-1747-2025)
		25-12-035	Request for quotation requirements of Governor Celestino Gallares Memorial Medical Center, for the 0.9% Sodium Chloride, 1L under Canvass Form No. (11-1792-2025)
		25-12-036	Request for quotation requirements of Governor Celestino Gallares Memorial Medical Center, for the Ipratropium Bromide + Salbutamol, 500mcg + 2.5mg x 2.5ml under Canvass Form No. (10-

			1532-2025)
		25-12-037	Request for quotation requirements of National Kidney and Transplant Institute, for the RFQ No. 26-027: Supply and Delivery of Various Pulmonary Drugs and Medicine (6 Line Items)
		25-12-038	Request for quotation requirements of National Kidney and Transplant Institute, for the RFQ No. 26-035: Supply and Delivery of Various Radiology Supplies (17 Line Items)
		25-12-039	Request for quotation requirements of Province of Misamis Occidental, for the Small Value Procurement under P.R. No. 2025-12-2417
		25-12-040	Request for quotation requirements of Corazon Locsin Montelibano Memorial Regional Hospital, for the Request for Quotation with (PR# 2026-01-0033)
		25-12-041	Request for quotation requirements of Adela Serra Ty Memorial Medical Center, for Procurement of Drugs and Medicines under RFQ No. 814
		25-12-042	Collection requirements of Mayor Hilarion A. Ramiro Sr. Medical Center (MHARSMC), for the Purchase Order No. 25-1158
		25-12-043	Post qualification requirements of Batangas Medical Center, for Supply and Delivery of Various Drugs and Medicines - Framework Agreement 2026 with (IB2025-066A)
		25-12-044	Purchase order requirements of Jose B. Lingad Memorial General Hospital, for the Procurement of 0.9% Sodium Chloride and Other Drugs and Medicines through RFQ No. 2025-11-217BAC under P.O. No. 25-11-1193
		25-12-045	Purchase order requirements of Philippine Heart Center, for the Pharmaceutical Supplies/Medicines
		25-12-046	Purchase order requirements of Philippine Heart Center, for the Medical Supplies
		25-12-047	Emergency purchase requirements of Governor Celestino Gallares Memorial Medical Center, for the Emergency Purchase under PR No. 2025-12-26
		25-12-048	Authorization to transact, file, sign and receive all documents, in connection with its application for a Business Permit Renewal for the year 2026 from the City Hall of Davao for the Company's Davao Branch/Warehouse, located at Door 4, Purok 13, Genesis Auto Center, Inc., (Ma-a Road), Barangay Ma-a, Davao City
			Authorization to transact, file, sign and receive

		25-12-049	all documents, in connection with its application for a Business Permit Renewal for the year 2026 from the City Hall of Tacloban for the Company's Tacloban Branch/Warehouse, located at Purok 7 Brgy 91 Abucay Tacloban City, Leyte
		25-12-050	Authorize to transact, file, sign and receive all documents, in connection with its application for a Business Permit Renewal for the year 2026 from the City Hall of Bacolod for the Company's Bacolod Branch/Warehouse, located at RAM Foods Warehouse, Rio Vista Subdivision, Circumferential Road, Brgy. Taculing, Bacolod City
		25-12-051	Authorization to deliver, process, sign, execute and to transact business with the Bureau of Internal Revenue ("BIR"), for the issuance of the Company's Authority to Release Imported Goods (ATRIG), surety bond and securing TEC
		25-12-052	Authorization to deliver, process, sign, execute and to transact business with the Bureau of Internal Revenue ("BIR"), for the issuance of the Company's Authority to Release Imported Goods (ATRIG), surety bond and securing TEC
		25-12-053	Authorization to process and obtain the Bureau of Internal Revenue (BIR) Tax Clearance Certificate for Bidding Purposes
		25-12-054	Authorization to obtain a new mobile phone plan for its official activities, for the Isabela office/warehouse depot located at Prenza Highway, San Fermin, Cauayan City, Isabela
		25-12-055	Authorization to represent the Corporation in entering into a contract with Pioneer Insurance and Surety Corporation
		25-12-056	Authorization to borrow, obtain and/or contract a loan and/or other credit accommodation(s) from the Land Bank of the Philippines and enter into a Credit Line Agreement with the Bank

Throughout the year, the Company has regularly participated in competitive bids for government projects and has issued the required Board Resolutions for the grant of authority to bid. The Board of Directors has authorized the Company to bid in a total of four hundred seventy one (471) projects in 2025.

CERTIFICATION OF INDEPENDENT DIRECTOR

I, **ATTY. SALVADOR C. MEDIALDEA**, Filipino, of legal age and a resident of 24 Rocha St. San Lorenzo Village, Makati City, after having been duly sworn in accordance with law do hereby declare that :

- 1.) I am a nominee for independent director of Euro-Med Laboratories Phil., Inc. for the term 2026- 2027.
- 2.) I am currently affiliated with the following companies or organizations :

COMPANY/ORGANIZATION	POSITION/RELATIONSHIP	PERIOD OF SERVICE
Toyota Motor Philippines	Independent Director	2 years
Manila Hotel Corporation	Independent Director	3 years
DITO CME Holdings	Independent Director	2 years
Club Filipino	Director	3 years
University of Mindanao	Independent Director	2 years

- 3.) I possess all the qualifications and none of the disqualifications to serve as an independent director of Euro-Med Laboratories Phil., Inc., as provided for in Section 38 of the Securities Regulation Code and its Implementing Rules and Regulations and other SEC issuances.
- 4.) I am not related to any director/officer/substantial shareholder of Euro-Med Laboratories Phil., Inc., and to any of its subsidiaries and affiliates.
- 5.) To the best of my knowledge, I have not been found guilty or convicted of any criminal or administrative investigation or proceeding.
- 6.) I shall faithfully and diligently comply with my duties and responsibilities as independent director under the Securities Regulation Code and its Implementing Rules and Regulations, Code of Corporate Governance and other SEC issuances.
- 7.) I shall inform the Corporate Secretary of Euro-Med Laboratories Phil., Inc. of any changes in the above-mentioned information within five (5) days from its occurrence.


Done this day of 07 MAY 2026 at City of Manila, Philippines.


ATTY. SALVADOR C. MEDIALDEA

07 MAY 2026

SUBSCRIBED AND SWORN to before me on this day of _____ at City of Manila affiant personally appeared before me and exhibited to me his ID No. 144-493-414.

Doc. No. 443
Page No. 90
Book No. 35
Series of 2026.


ATTY. ERNESTO S. BAYOG
Notary Public Manila / Dec. 31, 2026
Notarial Commission No. 2025-075
Merchant Bldg. 509 Padre Faura St. Ermita, Manila
Roll of Attorney's No. 77572
PTR NO. MLA-0342938 Jan. 05, 2026; City of Manila
IBP O.R No. INV/583191; Jan. 02, 2026
MCLE Compliance No. VIII-0023702
Issued on March, 6, 2025
Valid until April 14, 2028.

CERTIFICATION OF INDEPENDENT DIRECTOR


I, **DR. EMIL Q. JAVIER**, Filipino, of legal age and a resident of 9941 Mt. Makiling Street, Los Baños Subd., Los Baños, Laguna after having been duly sworn in accordance with law do hereby declare that :

- 1.) I am a nominee for independent director of Euro-Med Laboratories Phil., Inc. for the term 2026-2027.
- 2.) I am currently affiliated with the following companies or organizations :

Company/Organization	Position/Relationship	Period of Service
National Academy of Science and Technology	Academician and National Scientist	1982 to date
International Service for the Acquisition of Agri-Biotechnology Applications, Inc.	Member, Board of Trustees	2000 to date
Del Monte Philippines, Inc.	Independent Director	April 2018 to date
Centro Escolar University	Independent Director	July 2002 to date
Nutrition Center of the Philippines	Chairman, Board of Directors	2015 to date
Japan International Cooperation Agency-Philippines	Member, Advisory Committee	2016 to date


- 3.) I possess all the qualifications and none of the disqualifications to serve as an independent director of Euro-Med Laboratories Phil., Inc., as provided for in Section 38 of the Securities Regulation Code and its Implementing Rules and Regulations and other SEC issuances.
- 4.) I am not related to any director/officer/substantial shareholder of Euro-Med Laboratories Phil., Inc., and to any of its subsidiaries and affiliates.
- 5.) To the best of my knowledge, I have not been found guilty or convicted of any criminal or administrative investigation or proceeding.
- 6.) I shall faithfully and diligently comply with my duties and responsibilities as independent director under the Securities Regulation Code and its Implementing Rules and Regulations, Code of Corporate Governance and other SEC issuances.
- 7.) I shall inform the Corporate Secretary of Euro-Med Laboratories Phil., Inc. of any changes in the above-mentioned information within five (5) days from its occurrence.

Done this day of 07 MAY 2026 at City of Manila, Philippines.


07 MAY 2026
DR. EMIL Q. JAVIER

SUBSCRIBED AND SWORN to before me on this day of _____ at City of Manila
affiant personally appeared before me and exhibited to me his ID TIN No. 113-982-760.

Doc. No. 441 :
Page No. 90 :
Book No. 35 :
Series of 2026.


ATTY. ERNESTO S. BAYOG
Notary Public Manila / Dec. 31, 2026
Notarial Commission No. 2025-075
Merchant Bldg. 509 Padre Faura St. Ermita, Manila
Roll of Attorney's No. 77572
PTR NO. MLA-0342938 Jan. 05, 2026: City of Manila
IBP O.R No. INV 583191: Jan. 02, 2026
MCLE Compliance No. VIII-0023702
Issued on March. 6, 2025
Valid until April 14, 2028

CERTIFICATION OF INDEPENDENT DIRECTOR

I, **DR. RAYMUNDO W. LO**, Filipino, of legal age and a resident of Dreamville Pekingese 38 London Avenue, Capitol Homes, Matandang Balara, Quezon City, after having been duly sworn in accordance with law do hereby declare that :

- 1.) I am a nominee for independent director of Euro-Med Laboratories Phil., Inc. for the term 2026-2027.
- 2.) I am currently affiliated with the following companies or organizations :

Company/Organization	Position/Relationship	Period of Service
Histosolutions Inc.	President	since 2014


- 3.) I possess all the qualifications and none of the disqualifications to serve as an independent director of Euro-Med Laboratories Phil., Inc., as provided for in Section 38 of the Securities Regulation Code and its Implementing Rules and Regulations and other SEC issuances.
- 4.) I am not related to any director/officer/substantial shareholder of Euro-Med Laboratories Phil., Inc., and to any of its subsidiaries and affiliates.
- 5.) To the best of my knowledge, I have not been found guilty or convicted of any criminal or administrative investigation or proceeding.
- 6.) I shall faithfully and diligently comply with my duties and responsibilities as independent director under the Securities Regulation Code and its Implementing Rules and Regulations, Code of Corporate Governance and other SEC issuances.
- 7.) I shall inform the Corporate Secretary of Euro-Med Laboratories Phil., Inc. of any changes in the above-mentioned information within five (5) days from its occurrence.

Done this day of 07 MAY 2026 at City of Manila, Philippines.


DR. RAYMUNDO W. LO

SUBSCRIBED AND SWORN to before me on this day of 07 MAY 2026 at City of Manila
affiant personally appeared before me and exhibited to me his ID TIN No. 107-954-261.

Doc. No. 442
Page No. 90
Book No. 35
Series of 2026.


ATTY. ERNESTO S. BAYOG
Notary Public Manila / Dec. 31, 2026
Notarial Commission No. 2025-075
Merchant Bldg. 509 Padre Faura St. Ermita, Manila
Roll of Attorney's No. 77572
PTR NO. MLA-0342938 Jan. 05, 2026: City of Manila
IBP O.R No. INV 583191: Jan. 02, 2026
MCLC Compliance No. VIII-0023702
Issued on March. 6, 2025
Valid until April 14, 2028



EURO-MED LABORATORIES PHIL., INC.
PPL Building, United Nations Avenue corner, San Marcelino St., Manila

MANAGEMENT REPORT

Item 1. NATURE AND SCOPE OF BUSINESS

A. In General

Euro-Med Laboratories Phil., Inc. (“Euro-Med” or the “Company”) is the largest manufacturer of high-quality intravenous fluids in the Philippines. It was incorporated and registered with the Securities and Exchange Commission (SEC) on January 29, 1988 and began commercial production in 1991 after securing all required licenses and product registration approvals from the Food and Drug Administration of the Philippines. The Company manufactures and distributes pharmaceutical products such as large and small volume parenterals, sterile water for injection as well as specialty solutions such as ophthalmic, inhalation, irrigation and dialysis solutions. Large volume parenterals (LVPs), commonly known as intravenous fluids, are those applied directly into the vein. LVPs are packaged in containers of more than 100mL while small volume parenterals (SVPs) are injections packaged in containers of 100mL or less. SVPs may also be used as solvent for other drugs.

B. Its Subsidiaries

1. Hemotek Renal Center, Inc. (“Hemotek” or the “Subsidiary”), a wholly-owned subsidiary incorporated in June 2008, is engaged in the business of operating a dialysis center.
2. CafeFrance Corp. (“CafeFrance” or the “Subsidiary”), another wholly-owned company incorporated in August 2010, is engaged in the operation and management of restaurants, bakeries, food services, catering, food production and other related services incidental thereto.

Item 2. DIRECTORS AND OFFICERS

Please refer to Annex “A” of the Information Statement.

FINANCIAL PERFORMANCE

The Company boost its Business Development Unit by placing it under the Office of the Executive Vice President, thereby intensifying the development of new products and acquiring distribution contracts of multinational products.

On Operations, the Sales team were given a reasonable quota as a motivation for them to exert more effort in pushing their sales. Personnel training were given to the staff of Customer Care Unit to equip them in handling customer concerns and developing more solid customer relations.

The Logistics Department plantilla were given extra Relievers/Roving Pharmacists to make the preparations and delivery of products to customers more efficient and on time.

On the Manufacturing side, advance production planning in coordination with the Head of Marketing Department is being done for more efficient utilization of all machines.

For the year 2025 and First Quarter of 2026, the Management is not aware of:

- a. Any known trends, demands, commitments, events or uncertainties that will have a material impact on the Company's liquidity.
- b. Any events that will trigger direct or contingent financial obligation that is material to the Company, including any default or acceleration of an obligation.
- c. Any material off-balance sheet transactions, arrangements, obligations (including contingent obligations) and other relationships of the Company with unconsolidated entities or other persons created during the reporting period.
- d. Any material commitments for capital expenditures, the general purpose of each commitments and the expected source of funds for such expenditures.
- e. Any known trends, events or uncertainties that have had or that are reasonably expected to have a material favorable or unfavorable on net sales/revenues/income from continuing operations.

- f. Any significant elements of income or loss that did not arise from the Company's continuing operations; and
- g. Any seasonal aspects that had a materials effect in the financial condition or results of operations.

The financial performance and causes of material change from period to period were disclosed in Management's Discussion and Analysis in the 2025 Annual Report (SEC Form 17-A).

First Quarter 2026 Financial Report

- (1) The Company's net sales decreased by 1.7% from ₱1,629.9 million for the first quarter of 2025 to ₱1,602.8 million for the first quarter of 2026. The decrease in sales was attributed to the decrease in local sales which decreased by 1.6% from ₱1,607.4 million for the first quarter of 2025 to ₱1,582.2 million for the first quarter of 2026. Export sales decreased by 8.2% from ₱22.5 million for the first quarter of 2025 to ₱20.7 million for the first quarter of 2026. The increase (decrease) in sales indicator was chosen by management as it discloses the level of performance the Company has attained against the forecast. The percentage change is computed by dividing the peso increase (decrease) in sales by the peso sales during the comparable period of previous year.
- (2) Gross profit from sales increased by 5.6% from ₱556.4 million for the first quarter of 2025 to ₱587.8 million for the first quarter of 2026. Cost of goods manufactured and sold decreased by 5.4% from ₱1,073.5 million for the first quarter of 2025 to ₱1,015.1 million for the first quarter of 2026. As a percentage of net sales, cost of goods manufactured and sold decreased from 65.8% for the first quarter of 2025 to 63.3% for the first quarter of 2026. The gross profit indicator provides information about product selling prices relative to production costs. The percentage change in gross profit is computed by dividing the peso increase (decrease) in gross profit by the peso gross profit during the comparable period of previous year.
- (3) Operating expenses (administrative, selling and distribution expenses) increased by 7.3% from ₱385.1 million for the first quarter of 2025 to ₱413.2 million for the first quarter of 2026. The increase was due to the increased of operating expenses i.e. gasoline expense, logistic expenses, taxes and licenses and other expenses. As a percentage of net sales, operating expenses increased from 23.6% for the first quarter of 2025 to 25.8% for the first quarter of 2026. Income from operations increased by 1.9% from ₱171.3 million for the first quarter of 2025 to ₱174.6 million for the first quarter of 2026. Changes in income from operations and operating expenses are management's indica-

tors for the degree of control over the Company's spending on administrative, selling, distribution and other expenses. The percentage change in operating expenses is calculated by dividing the peso increase (decrease) in operating expenses by the peso operating expenses during the comparable period of previous year.

- (4) Net Finance and miscellaneous income/cost decreased by 21.9% from ₱82.4 million for the first quarter of 2025 to ₱64.3million for the first quarter of 2026. Changes in net finance and miscellaneous income/cost indicator provides information on significant elements of income and other expenditures that did not arise from the Company's continuing operations. The percentage change is calculated by dividing the peso increase (decrease) in net finance and miscellaneous income/cost by the net finance and miscellaneous income/cost during the comparable period of previous year.
- (5) Provision for income tax increased by 20.7% from ₱22.9 million for the first quarter of 2025 to ₱27.6 million for the first quarter of 2026. Net income increased by 25.1% from ₱66.0 million for the first quarter of 2025 to ₱82.6 million for the first quarter of 2026. Changes in net income are indicators of the adequacy of amount to satisfy stockholders' dividend and rate-of- return expectations. The percentage change in net income is calculated by dividing the peso increase/decrease in net income by the peso net income during the comparable period of previous year.

The company's total assets decreased by 0.3% from ₱11,144.6 million in 2025 to ₱11,110.3 million in 2026. Current ratio is increased by 3.2% from 1.47:1 in 2025 to 1.51:1 in 2026 while Equity ratio increased from 1.54:1 in 2025 to 1.55:1 in 2026.

The increase in cash and cash equivalent was due to strategic and intensive approach in collecting the receivables. The decrease in inventory was due to strategy of the company to reduce carrying costs and improve cash flow by keeping inventory levels lean. The increase in other non-current assets was due the advances to supplier's contract. The decrease in right-of-use assets(net) was due to amortization. The increase in trust receipts payable was due to orders of raw materials for building stocks in 1st to 2nd qtrs. in preparation for the increase in sales in the second half of 2026. The decrease in loans payable-current was due to payments made for amortization of loans. The amount of income tax payable increased since the amount as of 31 Dec. 2025 represents the audited final and adjusted income tax payable as of the end of year 2025, while the amount as of 31 March 2026 includes the balance as of 31 December 2025 and the unaudited estimated tax on income for the first quarter of 2026. The net decrease of lease liabilities was due to the recording of amortization of lease contracts. The amount of income tax payable as of 31 December 2025 was paid on April 14, 2026. The increase in Retained Earnings was due to the net income for the first quarter of 2026.

Projection

The Company has implemented in 2021-2026 a reorganization of our nationwide sales field personnel to reduce their areas of coverage which would result to better coverage and higher sales. The consolidated sales forecast for 2026 would be an increase in sales of about 10%, totaling to about ₱7.5 billion. The expected net income for 2026 is about ₱503.0 million which is about 6.5% of sales.

2025, 2024 and 2023

Below is a comparative report on the Company's performance for the last three (3) years :

A. Calendar Year 2025 Compared to Calendar Year 2024

- (1) The Company's net sales increased by 18.5% from ₱5,796.0 million in 2024 to ₱6,868.2 million in 2025. The domestic sales increased by 22.9% from ₱5,461.7 million in 2024 to ₱6,709.8 million in 2025, while Export sales decreased by 52.6% from ₱334.4 million in 2024 to ₱158.4 million in 2025. The increase/decrease in sales indicator was chosen by management as it disclosed the level of performance the Company has attained against the targeted growth. The percentage change is computed by dividing the peso increase (decrease) in sales by the peso sales during the comparable period of previous year.
- (2) The gross profit on sales increased by 21.1% from ₱2,033.7 million for the year 2024 to ₱2,463.5 million for the year 2025. Cost of sales and service increased by 17.1% from ₱3,762.3 million in 2024 to ₱4,404.8 million in 2025. However, as a percentage of net sales, Cost of sales and service decreased from 64.9% in 2024 to 64.1% in 2025. The gross profit indicator provides information about product selling prices relative to production costs. The percentage change in gross profit is computed by dividing the peso increase (decrease) in gross profit by the peso gross profit during the comparable period of previous year.
- (3) Operating expenses (administrative, selling, distribution and other expenses) increased by 14.6% from ₱1,364.7 million in 2024 to ₱1,563.8 million in 2025. The increase was due to the increase in operating expenses i.e. logistic expenses, taxes and licenses, gasoline, electricity and other expenses. As a percentage of net sales, operating expenses decreased from 23.5% in 2024 to 22.7% in 2025. Changes in operating expenses are management's indicators for the degree of control over the Company's spending on administrative, selling, distribution and other expenses. The percentage change in operating expenses is calculated by dividing the peso increase (decrease) in op-

erating expenses by the peso operating expenses during the comparable period of previous year.

- (4) Net Finance and miscellaneous income/cost increased by 13.4% from ₱231.6 million in 2024 to ₱262.5 million for 2025. Changes in Net finance and miscellaneous income/cost indicator provides information on significant elements of income and other expenditures that did not arise from the Company's continuing operations. The percentage change is calculated by dividing the peso increase (decrease) in Net finance and miscellaneous income/cost by the net finance and miscellaneous income/cost during the comparable period of previous year.
- (5) Provision for income tax increased by 67.2% from ₱99.8 million in 2024 to ₱166.8 million in 2025. The total net income increased by 39.3% from ₱ 337.7 million for the year 2024 to ₱470.3 million for the year 2025. Changes in total net income are indicators of the adequacy of amount to satisfy stockholders' dividend and rate-of-return expectations. The percentage change in total net income is calculated by dividing the peso increase (decrease) in total net income by the peso total net income during the comparable period of previous year.

The Company's total assets increased by 1.8% from ₱10,949.9 million in 2024 to ₱11,144.6 million in 2025. Current ratio increased from 1.36:1 in 2024 to 1.47:1 in 2025. Debt ratio decreased by 1.6% from 0.46:1 in 2024 to 0.45:1 in 2025, while the equity ratio increased by 1.3% from 53:1 in 2024 to 0.54:1 in 2025.

The increase in cash and cash equivalents was due to intensified collections of overdue accounts from both Euro-Med and Hemotek. The increase in Financial assets at FVPL was due to the profit from FVPL and the conversion of unrealized foreign exchange gain. The decrease in inventories was due to the increase of goods sold. The increase in right of use assets and the decrease in Finance lease liability were due to adjustments of lease contracts, arising from the adaption of PFRS 16. The decrease in deferred tax assets was due to recognition of retirement expenses and retirement liability per PAS#19 (revised 2013) based on overall actuarial report. The decrease of other non-current assets was due to completion of various advances to suppliers for the expansion of production area. The decrease in Trade and other payables was due to payments made of distributed products and regular suppliers of goods and services. The decrease in Trust receipts payable was due to payments of trust receipts for the importation of raw materials and local distributed products. The increase in retirement liability was due to the set up of retirement expense based on actuarial report of 2025. The increase in total Notes and loans Payable (current & non-current) was due to availments on Omnibus credit line for additional working capital of the company. The increase in Income tax payable was due to the higher net income for year 2025. The decrease in other components of equity was due to the cumulative comprehensive gain/loss recognized in the comprehensive

income. The increase in retained earnings was due to the net income for year 2025.

Projections for 2026

The consolidated sales forecast for 2026 would be an increase in sales of about 10%, totaling to about ₱7.5 billion. The expected net income for 2026 is about ₱503.0 million which is about 6.5% of sales.

B. Calendar Year 2024 Compared to Calendar Year 2023

The Company's strategies are:

- a.) Restructuring of the territorial area of Marketing Division and intensify customer visits, thereby resulting in a better coverage and higher sales.
- b.) The Company has created the Business Development unit under the Senior Executive, with the primary objective of developing new product contracts, distribution of multinational products and generation of new revenue streams.
- c.) The Company has also created the Customer Care unit under the Treasury Department. This unit will endeavor to address all concerns, i.e. marketing, delivery, payments, credit terms, collections, etc. This holistic approach would further strengthen customer relationship in due course.
- d.) On the logistics area, the Company introduced an employee work schedule with rotational assignments. Since warehousing and distribution functions are on a 24-hour operations basis, this scheme would make the preparation and delivery of products to customers more efficient and on time. Likewise, the Logistics Department's plantilla includes reliever /roving pharmacists to have a ready remedy in cases of emergency leaves, immediate resignations, death, etc.
- e.) On the production area the strategy is to maximize the utilization of existing capacity. This is done by continuously do advanced planning and increasing flexibility through multi-line set-up.
- f.) The resumption in 2023 of the face-to-face annual sales conference to discuss strategies to strengthen the coordination between marketing and distribution and its procedures on faster resolution of customer issues and concerns to further improve customer relationship.

There are no known events that will trigger direct or contingent financial obligation that is material to the Company, including any default or acceleration of an obligation. There are no off-balance sheet transactions, arrangements, obligations and other relationships of the Company with unconsolidated entities or other persons created during the reporting period.

- (1) The Company's net sales increased by 10.1% from ₱5,263.9 million in 2023 to ₱5,796.0 million in 2024. The domestic sales increased by 9.4% from ₱4,994.0 million in 2023 to ₱5,461.7 million in 2024, while Export sales increased by 23.9% from ₱269.9 million in 2023 to ₱334.4 million in 2024. The increase/decrease in sales indicator was chosen by management as it disclosed the level of performance the Company has attained against the targeted growth. The percentage change is computed by dividing the peso increase (decrease) in sales by the peso sales during the comparable period of previous year.
- (2) The gross profit on sales increased by 6.1% from ₱1,917.2 million for the year 2023 to ₱2,033.7 million for the year 2024. Cost of sales and service increased by 12.4% from ₱3,346.7 million in 2023 to ₱3,762.3 million in 2024. However, as a percentage of net sales, Cost of sales and service increased from 63.5% in 2023 to 64.9% in 2024. The gross profit indicator provides information about product selling prices relative to production costs. The percentage change in gross profit is computed by dividing the peso increase (decrease) in gross profit by the peso gross profit during the comparable period of previous year.
- (3) Operating expenses (administrative, selling, distribution and other expenses) increased by 7.8% from ₱1,265.6 million in 2023 to ₱1,364.7 million in 2024. The increase was due to the increase in operating expenses i.e. gasoline, repairs, electricity and other expenses. As a percentage of net sales, operating expenses decreased from 24% in 2023 to 23.5% in 2024. Changes in operating expenses are management's indicators for the degree of control over the Company's spending on administrative, selling, distribution and other expenses. The percentage change in operating expenses is calculated by dividing the peso increase (decrease) in operating expenses by the peso operating expenses during the comparable period of previous year.
- (4) Net Finance and miscellaneous income/cost decreased by 8.5% from ₱253.1 million in 2023 to ₱231.6 million for 2024. Changes in Net finance and miscellaneous income/cost indicator provides information on significant elements of income and other expenditures that did not arise from the Company's continuing operations. The percentage change is calculated by dividing the peso increase (decrease) in Net finance and miscellaneous income/cost by the net finance and miscellaneous income/cost during the comparable period of previous year.
- (5) Provision for income tax decreased by 8% from ₱108.4 million in 2023 to ₱98.8 million in 2024. The total net income increased by 16.5% from ₱289.9 million for the year 2023 to ₱337.7 million for the year 2024. Changes in total net income are indicators of the adequacy of amount to satisfy stockholders' dividend and rate-of-return expectations. The percentage change in total net income is calculated by di-

viding the peso increase (decrease) in total net income by the peso total net income during the comparable period of previous year.

The Company's total assets increased by 1.7% from ₱10,763.9 million in 2023 to ₱10,949.9 million in 2023. Current ratio increased from 1.31:1 in 2023 to 1.36:1 in 2024. Debt ratio increased by 1.3% from 0.457:1 in 2023 to 0.46:1 in 2024, while the equity ratio decreased by 1.1% from 54:1 in 2023 to 0.53:1 in 2024.

The increase in financial assets at FVPL was due to the profit and the conversion of unrealized foreign exchange gain. The increase in trade and other receivables was due to increase in sales. The decrease in other current assets was due to the decrease on excess input VAT and increase in other assets. The increase in right of use assets was due to adjustments of lease contracts, arising from the adaption of PFRS 16. The increase deferred tax assets was due to recognition of retirement expenses and retirement liability per PAS#19 (revised 2013) based on overall actuarial report. The increase of other non-current assets was due to advances to suppliers for the expansion of production area. The decrease in Trade and other payables was due payments made of distributed products and regular suppliers of goods and services. The increase in Finance lease liability (current and non-current) was due to the recording of lease contracts. The increase in retirement liability was due to the set up of retirement expense based on actuarial report of 2024. The increase in acceptances /trust receipts payables was due to the purchased via trust receipts for the importation of raw materials and local distributed products. The increase in total Notes and loans Payable (current & non- current) was due to availment on Omnibus credit line for additional working capital of the company. The decrease in Income tax payable was due to the net effect of payments of income tax on a quarterly basis. The decrease in other components of equity was due to the cumulative comprehensive gain/loss recognized in the comprehensive income. The increase in retained earnings was due to the net income for year 2024.

Projections for 2025

The consolidated sales forecast for 2025 would be an increase in sales of about 10%, totalling to about ₱6.4 billion. The expected net income for 2025 is about ₱378.0 million which is about 6% of sales.

C. Calendar Year 2023 Compared to Calendar Year 2022

Strategies to mitigate the effects of Covid-19 Pandemic

The Company focused on building upon the recovery efforts from the effects of the Covid-19 pandemic in 2020 to 2022. In 2022, the Company worked hard to meet the challenges to mitigate the effects of the pandemic. The Company had a modest improvement in the year 2022 and notable increase in 2023 and continue to have a robust growth from then on.

The company's strategies are:

- a.) Restructuring of the territorial area of Marketing Division and intensify customer visits, thereby resulting in a better coverage and higher sales.
- b.) The Company has created the Business Development unit under the Senior Executive, with the primary objective of developing new product contracts, distribution of multinational products and generation of new revenue streams.
- c.) The Company has also created the Customer Care unit under the Treasury Department. This unit will endeavor to address all concerns, i.e. marketing, delivery, payments, credit terms, collections, etc. This holistic approach would further strengthen the customer relationship in due course.
- d.) On the logistic area, the Company introduced an employee work schedule with rotational assignments. Since warehousing and distribution functions are on a 24 hour operations basis, this scheme would make the preparation and delivery of products to customers more efficient and on time. Likewise, the Logistics Department's plantilla includes reliever /roving pharmacists to have a ready remedy in cases of emergency leaves, immediate resignations, death, etc.
- e.) On the production area the strategy is to maximize the utilization of existing capacity. This is done by continuously do advanced planning and increasing flexibility through multi-line set-up.
- f.) The resumption of the face to face annual sales conference to discuss strategies to strengthen the coordination between marketing and distribution and its procedures on faster resolution of customer issues and concerns to further improve customer relationship.

There are no known events that will trigger direct or contingent financial obligation that is material to the Company, including any default or acceleration of an obligation. There are no off-balance sheet transactions, arrangements, obligations and other relationships of the Company with unconsolidated entities or other persons created during the reporting period.

- (1) The Company's net sales increased by 24.6% from ₱4,224.1 million in 2022 to ₱5,263.9 million in 2023. The domestic sales increased by 26.2 % from ₱3,957.4 million in 2022 to ₱4,994.0 million in 2023, while Export sales increased by 1.2% from ₱266.6 million in 2022 to ₱269.9 million in 2023. The increase/decrease in sales indicator was chosen by management as it disclosed the level of performance the Company has attained against the targeted growth. The percentage change is computed by dividing the peso increase (decrease) in sales by the peso sales during the comparable period of previous year.

- (2) The gross profit on sales increased by 26.6% from ₱1,513.9 million for the year 2022 to ₱1,917.2 million for the year 2023. Cost of sales and service increased by 23.5% from ₱2,710.1 million in 2022 to ₱3,346.7 million in 2023. However, as a percentage of net sales, Cost of sales and service decreased from 64.1% in 2022 to 63.5% in 2023. The gross profit indicator provides information about product selling prices relative to production costs. The percentage change in gross profit is computed by dividing the peso increase (decrease) in gross profit by the peso gross profit during the comparable period of previous year.
- (3) Operating expenses (administrative, selling, distribution and other expenses) increased by 17.4% from ₱1,073.5 million in 2022 to ₱1,260.6 million in 2023. The increase was due to the increase in operating expenses i.e. gasoline, transportation expenses and other expenses. As a percentage of net sales, operating expenses decreased from 25.4% in 2022 to 23.9% in 2023. Changes in operating expenses are management's indicators for the degree of control over the Company's spending on administrative, selling, distribution and other expenses. The percentage change in operating expenses is calculated by dividing the peso increase (decrease) in operating expenses by the peso operating expenses during the comparable period of previous year.
- (4) Net Finance and miscellaneous income/cost increased by 58.7% from ₱160.1 million in 2022 to ₱254.2 million for 2023. Changes in Net finance and miscellaneous income/cost indicator provides information on significant elements of income and other expenditures that did not arise from the Company's continuing operations. The percentage change is calculated by dividing the peso increase (decrease) in Net finance and miscellaneous income/cost by the net finance and miscellaneous income/cost during the comparable period of previous year.
- (5) Provision for income tax increased by 34.9 % from ₱80.4 million in 2022 to ₱108.4 million in 2023. The total net income increased by 47.1% from ₱199.9 million for the year 2022 to ₱293.9 million for the year 2023. Changes in total net income are indicators of the adequacy of amount to satisfy stockholders' dividend and rate-of-return expectations. The percentage change in total net income is calculated by dividing the peso increase (decrease) in total net income by the peso total net income during the comparable period of previous year.

The Company's total assets increased by 7% from ₱10,058.7 million in 2022 to ₱10,763.9 million in 2023. Current ratio decreased from 1.33:1 in 2022 to 1.31:1 in 2023. Debt ratio increased by 5.7% from 0.43:1 in 2022 to 0.46:1 in 2023, while the equity ratio decreased by 4.3% from 57:1 in 2022 to 0.54:1 in 2023.

The increase in cash and cash equivalents was due to more cash sales during the year. The increase in Financial assets at FVPL was due to the conversion of unrealized foreign exchange gain. The increase in trade and other receivables was due to increase in sales. The increase in inventories was due to increase in finished goods produced. The increase in other current assets was due to the increase on excess input VAT, since almost of our IV products were classified to non-vatable sales resulting to lower VAT payable. The decrease in right of use assets was due to depreciation of lease contracts, arising from the adaption of PFRS 16. The increase deferred tax assets was due to recognition of retirement expenses and retirement liability per PAS#19 (revised 2013) based on overall actuarial report. The decrease of other non-current assets was due to full payment of advances to suppliers. The increase in Trade and other payables was due to the accrual of expenses of distributed products and regular suppliers of goods and services. The decrease in Finance lease liability (current and non-current) was due to the expiration of lease contracts. The increase in retirement liability was due to the set up of retirement expense. The increase in acceptances /trust receipts payables was due to the purchased via trust receipts for the importation of raw materials and local distributed products. The increase in total Notes and loans Payable (current & non- current) was due to additional working capital of the company. The increase in Income Tax Payable was due to the increase of the net income. The decrease in other components of equity was due to the cumulative comprehensive gain recognized in the comprehensive income. The increase in retained earnings was due to the net income for year 2023.

Projections and Effects of Covid -19 Pandemic

The Company felt the effect of Covid-19 pandemic starting March, 2020 and still raging in year 2021. The new variant, Omicron set in late 2021 and eases up at start of March 2022. Hardest hit is its subsidiary CaféFrance, however, the company sees a glim of hope in 2022 as the government and the private sector are closely coordinating to have a mass vaccination in the country, thereby opening up the economy towards the end of 2022.

The Company has implemented in 2021 a reorganization of our nationwide sales field personnel to reduce their areas of coverage which would result to better coverage and higher sales.

The consolidated sales forecast for 2024 would be an increase in sales of about 10%, totaling to about ₱5,790 million. The expected net income for 2024 is about ₱347.4 million which is about 5% of sales.

Item 4 MARKET INFORMATION

Euro-Med's shares are publicly traded at the Philippine Stock Exchange.

The high and low trading prices of the shares are :

2024		High	Low	
1 st Quarter	₱	1.01	₱	0.77
2 nd Quarter	₱	0.79	₱	0.70
3 rd Quarter	₱	0.78	₱	0.71
4 th Quarter	₱	1.01	₱	0.72
2025		High	Low	
1 st Quarter	₱	0.93	₱	0.72
2 nd Quarter	₱	0.92	₱	0.80
3 rd Quarter	₱	1.00	₱	0.72
4 th Quarter	₱	1.10	₱	0.87
2026		High	Low	
1 st Quarter	₱	1.07	₱	0.97

As of 30 April 2026, Euro-Med was trading at ₱1.02 (the latest practicable trading date before submission of the report).

2.) Holders

As of 30 April 2026, the Company has on record a total of 538 stockholders holding the Four Billion One Hundred Twelve Million One Hundred Forty Thousand Five Hundred Forty (4,112,140,540) issued and outstanding shares.

As of 30 April 2026, the top twenty (20) stockholders are as follows:

	<u>Stockholder's Name</u>	<u>Total Shares</u>	<u>%</u>
1.	U. S. Automotive Co., Inc.	2,401,747,112	58.41%
2.	USAUTOOCO, Inc.	855,505,147	20.80%
3.	Evergreen Stock Brokerage & Securities, Inc.	298,725,323	7.26%
4.	Philippine Trust Company	231,124,845	5.62%
	Philippine Trust Company (Trust Department)	133,986,446	3.26%
5.	Yap, Johnny C.	36,980,720	0.90%
6.	Yap, Emilio C.	35,695,668	0.87%
7.	Yap, Nichol C.	35,695,668	0.87%
8.	PCD Nominee Corp. (FIL)	35,658,948	0.90%
9.	Yap, Enrique Raymond I.	16,067,839	0.39%
10.	Ilusorio, Roberto Havel K.	5,000,000	0.12%
11.	Ilusorio, Carlo Daniel K.	5,000,000	0.12%
12.	Yap, Michael Vincent Y.	2,794,742	0.06%
13.	PCD Nominee Corp. (NON-FIL)	2,636,633	0.06%
14.	Maramba, Tomas P.	1,285,052	0.03%
15.	Evidente, Georgiana S.	1,285,052	0.03%
16.	Cohu, Marshall Cohu ITF: Marc C. Allan	822,430	0.02%
17.	Yap, Michael Vincent Y.	794,742	0.01%
18.	Cohu, Marshall Cohu ITF: Dianne Bernice C.	616,823	0.02%
19.	Cohu, Marshall Cohu ITF: Danica Marie C.	616,823	0.02%
20.	Goldclass Inc.	586,617	0.01%

The Company has not entered into any acquisition, business combination or other reorganization that would affect the amount and percentage of the present holding of the Company's common equity owned beneficially by: (i) more than five percent (5%) beneficial owner of Company's common equity; (ii) each director and nominee; and (iii) all directors and officers as a group, and the Company's present commitments to such persons with respect to the issuance of shares.

Voting Rights

Each share is entitled to one (1) vote. With respect to the election of directors, however, a shareholder may vote such number of shares in his own name in the stock transfer book of the Company for as many persons as there are directors to be elected, or he may cumulate said shares and give one candidate as many votes as the number of votes to be elected, or he may distribute them among as many candidates as he shall see fit; provided, that the total number of votes cast by him shall not exceed the number of shares owned by him multiplied by the number of directors to be elected.

3.) Dividends and Dividend Policy

Pursuant to the Company's By-Laws, dividends shall be declared only from the unrestricted retained earnings of the Company and shall be payable at such time, in such manner and in such amounts as the Board of Directors shall determine. No dividends which would impair the capital of the Company shall be declared.

The Company declared and paid the following dividends for the past three (3) years:

<u>Year</u>	<u>Kind</u>	<u>Amount</u>	<u>Rate</u>	<u>Record Date</u>	<u>Payment Date</u>
2023	Cash	₱ 143.9 Million	3.50%	November 10, 2023	November 27, 2023
2024	Cash	₱ 269.0 Million	6.00%	November 15, 2024	December 02, 2024
2025	Cash	₱ 287.0 Million	7.00%	November 14, 2025	December 01, 2025

The Company has not restricted any portion of its retained earnings for future expenses, contingencies or other purposes.

4.) Recent sales of unregistered or exempt securities, including recent issuance of securities constituting an exempt transaction.

For the past three (3) years, the Company has not sold securities, which were not registered under the Code. There were no sales of reacquired securities, as well as securities issued in exchange for property, service and other securities, resulting from the modification of outstanding securities.

**Item 5 CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS
ON ACCOUNTING AND FINANCIAL DISCLOSURE.**

Mendoza, Querido & Co., CPA's was appointed External Auditor of the Company for the years 2018 to 2021.

As the Audit & Risk Oversight Committee Charter prescribes the rotation of the External Auditor after every three to five years pursuant to SEC Rule 68, the Committee recommended the engagement of Aquino, Mata, Calica and Associates as External Auditor for the period 2022-2023. Aquino, Mata, Calica and Associates was also appointed as External Auditor for the years 2022 to 2025.

For the fiscal year 2026-2027, the Audit & Risk Oversight Committee in its meeting held on 24 March 2026, recommended the appointment of Aquino, Mata, Calica and Associates as External Auditor. Representatives of the said auditing firm are expected to be present during the stockholders' meeting and they will have the opportunity to make a statement if they desire to do so and to respond to appropriate questions.

There were no disagreements with the Company's accountants on any accounting and financial disclosure during the recent fiscal year or any subsequent interim period.

Item 6 EXTERNAL AUDIT FEES AND SERVICES

a.) Audit and Audit Related Fees

The aggregate fees billed by the Company's external auditors for the years 2025 and 2024 is ₱1,050,000 and ₱910,000 respectively. These amounts cover the cost of the regular audit of the Company's annual financial statements in connection with statutory and regulatory filings for those covered years. These fees also include consultation on minor accounting matters and minor tax matters, such as queries on new BIR regulations, computation of VAT, etc. Any work that will involve our external auditors to represent the company on cases with the Bureau of Internal Revenue and other regulatory bodies are considered major accounting and tax matters which shall be billed commensurate with the number of hours spent by the auditors working on such consultation.

b.) Tax fees - None

c.) All other fees - None

d.) The above-stated fees were approved by the Company's Audit and Risk Oversight Committee based on a written engagement letter subject to the mutual agreement of both parties.

Item 7 CORPORATE GOVERNANCE

1.) Evaluation System

The Board of Directors and Management, including the officers and staff of the Company hereby commit to the principles and the best practices contained in its Manual of Corporate Governance and acknowledge that the same may guide the attainment of the corporate goals. The Company has an established evaluation procedure which determines and measures compliance with this Manual.

Regular meetings of the Board are scheduled at the beginning of the year and are being held regularly every month. A Director's absence or non-participation in more than fifty (50%) of all meetings in a year is a ground for temporary disqualification in the succeeding election.

The Company conducts its annual performance evaluation through a Self-Evaluation Questionnaire. The questionnaire has been devised to enable assessment of the effectiveness of the Board and its individual members.

The Board has instituted on an annual basis that all Board members and key officers should attend a continuing education on good corporate governance practices. This would make them well-informed on governance related developments, regular annual education programs and other areas. These are conducted in coordination with the training providers duly accredited by the SEC. The Company plans to improve its corporate governance by applying appropriate and reasonable learnings from these education programs to have a more effective and efficient policies.

The Company's Manual of Corporate Governance institutionalizes the principles of good Corporate Governance in the entire Company. The Management believes that Corporate Governance, the framework of rules, system and processes governing the performance of the Board and Management of their respective duties and responsibilities and from which the Company's values and ethics emerge, is of utmost importance to our shareholders and other stakeholders. The Company undertakes every effort possible to create awareness throughout the entire organization.

2.) Compliance with the Adopted Leading Practices

The Board conducts an annual review of this Manual to determine if there is a need for amendment to fully comply with leading practices on good corporate governance. Our directors and officers have been attending the Corporate Governance seminar conducted by the Institute of Corporate Directors annually since year 2015. The Company

has been annually submitting its update on Consolidated Changes to the Corporate Governance Report with the SEC.

3.) Deviation from the Company's Manual of Corporate Governance

At present, the Company has no knowledge of any deviation committed by any of its personnel from the Company's Manual.

4.) Improvement of the Company's Manual of Corporate Governance

a.) On 29 May 2025, the Company submitted its Integrated Annual Corporate Governance (I-ACGR) which can be viewed and downloaded in the Company's website, and copies were furnished to the Securities and Exchange Commission.

b.) The Corporate Governance and Nomination Committee last January 30, 2024 has engaged the services of Mariano, Caguete & Co. CPAs as the external facilitator for the Corporation's annual self-assessment activity for a period of three (3) years starting 2024.

c.) On September 29, 2020, the company submitted its Revised Manual of Corporate Governance to the Securities and Exchange Commission in compliance with SEC Memorandum Circular No. 24 series of 2019 and Memorandum Circular No.19 Series of 2020.

Item 8 MINIMUM PUBLIC OWNERSHIP

As of 30 April 2026, (the latest practicable date prior to issuance of this annual report), the level of the Company's public float is at 14.09%.

THE COMPANY UNDERTAKES TO PROVIDE WITHOUT CHARGE TO EACH STOCKHOLDER, UPON WRITTEN REQUEST BY THE STOCKHOLDER, A COPY OF THE COMPANY'S ANNUAL REPORT OR SEC FORM 17-A. PLEASE DIRECT ALL SUCH REQUESTS TO THE CORPORATE SECRETARY, MS. JANICE R. ONG, PPL BUILDING, UNITED NATIONS AVENUE CORNER SAN MARCELINO ST., MANILA, PHILIPPINES.